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Abstract 
Purine transport in malaria parasites has become an important potential drug target because 
the malaria parasite is unable to synthesis purine de novo and has to salvage it from the 
host milieu through transporter(s). Knowledge of the number, selectivity and kinetic 
parameters of the transporters expressed by the parasite would therefore facilitate a rational 
purine-based chemotherapy of malaria 
 
The rates of transport of radiolabeled purines into Plasmodium falciparum-infected 
erythrocytes were measured using classical uptake techniques. We found that the uptake of 
purine into intact parasite-infected erythrocytes was mediated by the endogenous human 
erythrocyte nucleoside and nucleobase transporters (hENT1 and hFNT1) rather than the 
parasite-induced New Permeation Pathways (NPP). The overall rate of purine uptake was 
observed to be approximately doubled in parasite-infected cells compared to uninfected 
cells and the rate of adenosine uptake was seen to be faster than hypoxanthine in parasite-
infected cells. It was observed that transport of hypoxanthine and adenine through the 
hFNT1 was unexpectedly inhibited by furosemide. This inhibition by furosemide of [3H]-
hypoxanthine and [3H]-adenine uptake was not through inhibition of the NPP, as it was 
observed equally in infected and uninfected hRBC. 
 
To gain further understanding of purine transport in the malaria parasite, uptake was 
measured in saponin-freed P. falciparum trophozoites. Treatment of parasite infected 
erythrocytes with saponin render both the erythrocyte membrane and the parasitophorous 
vacuole membrane permeable to solutes, allowing transport to be measured across the 
parasite membrane. The data obtained from the uptake assays were analysed using 
Michaelis Menten plots to obtain the kinetic properties (Km and Vmax) of the parasite’s 
purine transporters. Three separate and novel transport activities were identified in 
saponin-freed P. falciparum trophozoites: (i) a high affinity hypoxanthine transporter with 
a secondary capacity for purine nucleosides, named PfNT1, (ii) a separate high affinity 
transporter for uptake of adenine (named PfADET1) and (iii) a low affinity/high capacity 
adenine carrier (denoted PfADET2). Additionally, the presence in the parasite of a low 
affinity adenosine transporter designated PfLAAT, with kinetic properties similar to that 
previously reported by other research groups was also confirmed. At room temperature, 
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uptake of hypoxanthine through PfNT1 was observed to be 12-fold more efficient than 
adenosine.  
 
The gene encoding the high affinity hypoxanthine/nucleoside transporter PfNT1 was 
disrupted by a single crossover event and the parasite clones obtained were designated 
3D7∆PfNT1. The characteristics of purine uptake into parasites lacking a functional PfNT1 
gene were then compared to uptake in wild-type parasites. The high affinity uptake of 
hypoxanthine or adenosine was completely abolished in 3D7∆PfNT1, whereas uptake of 
25µM [3H]-adenosine (through the low affinity transporter, PfLAAT) was similar in both 
3D7∆PfNT1 and wild-type P. falciparum parasites. Adenine transport was observed to 
increase in 3D7∆PfNT1, presumably to partly compensate for the loss of the high affinity 
hypoxanthine transporter.  
 
An improved microfluorometric technique for determining parasite’s sensitivity to 
antimalarial drugs was developed and the method was used to evaluate antiplasmodial 
potential of a small number of purine analogues. A ‘hypoxanthine-like’ purine analogue, 
JA-32, was found to inhibit the uptake of hypoxanthine by PfNT1, supporting the potential 
of purine transporters as targets for antimalarial drug development.  
 
The findings from this study provide evidence that purine salvage in P. falciparum is 
predominantly based on the highly efficient uptake of hypoxanthine by PfNT1 and 
secondarily on the high capacity uptake of nucleosides by a lower affinity carrier. The 
exact contribution to the overall purine salvage in parasite by the two transporters of 
adenine is not clear. Indeed, the issue of whether Plasmodium can utilise adenine as a 
purine source is controversial. These findings re-emphasise the importance of purine 
transporters as targets for novel antimalarial drugs and open the gateway for a systematic 
purine-based chemotherapy of malaria.  
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1.1 Background to the study 
Malaria, caused by protozoan parasites of the genus Plasmodium, is responsible for a 
significant proportion of the recorded morbidity and mortality, especially among children 
living in the tropics and subtropical areas of the world (Gubler, 1998;WHO, 2005). Of the 
four species of Plasmodium that infect humans, Plasmodium falciparum, Plasmodium 
malariae, Plasmodium vivax and Plasmodium ovale, the first is the most virulent ((WHO, 
2005). It must, however, be added that reports from recent studies indicate that non-human 
primate plasmodia are the source of malaria outbreaks among humans in some parts of the 
world. In this regard, the groups of Kanbara and Conway have described cases of naturally 
acquired infection with Plasmodium knowlesi in Thailand and Malaysia respectively 
(Jongwutiwes et al, 2004;Singh et al, 2004). 
Chemotherapy remains the mainstay of malaria control; however the malaria parasites, 
especially P. falciparum, have developed resistance to most of the antimalarial drugs 
currently available.(White, 2004). Resistance of P. vivax to chloroquine has also been 
reported (Rieckmann et al, 1989;Baird et al, 1991). The emergence and spread of P. 
falciparum parasites resistant to antimalarial drugs limits the treatment of the disease and 
makes its management difficult. This situation calls for the prompt identification and 
development of new antimalarial drugs. Unlike pyrimidine (which could be synthesised 
from glutamine and bicarbonate), the malaria parasites are incapable of de novo synthesis 
of the purine ring and have to depend on uptake of preformed purines from the host milieu 
through transporters. The salvage mechanism of purine has therefore become a target for 
novel antiplasmodial compounds (Gero et al, 2003;Joet et al, 2003). The identification and 
selection of appropriate inhibitors and cytotoxic compounds as antiplasmodial agents will 
depend on the detailed knowledge of the kinetic characteristics of the purine transporters. It 
is, therefore, an objective of this study to identify and characterise transporters of purine in 
P. falciparum in order to facilitate a purine-based chemotherapy of malaria. 
Prior to this study, two groups of researchers – Carter and co and Parker and co – 
investigated the characteristics of P. falciparum purine transporter expressed in the oocytes 
of Xenopus laevis (Parker et al, 2000;Carter et al, 2000). Although this first cloning and 
characterisation in Plasmodium of the Equilibrative Nucleoside Transporter (ENT) family 
was undoubtedly a breakthrough, the discrepancies between their findings caused some 
controversy. With regard to substrate affinities, the Km for adenosine was determined as 
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13 and 320 µM by the groups of Ullman (Carter et al, 2000) and Baldwin (Parker et al, 
2000) respectively. In terms of substrate specificity, Parker and colleagues demonstrated 
the uptake of nucleobases such as hypoxanthine, whereas the group of Ullman could not 
measure any uptake of these compounds. Whilst Carter and colleagues reported that the 
transporter was inhibited by 10 µM dipyridamole, a report from the group of Baldwin 
showed otherwise. Reasons for these significant differences have been hard to find. 
However, one possible cause of these discrepancies could be the system in which the 
transporter was expressed, i.e. Xenopus oocytes. Though the Xenopus oocyte system has 
been widely used and has yielded highly valuable data on human transporters (Griffith & 
Jarvis, 1991;Wright et al, 2002;Beene et al, 2003), yet it is also true, as with any 
heterologous expression system, that the functional properties of the expressed proteins 
may be affected by the activities of indigenous proteins (Buyse et al, 1997). It is, therefore, 
possible that the kinetic values reported by the two research groups may not accurately 
reflect that of the transporters when they exist in their natural location (i.e. the plasma 
membrane of parasite). Furthermore, the fact that the Plasmodium genome is extremely 
A+T-rich (Gardner et al, 2002) (PfNT1 is 72% A+T) explains the reported difficulties of 
expressing other P. falciparum ENT genes in this system (Downie et al, 2006). 
Furthermore, in the study by Carter and co, a parasite clone different from that of Parker 
and Downie studies (W2 and 3D7, respectively), which had a single amino acid difference 
in their PfNT1 gene (Leu replacing Phe, at position 385) was used. 
 
 Since concern is heightened in the light of the marked differences in the reports of the two 
groups it became necessary that purine transport be re-assessed using isolated P. 
falciparum parasites and that genes are subsequently matched to known transport activities 
by reverse genetics. Purine transport into saponin-freed P. falciparum trophozoites was 
therefore investigated in this study, followed by disruption of each of the known P. 
falciparum ENT genes. 
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1.2 Malaria- The disease burden 
 
 
Figure 1.1: Distribution of Malaria in the world as at April 2004. 
The deep blue colour indicates P. falciparum malaria endemic countries of the world. 
Reproduced with permission from the Centre for Disease Control 
(http://www.cdc.gov/malaria/impact). 
 
 
According to a World Health Organization report, an estimated 350 to 500 million clinical 
cases of malaria occur each year, resulting in more than 1 million deaths (WHO, 2005). 
Over 80% of these deaths occur among children living in sub-Saharan Africa. Globally, an 
estimated 40% of the world’s population are at risk of the disease in about 90 countries 
(see Figure 1.1). Plasmodium falciparum is responsible for about 95% of malaria deaths 
worldwide and has a mortality rate of 1-3% (WHO, 2005).  
 
The wide variation in the burden of the disease between different regions of the world has 
been attributed to several factors, such as the ‘variation in parasite species, differences in 
levels of socio-economic development and differences among the vulnerable groups in 
different parts of the world’ (WHO, 2005). Plasmodium falciparum, the most virulent of 
the different species of the parasite affecting human, is usually a common species in Africa 
south of the Sahara, hence the reported high incidence of malaria from this area. The 
climatic conditions in this part of the world favour the growth and multiplication of 
Anopheles mosquitoes, the vector responsible for transmission of the parasites (CDC, 
2004). At temperatures below 18°C (66°F), development of P. falciparum in the mosquito 
is retarded such that the intrinsic period in the vector exceeds the longevity of the insect 
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(Patz & Olson, 2006). P. vivax can, however, grow and multiply even at lower ambient 
temperatures, giving it a wider geographical range extending into the temperate regions. 
Socio-economic determinants such as ‘poverty, quality of housing and access to health 
care and health education, as well as the existence of active malaria control programmes’ 
among others could influence malaria transmission (WHO, 2005). It is obvious that poorer 
countries are likely to suffer the brunt of the disease, mostly because of the limited 
resources to combat the disease. The proportion of the vulnerable groups in different 
regions of the world where malaria transmission is stable may also contribute to the 
observed variation in the disease burden. 
 
 
1.3 Economic burden of malaria 
In addition to the high burden of mortality and morbidity, malaria severely limits 
productivity in most disease-endemic countries of the world. A report by Gallup and Sachs 
indicated that the disease imposes substantial costs to governments as well as families 
within the communities of the world (Gallup & Sachs, 2001). The economic burden on 
society, according to the report, takes the form of drugs purchased for home management 
of malaria, expenses incurred in travelling for treatment at clinics and hospitals, lost days 
of work, and children’s absence from school. Other effects of the disease mentioned in the 
report include expenses for preventive measures and expenses for burial in case of deaths.  
 
A survey conducted in six sub-Saharan African countries indicated that the cost of vector 
control through the use of mosquito coils, aerosol sprays, treated bed nets and mosquito 
repellents ranged between US$ 0.05 and US$ 2.08 per person per month (Shepard et al, 
1991). The report also revealed that ‘on average, a family of five spends US$ 55 annually 
on disease prevention alone and between US$ 0.39 and US$ 3.84 per person on its 
treatment’ (Shepard et al, 1991;Russell, 2004). Globally, about US$1800 million is spent 
annually on both the direct costs (prevention and control) and on indirect cost such as loss 
to productivity and time costs(Foster S & Phillips M, 1998;Malaney et al, 2004).  
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1.4 Life cycle of the malaria parasite 
 
Figure 1.2: The life Cycle of P. falciparum Malaria Parasite. 
 (Reproduced with permission from: http://www.malariatest.com/cycle). 
 
The life cycle of Plasmodium is complex and specific to the parasite species. The life cycle 
of P. falciparum infection is shown in Figure 1.2 and described below. Malaria parasites 
are transmitted to human when, in the course of taking a blood meal, an infected female 
Anopheles mosquito injects infectious sporozoites contained in its salivary glands into the 
peripheral circulation (Carucci et al, 1998). The sporozoites immediately invade the liver 
hepatocytes and undergo rounds of asexual multiplication over the next 5-7 days, 
producing thousands of merozoite forms of the parasite. When the infected hepatocyte 
ruptures, the merozoites are released into the peripheral circulation.and they quickly invade 
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the red blood cells (RBC). It has been reported that after the invasion of the RBCs, the 
parasites (ring forms) seemly lie dormant for up to 15 hours(Kirk, 2001). After this period, 
there is a rapid increase in metabolic and biosynthetic activities within the infected cell 
whilst the parasites develop from the trophozoite to reach the schizont stage, which occurs 
at 36 hours post-invasion. The schizont matures fully within the next 12 hours 
(approximately 48 hours post invasion). At this stage the parasite (schizont) has divided to 
produce 16–20 daughter cells (merozoites). It is worth noting that this part of the lifecycle 
is 72 hours for P. malariae. Upon the rupture of the erythrocyte, the released merozoites 
re-invade other RBC to carry on with the asexual erythrocytic cycle. It is the synchronous 
release of merozoites and toxic metabolic waste into the blood stream that causes the 
periodic fever associated with malaria. Some merozoites do not begin the divisions of 
schizogony, but rather differentiate into male (microgametocyte) and female 
(macrogametocyte) sexual forms (Figure 1.2). These sexual forms are then taken from the 
bloodstream by a feeding female Anopheles mosquito and fertilise in the mosquito midgut 
to form zygotes. The zygotes differentiate into motile forms, called ookinetes, which then 
migrate through the mosquito gut wall to form oocysts on the external gut wall. 
Replication occurs within the oocyst on the gut wall to form thousands of sporozoites. The 
infective sporozoites are released into the mosquito haemocoel and move to the salivary 
glands, where they await injection into another human host and thereby complete the life 
cycle. It must also be noted that with an infection with P. vivax, there are occasions where 
some of the invaded sporozoites do not immediately grow and divide after entering the 
hepatocyte, but rather remain in a dormant, hypnozoite stage for weeks or months. This 
may lead to relapse malaria, which is mostly found associated with P. vivax infections. 
 
 
1.5 Manifestation of malaria 
Clinical symptoms of malaria caused by an infection of P. falciparum manifest in many 
forms, some of which mimic other diseases such as typhoid, meningitis and gastroenteritis. 
The age, immune status, intensity of transmission and the Plasmodium species most often 
determine the symptoms. According to a WHO report, the disease shows flu-like 
symptoms with a rapid increase in temperature for those living in non-endemic areas 
(WHO, 1990). In disease-endemic areas, the symptoms are modified by immunity and the 
associated fever is often intermittent, occurring with periodicity (WHO, 2005). It has been 
observed that, particularly in children, the fever is variable with no periodicity. Other 
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manifestations of the disease observed in children are pallor, nausea, vomiting and refusal 
of feeds, lethargy, restlessness, headache, diarrhoea and cough (WHO, 2005). Severe 
forms of malaria, which are mostly associated with an infection with P. falciparum, 
include vomiting, diarrhoea, cerebral malaria, severe anaemia, algid malaria, hepatic-renal 
syndrome and black water fever among others (WHO, 2005). 
 
 
1.6 Laboratory diagnosis of malaria 
Direct microscopic examination of intracellular parasites on Giemsa’s-stained blood films 
is currently the gold standard for definitive diagnosis of malaria (WHO, 2005). Laboratory 
diagnosis of malaria by microscopy has many advantages over the other available methods, 
as it allows for quantification of parasite density and also for differentiation of the species 
(Bloland, 2001). Distinction between the sexual forms of the parasite (gametocytes) and 
the asexual forms is also possible with this method. However a major limitation of 
microscopy is that it can give false negative results if the blood smear is made when P. 
falciparum parasites are at trophozoites or schizont form, since these parasites are 
sequestered in the vessels of the internal organs and are not present in peripheral blood  
 
Fluorescent microscopy can also be used for laboratory diagnosis of malaria. Methods 
employed under this include the quantitative buffy coat (QBC) method (Baird et al, 
1992;Benito et al, 1994), the Kawamoto acridine orange method (Kawamoto, 1991), and 
the Benzothiocarboxypurine (BCP) method (Makler et al, 1991;Cook, 1992). Fluorescence 
microscopy has the advantage of providing rapid results but the equipment and reagents 
required are considerably more expensive than for light microscopy. 
 
Molecular diagnostic techniques such as Polymerase Chain Reaction (PCR) have also been 
developed for the identification of the presence of the malaria parasite in biological 
samples such as the blood (Vu et al, 1995). In this method, two primers, flanking the target 
sequence, and Taq polymerase, are used in successive cycles of DNA denaturation and 
extension to generate many copies of the target sequence. The genes mostly targeted in P. 
falciparum are the merozoite surface protein-1 (MSP1), merozoite surface protein-2 
(MSP2) and glutamine rich protein (GLURP). The amplified gene can be detected using 
internal probes (for which there are many types) or by gel electrophoresis. Although this 
technique is expensive and requires an expert to perform, it is very sensitive and highly 
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specific. This method is not used routinely in the diagnosis of malaria in disease endemic 
areas of the world.  
 
The recently developed Rapid Diagnostic Tests (RDTs) uses rapid immuno-
chromatographic techniques to detect specific antigens produced by malaria parasites that 
are present in the blood of infected or recently infected individuals. Whilst some RDTs can 
detect the presence of only P. falciparum, others can detect the presence of the other 
species of Plasmodium. The most commonly used tests detect the P. falciparum histidine-
rich protein-2 (pHRP-2) and the parasite lactate dehydrogenase (pLDH) (Howard et al, 
1986). These two antigens are present in the blood of infected people during the asexual 
stages of the parasite. The tests are rapid, simple to perform and have good detection 
limits. However a disadvantage of the method is that parasite antigen continues to circulate 
after the infection has been cleared, for example by chemotherapy, which can lead to false 
positives. 
 
 
1.7 Chemotherapy of Malaria  
Antimalarial drugs can be classified into two broad groups of compounds, namely blood 
schizonticides and tissue schizonticides. Blood schizonticides kill the erythrocytic stages of 
the parasite within the red blood cells whilst tissue schizonticides destroy the liver stages 
of the parasite (Black et al, 1986). Some of the common antimalarial drugs belonging to 
these classes are discussed in the next sub-sections of this thesis. 
 
1.7.1 Chloroquine 
Chloroquine, a potent blood schizonticidal drug, is effective against all asexual forms of 
the malaria parasites (Black et al, 1986). The drug is also effective against gametocytes of 
P. vivax, P. malariae, and P. ovale. The mechanism of action of chloroquine remains 
unclear. Being a weak base, the drug may concentrate in the acidic lysosome of the 
parasites. It has been reported that chloroquine interferes with the parasite’s metabolism of 
haemoglobin (Ward, 1988). Haeme (ferriprotoporphorin IX), a by-product of haemoglobin 
digestion, is very toxic to the parasite and is converted by polymerisation in the food 
vacuole to harmless haemozoin. Chloroquine is thought to exert its antimalarial effect by 
preventing the polymerization of the toxic haeme released during the proteolysis of 
Neils Ben Quashie, 2008 Chapter One  
 
10
haemoglobin leading to the accumulation of the toxic free haeme, which eventually kills 
the parasite. The mechanism of this blockade has not been established. 
Chloroquine was the drug of choice in many disease endemic countries for the treatment of 
uncomplicated malaria and for chemoprophylaxis until the late 1950s when P. falciparum 
parasites that are resistant to the drug emerged and spread throughout the world. The drug 
is now not recommended for treatment of P. falciparum, but is still effective against the 
other 3 species of malaria, although there have been reports of resistance in P. vivax 
(Rieckmann et al, 1989;Baird, 2004).  
 
 
1.7.2 Sulphadoxine/pyrimethamine (SP) 
Sulphadoxine/pyrimethamine (SP), marketed under the trade name Fansidar®, is a blood 
schizonticide with fixed-dose combination of 500 mg sulphadoxine and 25 mg 
pyrimethamine. Both drugs are antifolates and interfere with the synthesis of thymidylate 
in the parasite. Sulphadoxine competes with para-aminobenzoic acid (PABA) for binding 
to the enzyme dihydropteroate synthase in the synthesis of dihydropteroate, an essential 
compound needed for folic acid synthesis (Hyde, 2002). Pyrimethamine inhibits the 
actions of dihydrofolate reductase, which is necessary for folic acid synthesis in the 
parasite (Black et al, 1986). When both drugs are combined, synergy occurs making the 
combination drug more efficacious than the monotherapy drugs (Chulay et al, 1984).  
 
 
1.7.3 Quinine 
Quinine, which is found in the bark of the American cinchona tree, is also a blood 
schizonticide. Quinine is used for the treatment of severe forms of malaria in most disease 
endemic areas. The drug, which is reported to destroy the trophozoite stage in the 
erythrocytes, has no effect on the exo-erythrocytic stages that develop in the liver or the 
gametocytic stage. Though the mode of action of quinine is not well understood, it is 
thought to be similar to that of chloroquine, causing cytotoxicity by inhibiting the 
polymerisation of haeme into haemozoin, with the consequent built up of free haeme, 
which is toxic to the parasite (Yakuob et al, 1995). Another proposed mode of action is 
that the drug forms a complex with double-stranded DNA to prevent strand separation or 
that it blocks DNA replication and transcription. 
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1.7.4 Primaquine 
Primaquine, a tissue schizonticide, is a member of the 8 aminoquinoline group of 
compounds used for treatment of malaria infection especially those caused by P. vivax or 
P. ovale. It is used in ‘radical cure’ to destroy the hypnozoites which are lodged in the liver 
cells. For effective treatment of such an infection primaquine is usually combined with 
chloroquine or quinine. Although the mechanism of action of primaquine is not well 
understood, it is thought to interfere with the electron transport chain in the parasite. 
Studies in a cell-free assay of protein transport through the Golgi apparatus performed by 
Hiebsch and his colleagues also showed that primaquine works by inhibiting the formation 
of functional transport vesicles (Hiebsch et al, 1991). 
 
 
1.7.5 Artemisinin or Qinghaosu 
Artemisinin, a sesquiterpene lactone, is an ancient Chinese medicine, derived from the 
plant Artemisia annua, which grows in the wild in China and elsewhere. Artemisinin acts 
on blood schizonts and young gametocytes. Derivatives of artemisinin are artemether, 
artesunate, arteether and artelinate. These compounds are quickly converted to their active 
plasma metabolite, dihydroartemisinin, which is the active compound that exhibits the anti-
malarial activity (Wilairatana et al, 1998). Though the specific mechanism of action of 
artemisinin is not known, it is thought that the iron in the iron-porphyrin complex (from the 
breakdown of haemoglobin) ‘reduces the peroxide bond in artemisinin generating high-
valent iron-oxo species resulting in a cascade of reactions that produce reactive oxygen 
radicals which damage the parasite leading to its death’ (Cumming et al, 1997). A 2005 
study investigating the mode of action of artemisinin using a yeast model also 
demonstrated that the ‘drug acts on the electron transport chain, generates local reactive 
oxygen species, and causes the depolarization of the mitochondrial membrane’ (Li et al, 
2005). Due to the short half-life of the derivatives they are recommended for combination 
with drugs of longer half-life (White, 2004).  
 
Artemisinin combination therapy (ACT) has been shown to be effective in the treatment of 
chloroquine-resistant malaria (Price et al, 1996). ACTs have become the first line 
antimalarial drug in many malaria-endemic countries, and to date there is no confirmed 
case of drug resistance. 
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Figure 1.3: Site of action of most of the available antimalarial drugs. 
 A=site of action of blood schizonticides (eg chloroquine, mefloquine, quinine, sulphadoxine, 
pyrimethamine) used in the treatment of acute disease; B=site of action of tissue 
schizonticides (eg primaquine) used for radical cure i.e. to destroy the hypnozoites (P. vivax 
or P. ovale infection); C=site of action of most of the common drugs used for 
chemoprophylaxis (eg chloroquine, mefloquine, pyrimethamine); D=site of action of 
gametocidal drugs (eg arteminsinin). 
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Figure 1.4:Chemical structures of some of the commonly used antimalarial drugs. 
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A summary of antimalarial drug targets in Plasmodium is shown in Figure 1.5  
 
 
 
Figure 1.5: Representation of an intra-erythrocytic P. falciparum trophozoite, highlighting 
key parasite intracellular compartments and the site of action of some of the major classes 
of antimalarial drugs.  
(Reproduced with permission from Fidock et al., 2004).  
 
 
1.8 Resistance to Antimalarial Drugs  
P. falciparum has developed resistance to most of the available antimalarial drugs (White, 
2004). This situation is a major public health problem, hindering the control and treatment 
of the disease. Antimalarial drug resistance is defined as the ‘ability of a parasite strain to 
survive and multiply despite the administration and absorption of drug given in doses equal 
to or higher than those usually recommended but within the tolerance level of the subject’ 
(Bruce-Chwatt, 1986). Resistance to the major antimalarial drug, chloroquine, was 
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believed to have emerged in 1957 both in Colombia and along the then Cambodia-
Thailand border area(Moore & Lanier, 1961). However it was not until 1960 that 
resistance in these areas was confirmed(Moore & Lanier, 1961;Payne, 1987). Thereafter, 
resistance to the drug spread throughout Southeast Asia in the 1970s (Chongsuphajaisiddhi 
et al, 1979). The first observation of the parasite’s resistance to the drug in Africa was 
made in East Africa (Tanzania) in 1977 (Payne, 1987;Payne, 1988). From East Africa, 
resistance to the drug spread throughout the continent. The worldwide distribution of 
parasites resistant to chloroquine is shown in Figure 1.6. Several factors have contributed 
to the rapid development and spread of parasite resistance, including human behaviour, 
vector and parasite biology, pharmacokinetics and economics (Bloland, 2001).  
 
 
 
Figure 1.6: The global distribution of malaria. 
The global distribution of malaria (in red) showing areas where Plasmodium falciparum 
resistance to the most commonly used antimalarial drugs, chloroquine and sulphadoxine-
pyrimethamine, has been documented (Reproduced with permission from Fidock et al., 
2004).  
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1.9  Vaccines to combat malaria?  
A vaccine against malaria is an important option for the control or elimination of malaria 
in disease endemic countries of the world, and progress has been made in the development 
of an effective vaccine, although there is currently no vaccine clinically available.  
 
According to Gardiner and colleagues, there are three separate but overlapping approaches 
in malaria vaccine development (Gardiner et al, 2005). The first is a pre-erythrocytic 
vaccine that would act in a way to prevent the invasion of hepatocytes by the sporozoites 
injected from the mosquito during a blood meal. The second is a blood-stage vaccine that 
would prevent development of the disease, especially in vulnerable groups such as children 
and pregnant women. The third is a transmission blocking vaccine that would prevent the 
parasites from developing in the mosquito and thereby stop transmission of the disease. 
 
A report by the Malaria Vaccine Initiative (MVI) indicates that ‘each malaria infection 
presents thousands of antigens to the human host immune system and understanding which 
of these antigens is important and thus a useful target for vaccine development has been a 
difficult task’ (MVI, 2006 [http://www.malariavaccine.org]). It is on record that the 
parasite goes through different stages in its lifecycle and at each point it presents a 
different subset of molecules for the immune system to combat, making the selection of a 
single antigen for vaccine development difficult (MVI, 2006).  
 
The presence of ‘multiple infections comprising different species and strains of parasites in 
a single episode of the disease also pose a challenge to the development of an effective 
vaccine’ (MVI, 2006). Notwithstanding these difficulties, some antigens have been 
identified and are currently receiving attention in vaccine development (Figure 1.7)  
 
Results from the field trial of a malaria vaccine named RTS, S/AS02A in Mozambique 
showed a promising outcome. The outcome indicates a reduction in the risk of malaria 
infection among children by 30% (Alonso et al, 2004). Additionally, the vaccine, which 
carries two proteins, RTS and S, recognised by the immune system reduced the risk of 
young children developing severe malaria by 77%. Bojang and his colleagues also carried 
out a randomised trial of the efficacy of RTS, S/AS02A against natural P. falciparum 
infection in semi-immune Gambian men (Bojang et al, 2001). The estimated efficacy of 
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the vaccine during the first nine months of follow up was reported as 71% (Bojang et al, 
2001). 
 
 
 
 
Figure 1.7: Antigens listed according to the stage in which they would be expected to 
provoke a protective immune response. 
 Reproduced with permission from Malaria Vaccine Initiative (MVI) 
(http://www.malariavaccine.org/mal-vac2-challenge.htm#Top). 
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1.10  Search for novel antimalarial drugs: purine 
transporters as a potential chemotherapeutic target 
The emergence and spread of P. falciparum parasites resistant to currently available 
antimalarial drugs calls for an immediate identification and development of novel 
antiplasmodial compounds. Compounds that take advantage of the unique metabolic 
pathways of the parasite are likely to make selective antimalarial drugs. In this respect, 
purine transporters of the malaria parasite can be considered good targets for novel 
antiplasmodial drugs. This is because the parasite is unable to synthesis purine de novo and 
has to salvage it from the host through nucleoside/nucleobase transporters(Kirk, 2001). 
Compounds that would inhibit these transporters could be considered as potential 
antimalarial drugs, since in the absence or reduction of purine salvage the parasite would 
be unable to synthesise nucleic acids and many common metabolites and therefore unable 
to replicate. In this regard, a well-characterised purine transporter will provide information 
that would facilitate the identification of lead compounds for future drug development. 
Alternatively, subversive substrates or cytotoxic compounds could be developed for 
selective delivery into the parasite via these transporters to cause parasite death whilst 
sparing the host cells. 
 
 
1.11 An Overview of the Biochemistry of 
Plasmodium 
The intra-erythrocytic stages of the malaria parasite obtain their basic energy needs 
through the glycolytic pathway (Sherman, 1979). It had been observed that there is more 
than 75 times utilization of glucose in infected erythrocytes than in non-infected cells 
(Ginsburg, 1994). The measurement of a high-level activity of lactate dehydrogenase 
(LDH) in parasitized erythrocytes confirms that the parasite metabolises glucose through 
glycolysis(Ginsburg, 1994). NAD is also regenerated from NADH in the parasite (Makler 
et al, 1993;Becker & Kirk, 2004). The detection in parasitized erythrocytes of some of the 
enzymes involved in the pentose phosphate pathway (PPP) indicates that PPP may be 
operational in the parasites (Sherman, 1979;Ginsburg, 1994). The PPP is likely to be the 
source of ribose sugar required by the parasite for the synthesis of nucleotides (Sherman, 
1979;Ginsburg, 1994). Although the presence of the electron transport chain and oxidative 
phosphorylation within infected erythrocytes has been reported, there is no evidence to 
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suggest the existence of the tricarboxylic acid cycle (citric acid cycle) cycle in the parasite 
(Uyemura et al, 2000). 
 
Malaria parasites obtain most of their supply of protein from the ordered degradation of 
haemoglobin. It has been reported that about 70% of the host cell haemoglobin is digested 
through a mechanism initiated by the parasite (Rudzinska et al, 1965;Krugliak et al, 2002). 
Of this quantity of protein, only 16% is utilized by the parasite to make its own protein 
(Rudzinska et al, 1965;Krugliak et al, 2002). Additionally the parasites are capable of de 
novo synthesis of some amino acids and can also salvage some of the host’s amino acid 
(Kirk, 2001;Krugliak et al, 2002). Some amino acids such as alanine, aspartate and 
glutamate can be synthesised by the parasite through the process of carbon fixation 
(Sherman, 1979). In contrast to a previous report that the parasite excretes most of the 
amino acids from haemoglobin degradation (Krugliak et al, 2002), Liu and co provided 
evidence showing that the parasites rely on haemoglobin degradation, for all its amino acid 
supply and parasite growth was enhanced when cultures were supplemented with 
isoleucine, the only amino acid absent from the haemoglobin (Liu et al, 2006). 
 
The malaria parasites require purines for the synthesis of important biomolecules such as 
DNA and RNA. Since the parasites are incapable of de novo synthesis of this important 
compound, they salvage it from the host (Ginsburg, 1994;Kirk, 2001). The primary purine 
required by the parasite is reported to be hypoxanthine (Reyes et al, 1982). Additionally 
parasites are able to convert adenosine taken up from the host to hypoxanthine through the 
process of deamination and dephosphorylation (Reyes et al, 1982). This is because P. 
falciparum possessed the purine salvage enzymes: adenosine deaminase, purine nucleoside 
phosphorylase, hypoxanthine-guanine phosphoribosyltransferase (PRTase), xanthine 
PRTase and at a lower activity level adenine PRTase and adenosine kinase (Reyes et al, 
1982). The parasite is able to synthesise its own pyrimidines from bicarbonate and 
glutamine (Kirk, 2001). 
 
The intraerythrocytic malaria parasite has most of the enzymes involved in the metabolism 
of glycerides and fatty acids (Matesanz et al, 1999;Mitamura & Palacpac, 2003). The 
parasite can thus synthesise most of its lipid requirement. 
 
The blood-stage malaria parasite possesses a functional vitamin B6 de novo biosynthesis 
pathway (Gengenbacher et al, 2006). One of the most important vitamins required by the 
Neils Ben Quashie, 2008 Chapter One  
 
19
parasite is folate, which is used in the replication of parasite DNA. Since the parasite is 
unable to utilized preformed folate, it synthesises dihydrofolate from GTP, para-
aminobenzoic acid and glutamate(Kirk, 2001). Pantothenate, the precursor of coenzyme A, 
is an essential nutrient for the intraerythrocytic stage of the malaria parasite. Yet it appears 
that the vitamin is the only one not available in the eythrocytes (Saliba & Kirk, 2001). The 
parasites, therefore, have to salvage it from the outside milieu through an H+-coupled 
transporter (Saliba & Kirk, 2001). Available evidence suggests that the only vitamin that 
the parasite does not seem to require is biotin. In support of this, growth of P. falciparum 
in the presence of several biotin antagonists, including avidin has been demonstrated 
(Geary et al, 1985). 
 
 
1.12 Mode of Transport in cells 
The lipid bilayer of cell membrane serves as a barrier, controlling the movement of polar 
molecules across the plasma membrane (Figure 1.8). This allows the cells to maintain 
concentrations of solutes in their cytosol (Alberts et al, 1994).  
Transport of inorganic ions and small hydrophilic organic molecules across this barrier is 
therefore facilitated by specific transmembrane proteins (Alberts et al, 1994). The 
membrane transport proteins have been reported to be ‘multipass transmembrane proteins 
with their polypeptide chains traversing the lipid bilayer multiple times’ (Alberts et al, 
1994). This enables specific hydrophilic solutes to cross the membrane without coming 
into contact with the hydrophobic interior of the lipid bilayer. The two major membrane 
transport proteins are carrier protein (permeases or transporters) and channel protein 
(Alberts et al, 1994). Whilst carrier protein binds the solute to be transported and 
undergoes conformational changes in order to translocate the solute across the membrane, 
the Channel protein translocate solutes by forming ‘hydrophilic pores that extend across 
the lipid bilayer, which when open allows specific solutes such as inorganic ions to pass 
through’ (Alberts et al, 1994). All channel proteins and some carrier proteins are involved 
in a transport process referred to as passive transport or facilitated diffusion (Figure 1.9) 
allowing solutes to pass through down their concentration gradient. If the solute is charged 
a combination of the influence of the electrical gradient and the concentration gradient, 
referred to as the electrochemical gradient, is the net driving force behind the translocation. 
In contrast to the above processes is simple diffusion, where solute translocation occurs 
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freely, down their concentration gradient without the involvement of channel or carrier 
proteins (see (Figure 1.9) [(Alberts et al, 1994)].  
 
 
 
Figure 1.8:The relative permeability of the lipid bilayer of cell to different classes of 
molecules. 
The smaller the molecule and the fewer hydrogen bonds it forms with water the more 
rapidly the molecule diffuses across the lipid bilayer. Redrawn from (Alberts et al, 1994). 
 
 
Active transport, which is mostly mediated by carrier proteins, is a process where solutes 
are pumped across the membrane against their electrochemical gradient (uphill). This 
process is coupled to energy (ATP hydrolysis or an ion gradient) [(Alberts et al, 1994)]. 
ABC transporter proteins belong to a super family of transporters each of which contains a 
highly conserved ATP-Binding Cassette (ABC) [(Alberts et al, 1994)]. They mostly 
function as efflux transporters (Pastor-Anglada et al, 2005). One of such class of 
transporters is the multidrug resistance (MDR) protein, which is implicated in P. 
falciparum antimalarial drug resistance.  
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Passive and active membrane transport systems exist in protozoan organisms (Tanabe, 
1990a;Tanabe, 1990b;Bakker-Grunwald, 1992). Protozoan active transporters are likely to 
use the proton-motive force whereas mammalian transport uses the sodium gradient across 
the membrane. Examples of primary active transport are ion pumps and ABC 
transporters/P-glycoproteins. The latter category is directly implicated in chloroquine 
resistance. 
 
Uptake of purines in P. falciparum is reported to be mediated by facilitated diffusion 
involving transporters located on the plasma membrane of the parasite (Parker et al, 
2000;Rager et al, 2001).   
Active uptake
(Na+ or H+ gradient)
Simple diffusion
(unaided diffusion of 
lipophilic compounds)
Nutrients
accumulated Equilibrium
Equilibrium
Facilitated diffusion
(no energy required)
Active extrusion
(ABC, P-glycoprotein)
ATP
ADP
Foreign substances
Exported from cell
 
 
Figure 1.9: Mechanism of transport in cells showing simple diffusion, facilitated diffusion, 
active uptake and active extrusion of compounds. 
Each of these processes is marked appropriately in the figure. The red dots represent the 
chemical compound being transported and the arrows shows the direction of movement of 
the compound. The blue cylinders represent the transporter in the plasma membrane of the 
cell. 
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1.13 Purine transport in human cells 
Nucleoside transporters play key roles in the salvage of nucleosides used in biosynthesis of 
nucleic acids (Baldwin et al, 1999) and in regulating endogenous adenosine concentrations 
in the human central nervous system (Mubagwa & Flameng, 2001). Additionally 
adenosine is involved in the ‘regulation of blood flow, myocardial slow action potentials, 
lymphocyte function, glucose metabolism, and neurotransmission’ (Mubagwa & Flameng, 
2001;Rosales et al, 2004). Even though the effects of adenosine involve a variety of 
different cells, ‘its action is basically inhibitory in nature and involves the interaction of 
adenosine with several adenosine-specific receptors on the cell surface, which are coupled 
to membrane-associated adenylate cyclase’ (Yeung & Green, 1983). Purine transport 
systems in human cells also mediate the uptake of many synthetic nucleoside analogues 
used in cancer (and viral) chemotherapy (Sundaram et al, 2001).  
 
Mammalian cells possess two major nucleoside transporter families: (i) equilibrative 
nucleoside transporter (ENT) and (ii) concentrative nucleoside transporter (CNT), which is 
Na+-dependent (Baldwin et al, 2004;Gray et al, 2004;Kong et al, 2004). In human plasma 
membrane, transport of nucleosides is brought about by members of ‘the concentrative, 
Na+-dependent (CNT) and equilibrative, Na+-independent (ENT) nucleoside transporter 
families’ (Gray et al, 2004;Kong et al, 2004). ‘CNTs are expressed in a tissue-specific 
fashion whilst ENTs are present in most, possibly all, cell types’ (Baldwin et al, 2004). 
 
As shown schematically in Figure 1.10, ‘the equilibrative transport system mediates 
nucleoside transport in both directions depending on the nucleoside concentration gradient 
across the plasma membrane whilst the concentrative transport system is Na+-dependent 
and the movement of nucleoside, regardless of its concentration gradient, is coupled to that 
of the sodium ion’ (Podgorska et al, 2005). 
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Figure 1.10: Nucleoside transport mediated by the concentrative nucleoside transporter 
(CNT) and equilibrative nucleoside transporter (ENT). 
There are two types of ENT, NBMPR equilibrative sensitive (es) and equilibrative insensitive 
(ei). Nuc=nucleoside; NBT1=nitrobenzylthioinosine. 
 
Four nucleoside transporters exhibiting characteristics of members of the equilibrative 
nucleoside transporter family have been identified. These transport system are reported to 
be present in various cell types (Podgorska et al, 2005). In some cases the number of these 
transport systems present is determined by the cell and tissue type (Podgorska et al, 2005). 
Although all the transporters are capable of adenosine salvage, however, their ability to 
transport the other nucleosides and nucleobases varies (Baldwin et al, 2004;Kong et al, 
2004).  
 
The first two of these transporters, designated hENT1 and hENT2, showed different 
sensitivities to the classical inhibitor, nitrobenzylmercaptopurine ribonucleoside (NBMPR) 
[(Baldwin et al, 2004;Kong et al, 2004)]. Although hENT1 and hENT2 salvage a broad 
variety of nucleoside permeants, reports indicate that hENT2 exhibits relatively lower 
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affinity for most of the permeants(Baldwin et al, 2004;Kong et al, 2004). Additionally Yao 
and her colleagues have shown that unlike hENT1, hENT2 can transport nucleobases (Yao 
et al, 2002). hENT1 have been reported to be equilibrative-sensitive (es) to the NBMPR 
whilst hENT2 was insensitive (ei) (Crawford et al, 1998)).  
 
A study by Baldwin and his colleagues indicated that the ‘topology of hENT3 is slightly 
different from the other member of the ENT family’(Baldwin et al, 2005). This transporter 
has a long (51 residue) hydrophilic N-terminal region precedingTM1 that possesses a 
putative dileucine-based endosomal/lysosomal targeting motif’ (Baldwin et al, 2005). 
Apart from being a low affinity nucleoside transporter, hENT3 also mediates the uptake of 
adenine (Baldwin et al, 2005).  
 
hENT4 was discovered quite recently and hence its transporting characteristics have not 
been fully determined. However, indications are that hENT4 has a relatively low affinity 
for adenosine (Kong et al, 2004). Concentrations of exogenous purines in mammalian cells 
are shown in Table 1.1 
 
Purine Pyrimidine 
Compounds Concentrations 
(µM) 
Compound Concentrations 
(µM) 
Adenine 0.4 Cytosine 15 
Adenosine 0.5 Cytidine 0.6 
Guanine 97 Uracil 13 
Guanosine 0.9 Uridine 52 
Hypoxanthine 172 Orotate <5 
Inosine 168 Orotidine 13 
Xanthine 20 Thymine NA 
  Deoxythymidine 0.5 
 
Table 1.1: Physiological average concentrations of salvageable purines in mammalian cells or 
tissues. 
(Reproduced from (Traut, 1994). 
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1.14 Purine metabolism in mature uninfected human 
erythrocytes 
Since mature erythrocytes lack a functional nucleus, they have a limited requirement for 
nucleotides. The mature erythrocyte lacks the enzymes for de novo purine and pyrimidine 
biosynthesis pathways (Gero & O'Sullivan, 1990). However they possess the ability to take 
up these nutrients from the external environment. The mature non-infected erythrocytes 
take up nucleosides through the NBMPR-sensitive equilibrative nucleoside transporter (es, 
ENT1)(Plagemann et al, 1988), and purine nucleobases through the facilitative nucleobase 
transporter (FNT1) (Domin et al, 1988). Both transporters are located on the plasma 
membrane of the cell. Hypoxanthine is rapidly transported across the red cell membrane by 
facilitated diffusion, so that equilibrium is reached rapidly even at millimolar 
concentrations of the oxypurine (Lassen, 1967). It has been documented that within the 
cytosol of the matured erythrocyte hypoxanthine is converted to inosine 5-monophosphate 
(IMP). However this conversion depends on the concentration of inorganic phosphate (Pi) 
present in the medium (Giacomello & Salerno, 1979): stimulation of 5-phosphoribosyl- l-
pyrophosphate (PRPP), a co-substrate of and rate-limiting step in the phosphoribosylation 
of hypoxanthine to IMP needs organic phosphate (Giacomello & Salerno, 1979). 
 
Domin and his colleagues used the inhibitor-stop method (using cold 19 mM papaverine as 
stop solution) to study the transport of purine nucleobase into mature erythrocytes (Domin 
et al, 1988). They reported that adenine (Ki = 13 ± 1 µM), guanine (Ki = 37 ± 2 µM), and 
hypoxanthine (Ki = 180 ± 12 µM) were mutually competitive substrates for the transporter. 
They further revealed that transport of the purine nucleobases was not inhibited by 
nucleosides (uridine, inosine) or by inhibitors of nucleoside transport (6-[(4- 
nitrobenzyl)thio]-9-β-D-ribofuranosylpurine, dilazep, dipyridamole). They therefore 
concluded that ‘all three purine nucleobases share a common facilitated transport system in 
human erythrocytes which is functionally distinct from the nucleoside transporter’. 
Since human erythrocytes lack the ability to convert IMP to AMP, adenosine or adenine 
have to be converted to adenine nucleotides in order to maintain ATP level within the 
erythrocyte. There is, therefore, a rapid uptake of adenosine from the extracellular fluid 
and this probably explains the observation of a low level adenosine concentrations in 
human blood (generally reported to be less than 1 pM) [(Schrader et al, 1983)]. Uptake of 
adenosine into matured erythrocyte is reported to be predominantly through the 
equilibrative nucleoside transporter (Plagemann et al, 1988). In matured human 
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erythrocytes, adenosine is usually used as a substrate for adenylate synthesis (Perrett, 
1976). The nucleoside can either be phosphorylated to AMP by adenosine kinase, or 
deaminated to inosine by adenosine deaminase (see Figure 1.11)[(Paglia et al, 
1986;Rapoport et al, 1987)]. Due to the presence of high adenylate kinase activity within 
the cytosol of the erythrocytes, AMP is rapidly phosphorylated to ATP (Mohrenweiser et 
al, 1981;Beutler, 1983). The physiological concentrations of salvageable purines in 
mammalian cells or tissues are shown in Table 1.1. 
 
 
Figure 1.11:Schematic representation of adenosine metabolism in human erythrocytes. 
It also shows the relation between metabolism of adenosine and energy. Abbreviations: Ads, 
adenosine; AMP, adenosine monophosphate; ADP, adenosine diphosphate; ATP, adenosine 
triphosphate; Glu, glucose; Hx, hypoxanthine; IMP, inosine monophosphate; Ins, inosine; 
Lac, lactic acid; R1P, ribose-1-phosphate; AK, adenylate kinase; AdsK, adenosine kinase; 
AdsD, adenosine deaminase; AMPD, AMP deaminase; PNA, purine-5’-nucleotidase; PNP, 
purine nucleoside phosphorylase; PPRT, purine phosphorybosyl transferase; ATPases, sum of 
ATP consuming processes. (Reproduced with permission from (Komarova et al, 1999). 
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1.15 Transportation systems in infected erythrocytes 
Invasion of the erythrocyte by the malaria parasite poses another form of challenge to the 
parasite. Within the erythrocytes, the malaria parasite is faced with the problem of 
obtaining the nutrients needed for synthesis of required biomolecules. To reach the cytosol 
of the parasite, nutrients from exogenous sources have to cross the host plasma membrane, 
the parasitophorus vacuole membrane and finally the parasite’s own plasma membrane 
(Figure 1.12). Each of these membranes possesses unique properties, which influence the 
movement of compounds across them (Kirk, 2001). To facilitate the parasite’s access to an 
exogenous source of these essential nutrients, transporters for different groups of 
compounds are located in the membrane barriers. In order to increase parasite’s nutrient 
acquisition after invasion, there occurs formation of a broad specificity channel-like system 
on the host plasma membrane for the uptake of various kinds of nutrients (Cabantchik, 
1989;Elford et al, 1990;Cabantchik, 1990). The induced pathway (shown schematically in 
Figure 1.12), which results in an increased ability of parasite-infected erythrocytes to take 
up nutrients, is referred to as the New Permeation Pathway, NPP (Kirk, 2001). Details of 
the channel are discussed in the next section of this thesis. Currently no evidence exists to 
suggest that the parasite introduces other salvage mechanisms in addition to the NPP on the 
erythrocyte membrane to maximize the uptake of essential nutrients.  
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Figure 1.12: Transport systems before and after parasite invasion of the erythrocyte  
(Redrawn from Kirk (2001); http://sites.huji.ac.il/malaria/maps/prbc.html). 
 
 
 
1.15.1 The New Permeation Pathway 
The NPP is induced in the host plasma membrane of the malaria parasite at about 10-20 
hours post invasion (Kirk, 2001). The NPP has been shown to be a non-saturable channel-
like system with preference for anionic compounds (Desai et al, 2000). According to 
reports the pathway is responsible for the uptake of nucleosides, amino acids and sugars 
among others (Desai et al, 2000;Kirk, 2001;Krishna et al, 2002). However as will be 
shown later in this thesis the NPP plays at best a minor role in the uptake of purine 
nucleoside into P. falciparum infected erythrocytes.  
 
Classical anion channel inhibitors such as furosemide and 5-nitro-2- (3-
phenylpropylamino) benzoic acid (NPPB) have been demonstrated to block the uptake of 
permeant through the NPP (Kirk et al, 1994;Kirk & Horner, 1995;Kirk, 2001). Using the 
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Neils Ben Quashie, 2008 Chapter One  
 
29
patch-clamp technique, it was demonstrated that the NPP is localised in the host plasma 
membrane of P. falciparum infected human erythrocytes (Desai et al, 2000;Egee et al, 
2002;Huber et al, 2002). 
 
Various models speculating on the origin of the NPP have been published (Figure 1.13).  
Whilst one model suggests that the NPP is a single channel type, another model depicts it 
as originating from at least three separate channel types (Huber et al, 2002;Duranton et al, 
2003). Others have also suggested that the NPP originates from an upregulation and/or a 
modification of endogenous pathways 
 
Until analysis of the NPP is performed at the molecular level, it will remain unclear 
whether it is an upregulated/modified endogenous membrane transporter or whether it 
originates from proteins synthesized by the parasite and inserted into the host plasma 
membrane.  
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Figure 1.13: Models for the formation and induction of the new permeability pathway (NPP) 
in P. falciparum-infected human RBCs. 
Abbreviations; cystic fibrosis transmembrane regulator, CFTR; volume-regulated anion 
channel, VRAC; chloride channel family, ClC; the anion exchanger, Band 3. Re-drawn from 
(Staines et al, 2004). 
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1.15.2 The Parasitophorous Vacuole Membrane  
During parasite invasion of the erythrocyte, the indentation created at the meeting points of 
the two cells continues to develop as the parasite moves inward into the erythrocyte (Ward 
et al, 1993). Eventually the parasite becomes completely enveloped by a membrane 
referred to as the parasitophorus vacuole membrane (PVM) (Ward et al, 1993). The 
parasite therefore has its own plasma membrane and sits within a parasitophorus vacuole 
enclosed by the PVM.  
 
Using fluorescent probes, it has been demonstrated that the PVM is derived from the host 
cell membrane ((Ward et al, 1993). Desai and colleagues used the cell-attached patch-
clamp method to demonstrate that pores existing in the PVM allow low molecular weight 
compounds to move freely through the membrane (Desai et al, 1993). ‘These channels 
were open more than 98% of the time at the resting potential of the PVM’ (Desai et al, 
1993). 
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1.16 Chemical structures of purines 
Purines can be grouped as oxy-purine or amino purine depending on which chemical group 
is present at position 6 of the purine ring. Adenine is a 6-amino purine whilst hypoxanthine 
is 6-oxy purine. Guanine is 2-amino-6-oxy purine and xanthine is a 2, 6-dioxy purine. 
Nucleosides consist of a purine base attached to a ribose sugar (Figure 1.14). 
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Figure 1.14: Chemical structures of purines. 
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1.17 Salvage and metabolism of purine in parasitic 
protozoa 
Purine nucleosides are important requirement for the growth and development of all 
protozoans. The compounds are necessary for the synthesis of biomolecules such as the 
hereditary material, DNA (Gherardi & Sarciron, 2007). Purines are also constituents of co-
enzymes, such as nicotinamide adenine dinucleotide (NAD), which play significant roles 
in the modulation of enzymatic reactions. Purines also constitute the backbone for the 
synthesis of ATP during energy metabolism in most organisms. 
 
Nucleoside and nucleobase being hydrophilic compounds cannot easily diffuse across the 
lipid bilayer of the plasma membrane of the protozoan parasite. Specialised transport 
system therefore exist in the parasite for their translocation (Cohn & Gottlieb, 1997;Carter 
et al, 2000). Salvage of purine nucleobases or nucleosides in protozoa is mediated by 
various transporters, which are localised in the plasma membrane of the parasites 
(Landfear et al, 2004). Some protozoans have been shown to possess two nucleoside 
transporters in addition to one or more transporters for the salvage of nucleobase’ (de 
Koning et al, 2003). All the nucleoside transporter genes identified in protozoa up to date 
have been found to belong to the equilibrative nucleoside transporter family, which is 
described in detail in section 1.19. Studies of these transporters at the molecular level have 
allowed for a better understanding of the physiology of the parasites. The purine metabolic 
pathway for P. falciparum is shown in Figure 1.15. 
 
 
1.18 Purine metabolism in P. falciparum 
An estimated 80% of the purine content of erythrocytes exists in the form of ATP, which 
could be a good source of purine for the growing parasite. However, work done in vitro has 
revealed that the parasites are unable to incorporate this form of nucleotides directly (Tracy 
& Sherman, 1972). Berman and co-workers reported that no more than 2% of the purine 
required by P. falciparum could be met by the intracellular stores of purine nucleotides, 
implying that most of this essential nutrient should come from exogenous source (Berman 
et al, 1991).  
 
Although it has been documented that any of the purines, including hypoxanthine, guanine, 
adenine, inosine and adenosine can satistisfy the purine requirement of the growing P. 
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falciparum parasite (Marr et al, 2003), available evidence indicates that hypoxanthine is 
the preferred purine required by the malaria parasite for nucleotide synthesis (Berman et al, 
1991). Adenosine can be converted to hypoxanthine through deamination by adenosine 
deaminase and dephosphorylation by purine nucleoside phosphorylase (Daddona et al, 
1984). Details of interconversion of the purines in P. falciparum and the enzymes involved 
are shown in Figure 1.15. The important contribution of hypoxanthine to the growth and 
development of the malaria parasites had been demonstrated in vitro. By making 
hypoxanthine unavailable to the parasite, through the addition of xanthine oxidase to the 
culture medium, it was shown that parasite growth was retarded (Berman & Human, 
1990;Berman et al, 1991). Asahi and colleagues also demonstrated that addition of 15-
150µM hypoxanthine into culture medium enhance growth of malaria parasites (Asahi et 
al, 1996).  
 
The malaria parasites have been shown to be able to metabolise adenosine, guanosine, and 
guanine. However, there is much controversy with regard to utilisation of adenine in the 
parasite. Some reports have shown the absence of the gene encoding adenine 
phosphoribosyltransferase (APRT) and methylthioadenosine phosphorylase in any of the 
Plasmodium spp (Chaudhary et al, 2004;Ting et al, 2005), suggesting that the nucleobase 
cannot be metabolised in the parasite’s cytosol. Additionally absence of the activity of 
adenine deaminase in the parasite has been reported. These reports raises the question of 
whether Plasmodium spp is capable of utilising adenine in biomolecule synthesis. 
However, the characterisation of APRT from P. chabaudi and P. falciparum reported by 
Walter and konigk, (1974) and Queen, (1989) respectively heightens the aforementioned 
controversy(Walter & Konigk, 1974;Queen et al, 1989). Other reports indicating that P. 
falciparum is able to grow in vitro with adenine as sole purine source (Geary et al, 1985) 
and that P. knowlesi incorporated adenine into nucleic acids (Gutteridge & Trigg, 1970) 
must be taken with caution. This is because adenine is easily converted to hypoxanthine in 
the erythrocyte cytosol and the growth observed could be due to the utilisation of the 
formed hypxanthine rather than adenine. Van Dyke has demonstrated that the parasite can 
incorporate adenine into nucleic acids but only at 1% of the efficiency by which 
hypoxanthine is incorporated into free parasites and 2% at parasitized cell level (Van 
Dyke, 1975). 
 
During purine metabolism in the cytosol of the parasite, hypoxanthine is converted to 
inosine monophosphate through the action of hypoxanthine phosphoribosyltransferase 
Neils Ben Quashie, 2008 Chapter One  
 
34
(Berman et al, 1991). The compound is finally converted to ATP and GTP, which are used 
in the synthesis of RNA or DNA (Figure 1.15). 
 
 
 
Figure 1.15: The purine pathway in P. falciparum. 
Abbreviations: ADSS, adenylosuccinate synthase; ADSL, adenylosuccinate lyase; GMP, 
guanosine monophosphate; NMK, nucleoside monophosphate kinase; NDK, nucleoside 
diphosphate kinase; NK, nucleoside kinase; APRT, adenine phosphoribosyltransferase; HPRT, 
hypoxanthine phosphoribosyltransferase; GPRT, guanine phosphoribosyltransferase; IMP, 
inosine 50-monophosphate; XPRT, xanthine phosphoribosyltransferase; ADA, adenosine 
deaminase; and PNP, purine nucleoside phosphorylase; XMP, xanthosine monophosphate. 
Although literature report the conversion of adenine to AMP current evidence is not 
supportive of this. Reproduced with permission from: (Gherardi & Sarciron, 2007).  
 
 
1.19 The Equilibrative Nucleoside Transporters  
The equilibrative nucleoside transporter are a family of protein which allows facilitated 
diffusion of nucleosides, such as adenosine, down their concentration gradients across cell 
membranes (Hyde et al, 2001). However some report suggest they can act as proton-
dependent, concentrative transporters.  
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Members belonging to the ENT family possess 11 transmembrane (TM) spanning 
segments with a cytoplasmic N-terminus and extracellular C-terminus (Figure 1.16) 
(Baldwin et al., 2000 [http://www.astbury.leeds.ac.uk/Report/2000/Baldwin.2.htm]). TM 
3-6 region in the mammalian ENT is implicated in solute recognition (Hyde et al, 2001;de 
Koning et al, 2005). Apart from transportation of nucleoside, ENT can also transport 
nucleobases (Parker et al, 2000). Additionally they have been reported to be targets for 
coronary vasodilator drugs and can also act as a route for the uptake of cytotoxic drugs into 
human and protozoan cells (Molina-Arcas et al, 2006). The ENT family has been reported 
in mammals, plants, yeast, insects, nematodes and protozoa among others (Hyde et al, 
2001;Acimovic & Coe, 2002;Martin et al, 2005). 
 
 
 
Figure 1.16: Topology of mammalian members of the ENT family. 
Reproduced with permission from Baldwin et al., 2000; 
http://www.astbury.leeds.ac.uk/report/2000/baldwin.2.htm). 
 
Transport through the ENT, which was first identified at the molecular level in 1997 
(Griffiths et al, 1997) is reported to be equilibrative (Parker et al, 2000). On the basis of 
their sensitivity to nitrobenzylthioinosine (Nitrobenzylmercaptopurine riboside; 
NBMPR), members of the ENT family can be either equilibrative sensitive (es) or 
equilibrative insensitive (ei). The es subclass is inhibited by nanomolar concentrations of 
NBMPR (Ki: 0.1-10 nM) whilst the ei subclass, are insensitive to NBMPR at micromolar 
concentrations (Baldwin et al, 2005). Additionally, transporters of the es-type are inhibited 
by the coronary vasodilators such as dipyridamole (see Figure 1.17 for structure) and 
dilazep while ei-type transporters are not affected by these compounds. 
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In 1997 Griffiths and his colleagues reported the cloning from human placenta of es and ei 
transporters, which they named hENT1 and hENT2 respectively (Griffiths et al, 1997). 
Both hENT 1 and hENT2 were observed to transport a broad range of purine and 
pyrimidine nucleosides, while hENT2 is also capable of transporting nucleobases (Baldwin 
et al, 2004;Baldwin et al, 2005). Two other human nucleoside transporters, designated 
hENT3 and hENT4 have also been identified (Kong et al, 2004;Baldwin et al, 2005). 
 
 
 
Figure 1.17: Structures of some of the inhibitors of the exogenous purine transporters. 
 
 
1.20 Identification of ENT transporter genes in 
Plasmodium falciparum 
In 2000, Baldwin and his group did data-mining of the malaria-genome database for 
homologues of mammalian nucleoside transporters that could be responsible for purine 
salvage in P. falciparum (Parker et al, 2000). They identified a gene that is homologous to 
the mammalian ENT family. The gene, which was later isolated and cloned, encodes a 
protein of 422 amino acids with 11 predicted trans membrane domains. The gene was 
originally named PfENT1 with an accession number, PF13_0252.  
 
Oocytes of Xenopus laevis were injected with PfENT1 RNA transcript and maintained in a 
modified Barth’s medium supplemented with 5% horse serum, for two days for the 
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expression of the protein. The kinetic properties of the expressed purine transporters were 
then investigated. PfENT1, was found to be capable of transporting 3’-deoxynucleoside 
analogues such as the antiviral drug 3'-azido-2', 3’-dideoxythymidine (AZT). Unlike the 
mammalian ENT transporters, PfENT1 was not inhibited by NBMPR and by coronary 
vasodilators such as dipyridamole, which are known to inhibit members of the mammalian 
ENT family (Parker et al, 2000). PfENT1 was found to be a saturable transporter of 
nucleosides and nucleobases (Parker et al, 2000). A similar protein was reported 
simultaneously by a different group (Carter et al, 2000). The gene, which they named 
PfNT1, was found to be identical to that reported by Parker and colleagues (PfENT1), 
except for a single nucleotide difference at codon 385: with leucine reported by Parker and 
co and Phenylalanine by Carter and his colleagues. Kinetic data presented on the transport 
activities of the two proteins also differed markedly. Detailed comparison of the two 
studies is presented elsewhere in this thesis.  
 
Further data mining of the malaria genome database revealed the presence of additional 
members of the ENT family. A gene denoted MAL8P1.32, is annotated in the genome 
database as a putative nucleoside transporter (Martin et al, 2005). The genes with 
accession numbers PFA0160c and PF14_0662 respectively have also be found to belong to 
the ENT family (Martin et al, 2005). Detailed analysis of each gene indicates that they 
probably encode for proteins with secondary structure similar to that of the ENT family 
(Martin et al, 2005).  
 
The genes denoted PFA0160c, MAL8P1.32 and PF13_0252 were reported to have similar 
expression profiles, with an increasing abundance of the mRNA between 16 and 24 hours 
after merozoite invasion of the erythrocyte, and reaching a peak in 32 hours post invasion 
(Martin et al, 2005). PF14_0662 was shown to differ slightly, with mRNA levels 
increasing in abundance between 8-20 hours, reaching a peak around 36 hours post-
invasion. 
 
Neils Ben Quashie, 2008 Chapter One  
 
38
 
Figure 1.18: Stage-dependent gene expression of the four P. falciparum members of the 
equilibrative nucleoside transporter family, throughout the intraerythrocytic cycle of the 
parasite. 
RT-PCR was conducted to semi-quantify the level of gene expression in ~1.5 × 104 
parasitized cells at each growth stage. Relative expression (y-axis) is the ratio of the density 
of the band from the PCR product at each time point in the life cycle relative to that at the 
time point giving the largest yield of PCR product. Ratios calculated from replicate gels from 
the same PCR were averaged before the data from the two time courses (carried out 
approximately 4 months apart and each consisting of ≥ 2 PCRs) were combined to give the 
mean ± S.E. For comparison, the relative amount of total RNA in the parasitized cell over the 
same growth stages is also presented (dotted line)’. Reproduced with permission from 
(Martin et al, 2005). 
 
 
 
1.21 Cellular location of P. falciparum purine 
transporters 
The location of ENT designated PfNT1 in the malaria parasite has been determined 
through the application of techniques such as deconvolution immuno-fluorescence and 
immuno-electron microscopy (Rager et al, 2001). The procedure involves the initial 
stimulation of the production of polyclonal antisera against the NH2-terminal 36 amino 
acids of PfNT1 in rabbits. Western blot analysis of parasite lysates revealed that the 
antibodies were specific for PfNT1 and that ‘the level of PfNT1 protein in the infected 
erythrocyte was regulated in a stage-specific fashion’ (Rager et al, 2001). Additionally, the 
amount of PfNT1 polypeptide was reported to increase dramatically during the early 
trophozoite stage reaching its maximal level in the late trophozoite and schizont stages. 
Following up with a deconvolution and immunoelectron microscopy using the prepared 
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monospecific antibodies, the group of Ullman concluded that ‘PfNT1 is localized 
predominantly, if not exclusively, to the plasma membrane of the parasite and not to the 
parasitophorous vacuolar or erythrocyte membranes’ (Rager et al, 2001). The locations of 
the transporters encoded by the three other putative ENT genes in P. falciparum have not 
yet been elucidated. 
 
 
1.22 Purine antimetabolites as antimalarial drugs  
Depriving malaria parasites of their purine requirements, through controlled blockage of 
the salvage pathways is certain to cause parasite death, as shown by (El Bissati et al, 
2006). Additionally, the purine salvage system present in the parasite could be utilized to 
deliver cytotoxic compounds into the parasite to cause its death. Compounds that mimic 
purine in structure (analogues) and in other chemical properties could be used to block 
components of the purine salvage pathways in the parasite. Alternatively, nucleotide 
analogues may be built into nucleic acids, or interact with the binding sites of enzymes 
using ATP or GTP as substrates, and thus disrupt cellular functions and/or replication. 
In the light of this, purine analogues have become the focus of intense study in the search 
for novel antimalarial drugs. 
 
 In 1994, Coomber and his colleagues investigated the antiplasmodial activities of some 
adenosine analogues (Coomber et al, 1994). They reported that alterations of the purine 
ring at the 7 or 8 positions significantly increased the toxicity of the compound against P. 
falciparum: sangivamycin (7-deaza-7-amido-adenosine), tubercidin (7 deaza-adenosine), 
6-methylamino-deoxyadenosine, 8-aza-2-amino-deoxy-adenosine and 2-chloro-adenosine 
(Figure 1.19) were found to inhibit parasite growth within IC37 range of 0.3-11µM. 
 
Smeijsters and his colleagues (1999) evaluated forty-eight acyclic nucleoside phosphonates 
for in vitro antiplasmodial activities(Smeijsters et al, 1999). They reported that only the 
derivatives with a hydroxyl group attached to the acyclic sugar moiety were potent 
inhibitors of growth. The two most active analogues were (S)-9-(3-hydroxy-2-
phosphonylmethoxypropyl) adenine ((S)-HPMPA, and (S)-3-deaza-HPMPA (Figure 1.20). 
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Figure 1.19: Chemical structures of adenosine analogues. 
Source: (Coomber et al, 1994). 
 
 
 
 
Figure 1.20: Structural formula of HPMPA, an acyclic purine nucleoside phosphonate. 
Source: (Smeijsters et al, 1999). 
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Queen and her colleagues also determined the susceptibility of P. falciparum to 64 purine 
and pyrimedine analogues in vitro. Twenty two of the analogues produced an IC50 of 50 
µM or less (Queen et al, 1990).  
 
Recently, Rodenko and his colleagues tested 2,N6-disubstituted adenosine analogues in 
vitro for their antiprotozoal activities (Rodenko et al, 2007). They reported that those with 
promising antiplasmodial activity have large aromatic substitutions, such as N6-2,2-
diphenylethyl and naphthylmethyl. This observation suggest that the mode of action of the 
compounds was through aromatic stacking with haeme in the digestive vacuole of 
Plasmodium (Rodenko et al, 2007). 
 
The cyclin-dependent kinases (CDKs), which are essential for the regulation of the 
eukaryotic cell cycle were the target of a group of purine-derived kinase inhibitors tested 
by Harmse and his colleagues (Harmse et al, 2001). The group reported that ‘subfamilies 
of purines with moderate to poor activity against CDK1/cyclin B activity showed 
submicromolar activity against P. falciparum’. 
 
Studies by Brown and co also show that L-stereoisomer analogues of D-coformycin 
selectively inhibited P. falciparum adenosine deaminase (ADA) in the picomolar range 
(Brown et al, 1999). They further demonstrated that L-nucleoside analogues, L-adenosine, 
2,6-diamino-9-(L-ribofuranosyl)purine and 4-amino-1-(L-ribofuranosyl)pyrazolo[3,4-d]-
pyrimidine were selectively deaminated by P. falciparum ADA,whilst L-thioinosine and L-
thioguanosine were not.  
 
 
1.23 Nucleoside and Nucleobase transport in other 
apicomplexa 
Toxoplasma gondii, which causes toxoplasmosis, is an obligate intracellular parasite 
belonging to the apicomplexan of which P. falciparum is also a member. Like P. 
falciparum, T. gondii parasites obtain their supply of purine from exogenous sources 
because they are incapable of de novo synthesis (Schwartzman & Pfefferkorn, 1982;Krug 
et al, 1989). Since Toxoplasma lives in nucleated cells it obtains free purines from the host 
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cell cytoplasm by diffusion through pores in the parasitophorous vacuole membrane 
(Schwab et al, 1994). 
 
 It has been shown that adenosine is the major purine salvaged by T. gondii. Adenosine 
enters the cytoplasm through transporters (Krug et al, 1989): a low affinity, saturable 
adenosine transporter was identified in experiments performed with isolated tachyzoites 
(Schwab et al, 1995). This transporter, with a Km of 230µM, was reported to be inhibited 
by dipyridamole with an IC50 of 0.7µM. Uptake of hypoxanthine, adenine and inosine 
through this transporter was also reported to be inhibited at 10µM. This transporter is 
encoded by the TgAT1 gene, which belongs to the ENT family, and was the first purine 
transporter gene to be cloned from among the members of the apicomplexan group 
(Chiang et al, 1999). When expressed in Xenopus oocytes, the transporter was found to 
have broad substrate specificity for purines.  
 
De Koning and colleagues identified a nucleobase transporter in T. gondii, which was 
denoted TgNBT1 and observed to transport hypoxanthine with Km of 0.91µM. This 
transporter is reported to be inhibited by guanine and xanthine. This was the first high 
affinity nucleobase transporter to be identified in apicomplexan parasites. De Koning and 
co-workers also identified a nucleoside transporter named TgAT2, with higher affinity than 
TgAT1 (Km value of 0.28 µM) [(de Koning et al, 2003)]. TgAT2 was found to recognise 
several nucleoside analogues, making it a good target for novel drugs ((de Koning et al, 
2003). 
 
Very little is known about purine transporters of other apicomplexan parasites. 
Plasmodium berghei reportedly expresses a high affinity adenosine/hypoxanthine 
transporter with relatively low affinity for inosine, and a separate adenine transporter 
(Hansen et al, 1980). Purine uptake in the avian malaria parasite, P. lophurae is reported to 
be similar to that reported for P. berghei, although the report provides few details(Tracy & 
Sherman, 1972). An adenosine transporter has also been reported in Babesia bovis, but 
again few details are known (Matias et al, 1990). 
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1.24 Studies on P. falciparum purine transport 
published after conclusion of our own 
characterisation of purine salvage in isolated 
trophozoites. 
In the course of the studies reported in this thesis, two reports on purine transport were 
published. In the first, El Bissati and co-workers disrupted the gene encoding the 
nucleoside transporter PfNT1 in P. falciparum and studied the characteristics of the 
resultant phenotype (El Bissati et al, 2006). They demonstrated that parasite clones with a 
disrupted PfNT1 were auxotrophic for hypoxanthine, inosine, and adenosine under 
physiological conditions, and could only survive when the growing medium was 
supplemented with high levels of purine. Parental cells with an intact PfNT1 gene were 
able to survive on much lower purine concentrations. Uptake of hypoxanthine into parasite 
clones with a disrupted PfNT1 was observed to be significantly reduced, whereas 
adenosine and inosine transport were only partially affected. The study by El Bissati and 
co-workers provided evidence for conversion of exogenous purine into hypoxanthine using 
host enzymes followed by PfNT1-mediated transport into the parasite. 
 
In the second publication, Downie and his colleagues investigated the kinetic characteristic 
of isolated P. falciparum parasites (Downie et al, 2006). They reported that the transport of 
nucleosides into the parasite was, in the case of adenosine, inosine and thymidine, very 
fast, and saturable. A Michaelis-Menten plot revealed that the transporter has a low affinity 
for these purines. For example, the Km for adenosine was calculated as 1.45 ± 0.25 mM. 
There was also a report of cross-competition for adenosine, inosine and thymidine, but not 
cytidine. They concluded that the transporter is a major route for the uptake of nucleosides 
across the parasite plasma membrane. This conclusion, that PfNT1 was responsible for the 
low affinity adenosine transport, was backed up by an expression of this gene in Xenopus 
oocytes (Downie et al, 2006). 
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1.25 Aims and objectives of study 
The main aim of this study is to investigate the mechanism of purine transport in the 
intraerythrocytic stage of P. falciparum parasites. 
The specific objectives include: 
(i) To identify purine transporters in the plasma membrane of saponin-freed P. 
falciparum trophozoites (isolated P. falciparum parasites) 
(ii) To investigate the mechanism of purine transport in Percoll-concentrated intact 
P. falciparum infected erythrocytes 
(iii) To investigate the interaction between substrate and transporter binding sites 
that affect their affinity (Km) and selectivity, and the role they play in the 
salvage of purine from the host 
(iv) To test purine analogues for antiplasmodial activities against P. falciparum  
(v) To disrupt the genes encoding the equilibrative nucleoside transporter (ENT) 
and study the kinetic characteristics of the resultant parasites 
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CHAPTER TWO 
2 Materials and methods 
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2.1 In vitro cultivation of P. falciparum   
2.1.1 Parasite lines/clones 
All transport experiments were performed with the standard 3D7 drug-sensitive laboratory 
clone of P. falciparum at the University of Glasgow, Glasgow. The parasites were 
originally obtained from David Walliker, University of Edinburgh, UK. Clone 3D7 is 
known to be sensitive to chloroquine and pyrimethamine (Walliker et al, 1987). The K1 
line of parasites was also used in the drug sensitivity assays; this line is reported to be 
resistant to chloroquine and pyrimethamine (Lambros & Vanderberg, 1979;Thaithong & 
Beale, 1981). 
 
2.1.2 Preparation of culture media 
Parasites were cultured in RPMI 1640 medium supplemented with 5.94g/L HEPES 
(Sigma) and 50mg/L hypoxanthine (Sigma) (incomplete medium) to which 0.21% 
NaHCO3 (w/v) and 10% heat-activated normal human serum were added (complete 
medium). Human serum of group AB was obtained from the Glasgow and West Scotland 
Blood Transfusion Service. The serum was pooled from several donors, heat-inactivated at 
56oC for 1 hour to remove complement prior to use. 
 
2.1.3 Processing of red blood cells for parasite culture 
Fresh human whole blood used for the parasite cultures and uptake experiments was 
obtained from the Glasgow and West of Scotland Blood Transfusion Service. Blood of any 
group was supplied, although the most common was from donors with blood group O, 
rhesus positive. The blood was washed to remove the plasma, buffy coat and anticoagulant 
by centrifugation at 630 × g, 10 min, followed by removal of the supernatant and re-
suspension of the pellet in an equal volume of incomplete RPMI 1640. The washing was 
repeated twice more, and then the erythrocytes were finally re-suspended in an equal 
volume of incomplete RPMI 1640 (approx 50% packed cell volume (PCV). 
 
2.1.4 Culturing of malaria parasites 
Human erythrocytes infected with P. falciparum were maintained in continuous culture 
using standard method (Trager & Jensen, 1976;Haynes et al, 1976). The culture consisted 
of 5% suspension of human erythrocytes in complete RPMI 1640 medium. The culture was 
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kept at 37°C under a gas mixture of 1% O2, 3% CO2, and 96% N2. Determination of 
parasitaemia and changing of the medium was done daily. The culture was kept below 5% 
parasitaemia at all times. 
 
 
2.1.5 Synchronization of culture 
Using the method described by (Lambros & Vanderberg, 1979), a predominantly ring stage 
culture was synchronised by incubation with 5% w/v D-sorbitol (Sigma) for ten minutes. 
While the uninfected erythrocytes are impermeable to sorbitol, the changes caused in the 
erythrocyte permeability by the developing parasites allow sorbitol to enter the 
erythrocytes causing lysis of the cells. Therefore, incubation of parasite pellets with 
sorbitol results in cell suspensions having only ring stage parasites estimated to be up to 18 
hours old (Jensen, 1988). It has been demonstrated that intraerythrocytic parasites growth 
is not affected by their exposure to sorbitol (Lambros & Vanderberg, 1979;Ginsburg & 
Stein, 1987;Nakazawa et al, 1995). Briefly, the culture was centrifuged for 5 minutes at 
700 × g and the supernatant removed and discarded. The parasite pellet was then treated 
with ten pellet volumes of 5% D-sorbitol (w/v) and incubated at room temperature for 10 
minutes. After incubation, the culture was centrifuged at 630 × g for 5 min to pellet the 
cells and the supernatant removed and discarded. The cells were washed three times in 
incomplete RPMI1640 to remove traces of the sorbitol. Thin blood films were prepared, 
stained with 5% Giemsa’s stains and examined under the light microscope to determine the 
parasitaemia. The pellets were finally resuspended in complete RPMI 1640 and washed 
blood was added to give a PCV of 5% and about 1% parasitaemia, in a total volume of 
25ml. Incubation of the synchronised culture was resumed at 37°C under conditions 
previously described. A second round of synchronisation was performed if examination of 
the culture, 24 hours post-synchronisation, showed the presence of a high percentage of 
ring-stage parasites. This two-stage procedure results in an almost completely 
synchronised culture, although synchronisation breaks down after 1-2 cycles. 
 
 
2.1.6 Staining of malaria parasites 
Parasitaemia was estimated from methanol-fixed, Giemsa-stained blood smears. A thin 
film was prepared on a microscope slide and allowed to air dry. The film was fixed by 
brief contact with absolute methanol. The alcohol was allowed to evaporate and the slide 
put in a staining jar containing freshly prepared 5% Giemsa’s stain (v/v) in Giemsa’s 
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buffer, pH 7.4. After staining for 40 minutes at room temperature, the slide was rinsed with 
tap water, air-dried and examined under the light microscope with 1000× magnification. 
Parasitaemia was determined by counting both uninfected and parasite-infected 
erythrocytes in at least ten microscopic fields and expressing the parasite-infected 
erythrocytes as a percentage of the total erythrocytes. 
 
 
2.1.7 Cryopreservation of malaria parasites 
Parasite material was stored by cryopreservation using the method described by Jensen and 
colleagues (Jensen et al, 1979). A culture with a predominantly ring stage P. falciparum 
parasites (parasitaemia>2%) was centrifuged at 630 × g for 5 minutes to pellet the cells. 
The supernatant was carefully removed and discarded.  A volume equal to the volume of 
the pellet, of deep freezing solution (28% glycerol, 3% sorbitol, 0.65% NaCl) was added 
drop wise, whilst mixing gently with a Pasteur pipette. A volume of 0.3-0.5 ml of the 
mixture was aliquoted into cryo-ampoules (Nunc), labelled with pencil or waterproof pen 
and stored in liquid nitrogen immediately. 
 
 
2.1.8 Thawing of cyopreserved malaria parasites 
The method used to thaw cryopreserved malaria parasites was as described by Aley and co 
(Aley et al, 1984). Briefly, the frozen ampoule was rapidly thawed at 37°C and the 
contents transferred to a 15 ml centrifuge tube, and the cell volume, V, noted. A fifth of the 
cell volume V of thawing solution I (12% NaCl solution) was added drop-wise and mixed 
well with a Pasteur pipette. The mixture was left to stand for 2 minutes at room 
temperature to enable the freezing mix to be drawn out. Ten times the volume V of 
thawing solution II (1.6% NaCl solution) was added. The mixture was centrifuged at 630 × 
g for 5 min and the supernatant removed and discarded. Ten times the volume V of 
thawing solution III (0.9% NaCl plus 0.2% glucose solution) was then added with gentle 
mixing, and after centrifugation at 630 × g, 5 min, the cells were finally resuspended in 
3ml of complete RPMI 1640. This was transferred into a culture flask and a drop of blood 
was added and the flask was gassed and incubated as previously described.  
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2.1.9 Red blood cell counts using Improved Neubauer 
haemocytometer 
A counting chamber and cover slip were cleaned with ethanol to remove the presence of 
any grease. The cover slip was then aligned over the counting chamber and a gently 
downward pressure applied till “Newton’s rings” are produced between the cover slip and 
the chamber. The chamber was filled with the diluted sample by capillary action. Cells 
were counted under the light microscope using the ×10 objective (100 × magnification) 
Each square in the counting chamber is 1mm2 and the chamber depth is 0.1mm; therefore 
the volume overlying each square is 0.1mm3 (or 0.0001ml = 0.1µl). 
Therefore, cell count per ml (Cells/ml) = total count × 1000 × dilution factor 
 
 
2.2 Purine transport assays 
2.2.1 Chemicals used in the transport assays 
[2,8-3H] Adenine was purchased from Moravek (USA). [2,8-3H] adenosine and [8-3H] 
hypoxanthine were obtained from Amersham Pharmacia Biotech (UK). Unlabelled 
adenine, guanine, hypoxanthine, xanthine, inosine, adenosine, guanosine, uracil and 
thymine were obtained from Sigma. The chemicals used are of the highest purity available. 
The JA- and NA-compounds (purine analogues) used in the experiments described in 
chapter six are gifts to Harry de Koning from Dan Brown, the MRC Laboratory of 
Molecular Biology, Cambridge, UK and Gerrit-Jan Koomen, University of Amsterdam, 
The Netherlands 
 
2.2.2 Preparation of saponin-freed P. falciparum trophozoites for 
transport assays 
Permeabilised P. falciparum-infected erythrocytes were prepared by incubating the culture 
with 0.15% w/v saponin (Sigma). Saponin, a plant-derived detergent, renders cholesterol-
containing membranes freely permeable to macromolecules (Ansorge et al, 1996). Saponin 
interacts with cholesterol in the erythrocyte membrane to form lytic pores, but leaves the 
parasite plasma membrane (which lacks cholesterol) intact. Therefore treatment of 
parasitized erythrocytes with saponin permeabilised both the plasma membrane (PM) of 
the host erythrocyte and parasitophorous vacuole membrane (PVM) in which the 
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intracellular parasite is enclosed, thereby allowing solutes present in the extracellular 
medium unimpeded access to the parasite plasma membrane (Ansorge et al, 1996).  
The culture was first centrifuged 700 × g for 5 min and the supernatant removed and 
discarded. The cell pellets were resuspended in 5 cell volumes of 0.15% (w/v) saponin 
made up in phosphate-buffered saline (137 mM NaCl, 27mM KCl, 1.76mM K2HPO4, and 
8mM Na2HPO4) for up to 2 min at room temperature. The cells were washed three times 
with incomplete RPMI 1640 to remove all traces of saponin and re-suspended in the same 
medium for the uptake experiments. Success of permeabilisation of the infected 
erythrocytes was checked by examining a wet smear of the suspension: a drop of the 
suspension was put on a microscope slide, covered with a slip and examine under the × 
100 oil immersion. 
 
2.2.3 Percoll enrichment of infected erythrocytes 
Concentrated trophozoite-infected erythrocytes (60-90% parasitaemia) were obtained by 
density gradient sedimentation on Percoll (Amersham Biotech) using previously described 
methods (Gero et al, 1988;Kirk & Horner, 1995). Percoll consists of colloidal silica 
particles of 15-30 nM diameter (23% w/w in water), which have been coated with 
polyvinylpyrrolidone (PVP). Due to the heterogeneity in particle size, sedimentation 
occurs at different rates. This occurs spontaneously creating very smooth, isometric 
gradients in the range of 1.0-1.3 g/ml. Most biological particles having sedimentation 
coefficient values greater than 60 S can, therefore, be successfully isolated on Percoll 
gradients (http://www.sigmaaldrich.com). By following the manufacturer’s instructions, 
isotonic Percoll solution was prepared.  
 
A working solution of density 1.090 and osmolality 320 mosm (kg H2O)-1 was prepared. 
Concentration of the late stage parasitized red blood cells (PRBC) was achieved by 
layering an equal volume of culture at 10% PCV on top of the isotonic Percoll solution and 
centrifuging at 1000 × g for 12 minutes. The trophozoite-enriched red blood cells were 
harvested from the interface. The harvested cells were washed three times with incomplete 
RPMI1640 and left to stand for 30 minutes in incomplete RPMI1640 supplemented with 
glucose (0.2%) to allow for full recovery of the parasites, prior to use in uptake 
experiments.  
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2.2.4 Measurement of purine uptake in saponin-freed P. 
falciparum trophozoites 
The amount of radiolabeled permeant transported into P. falciparum parasites was 
measured using the rapid-stop/oil spin method (Figure 2.1) previously described by de 
Koning and Jarvis (de Koning & Jarvis, 1997). Time/dose dependent uptake described in 
detail in sections 2.2.5 and 2.2.6 were performed. 
Scintillation counter
Cell suspension Radio labelled purine
Mix to start influx
Spin to pellet the cells
Retrieve pellet and 
determine radioactivity
@ Pre-determined time Add mixture to a stop solution
Oil
Cold stop solution
Pellet
 
Figure 2.1: Classical uptake technique.  
 
 
2.2.5 Time-dependent uptake of permeant 
A time course uptake experiment measures the rate of movement of permeant across a 
biological membrane. Uptake of [3H]-hypoxanthine, [3H]-adenosine or [3H]-adenine by 
saponin-freed trophozoite-stage P. falciparum parasites were measured at various time 
intervals to generate plots of uptake rate versus time. Briefly, equal volumes of a 
suspension of permeabilised-infected erythrocytes (usually at a concentration of 2-6 × 107 
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cells/assay) and a radiolabeled permeant at twice its final concentration were mixed for a 
predetermined times. Influx of permeant into the cells was terminated by adding 1 ml ice-
cold stop solution (usually unlabelled permeant at saturating concentrations) and quickly 
spinning the cells at 13,000 x g in a microfuge through an oil-mix (300µl of 5 parts 
dibutylphthalate [Aldrich]: 4 parts dioctyl phthalate [Aldrich], v/v), thus preventing further 
uptake of permeant which remains in the aqueous layer. The pellets were retrieved and 
processed for scintillation counting of radiolabel incorporated into the cells using the 
protocol described below (section 2.2.7). 
Non-mediated uptake of the respective permeant was assessed by determining the rate of 
uptake of the radiolabeled permeant in the presence of 1mM unlabelled permeant as well 
as with cells and permeant at 0 oC. The rate of uptake of the permeant was obtained from a 
plot of permeant concentration against time using Prism 4, GraphPad computer program. 
Using correlation coefficients the linear phase of the uptake was determined from the plot. 
 
 
2.2.6 Dose-dependent uptake of permeant 
Dose dependent uptake experiments allowed for the determination of IC50 and Ki values.  
Four times the required final concentration of radiolabeled permeant was mixed with an 
equal volume of an inhibitor also at 4× its final concentration. Two hundred micro litres of 
the mixture were carefully layered on top of 300 µl oil-mix in a 1.5 ml microfuge tube. The 
tube was centrifuged briefly at 13000 × g to collect the permeant/inhibitor mix into a single 
bubble at the top of the oil layer. An equal volume of a suspension of saponin-freed P. 
falciparum parasites was added to the microfuge tube so that it mixed with the 
radiolabel/inhibitor, and incubated for a predetermined time. The flux of radiolabel was 
terminated by the addition of 1 ml cold stop solution (1 mM of unlabelled permeant) and 
centrifuged at 13000 × g for 30 s. The cell pellets were retrieved and processed as 
described in section 2.2.7 and the amount of radiolabel incorporated was determined using 
a scintillation counter.  
Inhibition and kinetic constants (IC50, Ki and Km) were generated by nonlinear curve fit 
using GraphPad Prism version 3.0 or 4.0. Ki values were calculated from the equation Ki = 
IC50 /(1+(L/Km)), where L is the permeant concentration. The Km and Vmax values were 
obtained for the transporter using the Michaelis-Menten plot.  
 
Neils Ben Quashie, 2008 Chapter Two  
 
53
 
2.2.7 Processing of sample after uptake assay 
The parasite pellets were processed after the uptake using the method previously described 
by Saliba and colleagues (1998), with a slight modification(Saliba et al, 1998). The 
aqueous phase (which contained the un-incorporated radiolabel) was removed by 
aspiration and the inside walls of the tube carefully washed with distilled water. The water 
was aspirated out followed by the oil-mix. Any radioactive material remaining on the walls 
of the tube was removed by carefully wiping the tube walls with a piece of folded tissue. 
The cells were resuspended in 200µl of 1% Triton X-100 in distilled water for 10 minutes 
at room temperature (for the cells to lyse). Proteins in the mixture were precipitated with 
200 µl of 5% trichloroacetic acid (TCA). The mixture was finally centrifuged for 7 minutes 
at 13000 × g and the supernatant transferred into a scintillation vial. 3ml scintillation fluid 
(OptiPhase ‘HiSafe (Perkin Elmer)) was added and the radioactivity determined with the 
Perkin-Elmer 1450 Microbeta Wallac Trilux liquid scintillation and luminescence counter. 
All uptake experiments were performed in triplicate. 
 
 
2.3 Molecular Techniques 
2.3.1 Extraction of parasite DNA using Instagene 
P. falciparum DNA was extracted from infected erythrocytes using the InstaGene™ matrix 
(BioRad). ‘InstaGene™ matrix is a specially formulated, 6% weight to volume Chelex® 
resin for the rapid isolation of small amounts of genomic DNA of sufficient purity for 
PCR’ (http://discover.bio-rad.com ). Five hundred microliters of culture material was 
centrifuged at 4000 × g, 5 min in a 1.5ml microfuge tube to pellet the cells. After 
discarding the supernatant, the cells were resuspended in 1ml autoclaved distilled water 
and incubated at room temperature for 30 minutes to lyse the erythrocytes. The suspension 
was centrifuged (10000 × g, 2 min) and the supernatant removed and discarded. The pellets 
were incubated with 200 µl of InstaGene™ matrix at 56°C for 30 minutes. The mixture 
was vortexed at high speed for 10 seconds and put into a heating block at 100°C for 8 
minutes. After a brief vortex, the mixture was centrifuged again at 10000 × g for a minute. 
The supernatant containing genomic DNA was transferred into a fresh tube and stored at -
20°C until required. DNA prepared using this method is suitable for amplification using 
PCR. 
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2.3.2  DNA extraction using the phenol-chloroform method 
The phenol-chloroform method described by Sambrook and co, is another DNA extraction 
method employed in this study, producing DNA of a higher purity, which is suitable for 
restriction digestion (Sambrook et al, 1989). Five milliliters of parasite culture at 5-10% 
parasitaemia were centrifuged at 630 × g for 10 minutes and the supernatant removed and 
discarded. The pellet was resuspended in equal volume of 0.15% saponin (w/v) and left to 
stand at room temperature for 20 minutes to lyse the erythrocytes. The mixture was 
centrifuged at 3112 × g for 10 minutes and the supernatant removed and discarded. The 
pellet was resuspended in equal volume of Buffer A (150mM NaCl, 25mM EDTA) and 
incubated for 30 minutes at room temperature. After centrifugation 4000 × g, 5 min, the 
pellet was washed 3 times with ice cold PBS and finally resuspended in 0.4ml of Buffer A. 
Next, 10µl of 10% SDS (sigma) and 50µg of proteinase K were added to the suspension 
and incubated overnight at 55°C. DNA was extracted by adding an equal volume of a 1:1 
mixture of phenol and chloroform followed by gentle inversion of the tube. The mixture 
was centrifuged for 2 minutes at 4000 × g and the top aqueous layer transferred into a fresh 
tube. The phenol/chloroform extraction was repeated three more times on the supernatant. 
Finally, 400µl of ether were added, and after centrifugation the top layer (the ether phase) 
was removed and discarded. The tube was left opened to allow for the remaining traces of 
ether to evaporate. Eight hundred microliter of ice-cold absolute ethanol and 120 µl of 3M 
sodium acetate were added and the mixture placed in a freezer at -70°C or in liquid 
nitrogen for 15-30 minutes. After centrifugation at 4000 × g, 5 min the ethanol was 
carefully removed and discarded and the tube left with its lid opened in a sterile flow to 
ensure complete evaporation of the ethanol. Finally, the residue (DNA) was resuspended in 
50 µl of distilled water or TE and stored at -20oC until required. 
 
 
2.3.3 Purification of DNA using a mini-, midi- and max-prep kit 
The QIAprep kits (QIAGEN) were used for purification of small to large amounts of DNA 
from plasmids. In all cases, the manufacturer’s instructions from the product handbook 
were followed. 
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2.3.4 Polymerase chain reaction (PCR) 
Polymerase Chain Reactions (PCR) were performed to amplify the DNA of interest from 
an appropriate template (mostly DNA extracted from P. falciparum clone 3D7). PCR 
reactions were performed in volumes of 20, 25 or 50µl containing up to 500ng of genomic 
DNA template, 1.5mM of MgCl2, 0.2 mM dNTP mix, 100nM of forward and backward 
primers (specifically designed for the gene of interest and 1 Unit Taq polymerase (Roche). 
The mixture was made up to the required volume with DNase and RNase-free deionised 
water treated with 0.001% DEPC filtered through 0.2 micron filter and autoclaved (MP 
Biomedicals inc, Ohio). Thermal cycling was performed on a DNA Engine PTC – 200 
Peltier Thermal Cycler (MJ Research Incorporated, USA). The annealing and extension 
temperatures chosen in this study were in most cases dependent on the average Tm of the 
two primers used. Details of the cycling conditions are given elsewhere in this thesis. 
 
 
2.3.5 Determination of DNA concentrations by spectrophotometry 
The DNA concentrations of samples were determined using the standard 
spectrophotometric method. This method takes advantage of the UV light absorption 
property of the purines and pyrimidines rings present in DNA to measure the amount of 
DNA present in a sample. 1 µl of the DNA was added to 99 µl of DNase/ RNase-free 
deionised water. Absorbance at 260 or 280 was first blanked using DNase/ RNase-free 
deionised water in a cuvette. Absorbance of the mixture containing the DNA was then 
measured at 260 and 280nm. DNA concentration was calculated based on an OD of 1 
corresponding to approximately 50 mg/ml for double-stranded DNA:  
DNA concentration of the sample (mg/ml) = 50 mg/ml × Measured A260 × dilution factor. 
The OD260/OD280 ratio for pure DNA is 1.8. Contamination by protein (which has an 
absorbance maximum of 280 nm) or phenol will cause the ratio to be significantly lower. 
2.3.6 Agarose electrophoresis of DNA 
DNA was separated on the basis of differences in molecular weight by electrophoresis on 
an agarose gel. The agarose gels (1.5%) were made in 1× Tris-Acetate-EDTA (TAE) with 
final solute concentrations of 40 mM Tris acetate and 1 mM EDTA, pH 8.0). The buffer 
contains 0.5 µg/ml of ethidium bromide for visualisation of the dsDNA under ultraviolet 
(UV) light. The gel was prepared using a standard gel apparatus (Horizon® Gibco BRL). 
DNA samples were mixed with ×6 Blue/orange loading buffer (15% Ficoll®400, 0.03% 
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bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 10mM Tris-HCl (pH 7.5) and 
50mM EDTA) supplied by Promega and ran at 120 mV. Voltage was obtained using the 
Whatman Biometra power supply model 250 supplied by Life technologies.   A 100bp 
DNA ladder (Promega) was run in one of the wells to allow an estimation of the size of the 
DNA fragments. 
 
2.3.7 Amplification of ENT DNA fragments  
Primers were designed for amplification of fragments of the four genes (PF13_0252, 
MAL8pl.32, PFa0160c and PF14_0662), which are predicted to encode the equilibrative 
nucleoside transporter proteins of P. falciparum. The designed primer pair for each ENT 
gene (see Table 2.1) was purchased from MWG Biotech, Germany. The forward and 
reverse oligonucleotides primers for amplifying each fragment contained the restriction site 
for either BamH1 or SacII at the 5′ end to facilitate cloning of insert (ENT fragment) into 
pCAM/BSD. Lyophilised primers received from suppliers were diluted appropriately as 
instructed by the manufacturers and stored at –20°C until required. DNA fragments from 
each of the four ENT genes were amplified by polymerase chain reaction (PCR), with a 
final reaction volume of 50µl, as described in section 2.3.7. The cycling conditions for 
each reaction are shown in Table 2.2. The size of each DNA fragment was verified by 
electrophoresis of 5µl amplicon on 1.5% agarose gel with the aid of a 1kb molecular 
weight maker (Invitrogen, UK) run alongside as described in section 2.3.4. The expected 
PCR product sizes are shown in Table 2.1.  
 
About 40µl of each amplicon were purified using the Wizard® PCR Preps DNA 
Purification System (Promega, USA), following the supplier’s instructions. The 
purification was necessary in order to remove excess nucleotides, enzymes, magnesium, 
buffer, DNA template and primers.  The concentration of the purified DNA was then 
estimated by running an aliquot of the product on 1.5% agarose gel as usual using a 
SMART® DNA ladder (Eurogentec, Belgium) as a molecular weight marker. The colour 
intensity of the bands in the SMART DNA ladder is associated with the concentration of 
the DNA loaded. This therefore allows for the concentration of DNA product to be 
estimated by comparison of the intensity of the bands. By this means the concentration of 
each ENT DNA fragment amplified was obtained. 
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Since the DNA fragment is to be used in a gene disruption strategy, it was carefully chosen 
to remove the central transmembrane domains that are believed to be responsible for the 
translocation of purine permeant (reviewed by (de Koning et al, 2005). The size of the 
fragment was also chosen to maximise the probability of homologous recombination with 
the genomic copy of the gene following transfection. The sizes of the four fragments 
amplified in this study ranged between 675bp and 938bp. The sequences of the four 
fragments are shown in Figure 2.2 - Figure 2.5. 
 
ATGAGTACCGGTAAAGAGTCATCTAAAGCTTATGCTGATATAGAATCCAGGGGTGATTATAAGGA
CGATGGAAAGAAAGGATCTACATTAAGCAGTAAACAACATTTCATGTTATCTTTAACCTTTATAT
TAATAGGTTTAAGTTCTTTGAATGTATGGAATACAGCCTTAGGATTAAATATAAATTTTAAATAT
AATACCTTTCAGATTACAGGTTTAGTATGTTCCTCAATTGTAGCTTTATTTGTTGAGATTCCCAA
AATAATGTTACCATTTCTTTTGGGTGGTTTATCAATTTTATGTGCAGGTTTTCAAATATCTCACA
GTTTTTTTACAGATACACAATTTGATACATATTGTTTAGTAGCTTTTATTGTTATTGGTGTAGTG
GCAGGATTAGCTCAAACCATTGCATTTAATATAGGATCAACCATGGAAGATAATATGGGTGGTTA
TATGTCAGCAGGTATTGGTATATCAGGAGTATTTATTTTTGTTATTAATTTATTACTTGATCAAT
TCGTATCTCCCGAAAAACATTATGGTGTTAATAAAGCAAAGTTATTATATTTATATATAATCTGT
GAACTTTGTTTAATATTAGCTATAGTATTTTGTGTATGTAATTTAGATTTAACAAACAAGAATAA
TAAAAAAGATGAAGAAAATAAAGAAAACAATGCCACATTATCTTATATGGAATTATTTAAAGATA
GTTACAAAGCTATATTAACTATGTTTCTTGTAAACTGGTTAACTTTACAATTATTTCCAGGTGTT
GGACACAAAAAATGGCAAGAAAGTCATAATATCTCCGATTATAATGTTACCATTATTGTTGGTAT
GTTTCAAGTTTTTGATTTTCTCAGTAGATATCCACCAAATCTTACACATATTAAAATCTTTAAAA
ATTTTACTTTCTCTTTAAATAAATTATTGGTTGCCAATTCATTGAGATTATTATTCATTCCATGG
TTTATTTTAAATGCATGTGTTGATCATCCATTTTTCAAAAACATTGTACAACAATGTGTATGTAT
GGCTATGTTAGCTTTTACAAATGGTTGGTTTAATACTGTACCATTCCTTGTATTTGTTAAAGAAT
TAAAAAAAGCCAAGAAAAAGAAAGAAATCGAAATTATATCCACATTCTTAGTTATTGCTATGTTT
GTTGGATTATTCTGTGGTATATGGACTACATACATTTATAACTTATTCAATATAGTTTTACCAAA
GCCAGATTTACCACCCATCGATGTAACACAATAA 
Figure 2.2: DNA sequence of gene encoding for ENT in P.falciparum. This is the gene with 
plasmoDB accession number PF13_0252 (designated PfNT1).  
Total size of the gene is 1269bp and the size of fragment prepared for disruption of the gene 
was 676 bp (shown in pink). Primers (including restriction sites, underlined) used to amplify 
the fragment are: PfNT1 F: GGGGGGATCCTACAGGTTTAGTATGTTCCTC and PfNT1 
R:GGGCCGCGGATTTGGTGGATATCTACTGAG. These are highlighted in light blue in the figure. 
There were no introns present. 
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ATGAGTGACAGTCAGAGTAAGGATACGTTTCATACAACAGTGGGTGGATTATATGAGAAG
CCTAACAAAGTTCGAGATATTGAATGTTTATATCCTTGTGATATTGAAAAAGTAGATACT
TTTGAAGAAGATAGGTATAAGAAGTTATTATGTGCAGCATATGCATTAATGGCTATAATA
GCTGATGCTCCATATTTTATGATTGTATCGATGGCTGATTATTTTAAAAGTACTTTTAAT
GTAAATGACGTTATGATAAATGAATTTGCCTTAATGGAAAGTTTAATATTGATTGTTGTT
TGTTCATTATTACATTTAATTGGAAGTTATCGTTTAAAATGGAATTTACTTATGCCTATA
TTTATGACGATGATATTAGTTGTGTTAAATTTTGTTGTTTATTTTAAACTTGACTACATT
GGACATAAGATTATCATCTTCAGTGCTATACCTTTAGGTTTAGTATCTTGTATATCTAAA
ATGACTACTATGAAAATATGTGTTTTGTTTAAAAACGCCTATTGTAGTGCTTATGTATGT
GGATTATCTTTTTCAGGTTTTATAGTGTTTATAATATATATGTTAGGGGCATATGTGTTT
TTTCCGAATGATGAAATGAAATTTTTTAAGATGTTTACTTTTTTTTGTTTGATTATTTGT
TCATTAGCATTAACATGTTTTTCTATCCTATACCGACTATACAAAAAACGATTTGTGAAA
ATATTGGAAGAAAAGTATAAAGATAAAGGATTAAAAATTAATAGAAAAATATTTTATGAC
TCTATAAAATCAATGAAAATATTGTGGCCATATATGTTGATTTCATATTTTACAAGTTTA
TTGACTTATCAAATATATCCATCTATATTTCCAACTTTTATGGATGTTAGTAAAGAATTA
AAAGGAACACTAGCTGGATTTTTATTATTTGGTGATTCTATGGCTCACTTATTAGTTCAT
TATAGAAGAAACGAATTTTTAAAAACAGATTTTTCTACATTAGTCTTTTGCACATTGTTC
GAATATTTTTTGTACCTATATTTTTATTCTTGCCAAAGCTTCATTATATATATAACTTTA
GTTATTTTATGTTGACTAGCTTTTCATTTTTATTCGGACTAATGAATGGATTGGTGAATA
ATTTAATTTTTTTGAAAGCACCAGAAACGTGTAAAGAAAAAAGCAAATATGAATATATTC
AATTAACTCCAAATATACTTTACTTATGTTTAATTTTTGGAATAACCAGTGGGTGTTTAA
TATCCAAGGTTCATGTAAGAATTGTGAATATAATTGCAGTTATTTTAAAATAA 
 
Figure 2.3: DNA sequence of genes encoding for ENT in P. falciparum. This is the gene with 
plasmoDB accession number, PF14_0662 (designated: PfNT2). 
Total size of the gene is 1314 bp. Size of DNA segment amplified for disruption of ENT was 
778 bp (shown in pink). Primers (including restriction sites, underlined)) are: PfNT2 F: 
GGGGGGATCCGGCTATAATAGCTGATGC, PfNT2 R:  GGGGCCGCGGGTGAGCCATGAATCACC. 
These are highlighted in yellow in the figure. There are no introns present.  
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ATGAGCAATTCTAATAGCAAGGAGCACTACAGAATGGACGGAATTACAGAAAATAAAATA
ATTAATGAAGATGATGAAAGTCTCTTGAACATGAAAAAAGAAGAAATAATTTTAAATGGA
AAATTTGAAGAAGAGCCAAAGCTTGATTTAACCGAAAACAAAATTGATATTGAAGAGAAG
AATAATAACATGAGTGAGTTTACAAATATTTTTCCAAATATAACATTATGTTTAATGGGA
ATGTCATCTGTATTAATGTATAATTGTGTATTAAATACAACACCTCATATACATGCATTA
TTAAATAAGAATATAGTAGTATCTTCAACCTTTTTTCTATATTTTTCTATTTTAGTTATT
GTATCATTGTTAAGTTCCTTATTTATAGAAGTAAAGACAAGAACATATGATGTGTGTTTT
ATATTATCATTCATATTACAAATGATATATCCATTTATTATAAAATATTTTTATGATAAA
ACCGTTTTTTTTTATGTACTAGTAGCATTAATTGGTGCTACGTGCTCTATGATGAAAACC
ATGATATTTTCCATATCTTCCATTGTTGTAAATGATTCAAAAGTTATTTGTTTATCATAT
GGTTTGACTGGGATATATTCTTTATTTATAACATCCACATTTTTTTATTTTGTTATTAAA
ATAAATAAAGATATACAAAAGTTGATGTTATCATTATTTATAACATCAGCCATCAATTGT
ATATTTATATTAGTGTCTTTTCTATGTTACACTGTATTAAAGAGAACAAATAATTTTAAA
GAAAAATTTAAAATTTATACAGAAGAGAGAAAAAATAATAAAAATTCACGTGATGATTCT
TATAAATATTATGAAAGTATAACTGAAAAAAAATCACAAAATATATCATATCCAATAAAT
ATTAATAGTATAATATATGAAAGTAAAACAGAAAATACGGAATCCAAATATTCATTAACA
AAAAATGATTCTAACTCAGTTGGTATAAAAAGTAGTAGTAATAATACTAATAATATGACT
AGTAATGAAATAGGAGATCATAAAATATTACAAGAATCTCATTCAAAAAATAAAAAATTT
AATGACATACTTCTTAATGAAAATAAAACATTATCACTTACTCATAGTAAAAAAGAAGAT
AACATAGATGACGAAAATAAAAATCATAAAAATCAATTCTTTCTATTTAATATAAATAAA
AAAAATTTAATAAAACAAGCCAAAATTAAAGCATTCTTATATAAAAAATCGTTCATATTT
TTATTTTGTAGCTTTTATAATATTTTTCTCAAAATATTATTATTCCCGGTTGTTTGTCCA
GAAATGTGGACTAATAATGTTGATGAAAGATATATATTAATTGGAATTGTGCAATTTGCT
GATTGTATAAGTCGTGTTTTCCCATCCCTTGCAGGAACATTTCCAGTATTTAAAATTTTC
CTCTTGACACAAAAAAAAGTATTAATTTATTCTTTATTAAGAACTATCTTATCTGTAATA
GGATTGATAATACCATTAACACAAGATACATTTATTAATAATTTCCTTTTTAAATGTGCA
CTCATTTTTTTAAATATATATTTAAATGGTTGGTTTGTTATCATGTCTTTTATTAATGTT
CCAGAAATTCTCAAACCTATTAATTCAATGAGTAATGTTGCAATAGTTAGTAGTTTTGGT
TCAACACTCCTTCGAGTTGGCTTGTTAACAGGCTATGGATGTTCCACACTATATAAATAT
ATCATATCAAAAATGTGA 
 
 
Figure 2.4: DNA sequence of genes encoding for ENT in P.falciparum.The is the gene with 
plasmoDB accession number MAL8P1.32 (designated PfNT3). 
Total size of the gene is 1758 bp and the size of fragment prepared for disruption of the 
gene was 913 bp (indicated in pink).  Primers (including restriction sites underlined) used to 
amplify the fragment are: PfNT3 F: GGGGGGATCCTAGTAGCATTAATTGGTGC and PfNT3 R: 
GGGGCCGCGGCAAGGGATGGGAAAACACG. The two primers are highlighted in green in the 
figure. There are no introns present. 
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ATGTTGAAGAAAAGCGAGGAGATCCAGATAAAGGTTATCTTTTTTTTTATAGGTTTGCTTTT
GAGTTTACCCTCCCATATTTTAATAAATGTATCTTTTTTGATTAATCACATATACAAGGAAG
AGATAGCTATAACGGTTATGGGTTTTTTATCAGGATTTATGATAATATCATCATTTTTACAA
TTAACTTTTGAATTTACATCTTTTAAATGGATTATGATATGTAACGGATTAAATGTTTTTAA
TTTATTATTATTATTAATTTTTGTATGTGTAATGAAATGTTCAAAATATTATATATATGGTA
TATCCGGGATTATCGGTTTTTTTATTGGTTATTTGTATTCATCGTGTACAAAATATTCTTTG
CTATTTCCTTTAAAAGTCAATGGTTATATGGTTACAGGAATTAGTTTCTCTTCATTATTTTT
TTTTGCTATAAATTTAATAATGTCGTATTTTTCTATCGAAGATGGTAATATAAGTTCATATT
ACAACACAATATATTTATCCATAGGAACTATAGTTCATTATACTTGTTTGTATAATTTTTAT
ACAATATAATTCTCCATATTTCAAGGAGCAAAAAGAGAAAATAGAAAGTGCACAGAACAAAA
AATGTATTGAATATAATGGATCGAATGATTTATGTGAAGTTGAAAAAGGAAAAAACAAATCA
TCAGAAAATATCCAGAGTAATAATGTCTCTATGATAAGTAAATGTAAAAATAAAATTAAAAA
TGTTGGAAAAATGTTTAATTGTGCTAATATAATTGAGGGAGCTTGTTTAATAAGATATTATT
ATTTATGTTTAATACCTATATTCTTTTCATTTTTCGTGACCTCTATAATATATCCTCACATG
AGTAAGCAAAAAAAAAAAAAAATAAAGGAAAATGAAACAAGTCTATAAATATTTAATATATT
ATATATATAGATAGATATATGTATGTATGTATGTTTATGTTTATGTTTATGTTTGTGTTTAT
GTTTATGTTTATGTTTATGTTTGTGTTTATGTTTATGTTTATGTTTGTGTTTATGTTTATGT
TTGTGTTTATGTTTATGTTTATGTTTGTGTGTATATTTTTATTTTATTATTTTTTTTAATTT
TTTTAGTTCCGAATAAGCTGAAGAAGAACGTATATTACAAATACCTGTTTATGTTTCTTTAC
CAACTCAGTGATCTTATATTTCATATCATTGTGACTGTTTATTATAGTGCTTTTAACTTTTT
TAAACAAAAATATGTTGCCATATTATGTTTAAGCAGAATCCTTCTTTTGCTATTATCCTTTA
AAATTAAGAATTTAACTGAAGCATCCTTTTTATATTCTAATACTTTTTTGTCATTCCTAATA
TTTGTAATAGGAGGTACGAATGGTTCTTTGATCAATATTAGTTATGCCAGAATATCAGACTG
TTTTGAAGAATCAAATAAGAAAACCAAACAAATCGCTGTGGCATCATCCTTCTGTGCTTTAT
GTCTATTAATGAGTTTTGCATTAGCACCATGGTTTTGTAATGCAATAATTCATTTGTAA 
 
 
Figure 2.5: Unspliced DNA sequence of genes encoding for ENT in P.falciparum. This is the 
gene with plasmo DB accession number PFA0160C (designated PfNT4).  
Total size of the gene is 1558 bp and the size of fragment prepared for disruption of the 
gene is 938 bp, (shown in pink). Primers (including restriction sites, underlined) used to 
amplify the fragment are PfNT4 F: GGGGGGATCCGAAGAGATAGCTATAACGG, PfNT4 R: 
GGGGCCGCGGGCTTATTCGGAATCATGTGA. The primers are highlighted in blue in the figure. A 
253bp intron is present and is highlighted in bright green. 
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Gene Size 
of 
DNA 
(bp) 
Fragment 
amplified 
(bp) 
 
Product 
size (bp) 
Primer sequence 
PF13_0252
(PfNT1) 
1269  210-885 
 
676 PfNT1 F=TACAGGTTTAGTATGTTCCTC 
PfNT1 R=ATTTGGTGGATATCTACTGAG 
PF14_0662
(PfNT2) 
1314  170-948 778 PfNT2 F=GGCTATAATAGCTGATG 
PfNT2 R=GTGAGCCATAGAATCAC 
MAL8pl.3
2 (PfNT3) 
1758  498-1411 913 PfNT3 F=CTAGTAGCATTAATTGGTGC 
PfNT3 R=CAAGGGATGGGAAAACACG 
PFA0160c 
(PfNT4) 
1558   270-955 938* PfNT4 F=GTATGTGTAATGAAATGTCC 
PfNT4 R=ATATAAGATCACTGAGTTGG 
Table 2.1: A table showing the size of each of the four P. falciparum equilibrative nucleoside 
transporter genes, the size of each fragment cloned into pCAM/BSD and the primer pairs 
used to amplify each of the DNA fragments.  
*Presence of 243 bp intron 
 
Gene Cycling conditions 
PF13_0252 (PfNT1) 94°C, 3 min/ 94°C, 30 s/ 48°C, 1 min/ 
70°C, 1 min/ ×35cycles/ 70°C, 5 min 
PF14_0662 (PfNT2) 94°C, 3 min/ 94°C, 30 s/ 53°C, 1 min/ 
65°C, 2 min/ ×30 cycles 65°C, 5 min 
MAL8pl.32 (PfNT3) 94°C, 3 min/ 94°C, 30 s/ 53°C, 1 min/ 
65°C, 2 min/ 30 cycles/ 65°C, 5 min 
PFA0160 (PfNT4) 94°C, 3 min/ 94°C, 30 s/ 53°C, 1 min/ 
65°C, 2 min/ ×30 cycles/ 65°C, 5 min 
Table 2.2:Cycling condition for the amplification of the four P. falciparum equilibrative 
nucleoside transporter genes. 
Order of events: Initial denaturation/ denaturation/ annealing/ extension/ number of cycles/ 
final extension.  
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2.3.8 Purification of the ENT DNA fragments 
The ENT amplicons prepared above were purified using the Wizard® PCR Preps DNA 
Purification kit (Promega). This process ensures removal of PCR enzyme, buffer, excess 
nucleotides, magnesium, template DNA and primers. 100µl of amplicon were prepared for 
each gene, and purified using the kit. Two micro litres of the purified product obtained 
were loaded and run on a 1.5% agarose gel to confirm the size as well as to estimate the 
DNA concentration. A SMART® DNA ladder (EUROGENTEC) was used as a molecular 
weight marker and to allow for an estimation of DNA concentration, as the 1000bp band 
contains a known quantity of DNA (100ng). 
 
2.3.9  Plasmid used in preparing DNA construct 
PCAM/BSD was the plasmid chosen for the preparation of the construct that would be 
used to disrupt the ENT gene in P. falciparum. The initial plasmid was a gift from the 
group of Christian Doering (INSERM U609, Wellcome Centre for Molecular Parasitology, 
Anderson College, Glasgow). pCAM-BSD is a 4519bp vector which expresses the 
blasticidin-S-deaminase (BSD) selectable marker that is under the control of a 0.6-kb P. 
falciparum calmodulin 5' untranslated region (UTR) and a 0.6-kb hrp2 3′ UTR (Sidhu et 
al., 2005). Transformed cells can be selected with 100mg/ml ampicillin in E. coli culture 
and with 2.5 µg/ml blasticidin in cultures containing P. falciparum. The plasmid has 
restriction site for numerous enzymes including Bam H1 and Sac II. 
 
A larger quantity of the plasmid was prepared from the gift received using the procedure 
described below. DH5-α chemically competent cells (Invitrogen, UK) were transformed 
with the plasmid as described in section 2.3.12. After propagation of the bacteria 
overnight, the plasmid was retrieved and purified using the method described in section 
2.3.13. Plasmid was store at -80°C until required. Stabilate of the transformed cells was 
also prepared by mixing 500µl of the transformed bacteria culture with 250 µl sterile 
glycerol. The mixture was allowed to stand for one hour at room temperature and stored at 
-80°C.  
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Figure 2.6:Schematic presentation of the vector pCAM-BSD.  
The plasmid has a total length of 4519 bp with ampicillin (AMP-R) resistance genes. 
Transformed cells can therefore be selected with 100 µg/ml ampicillin in E. coli culture. The 
figure also shows the BamH1 and SacII restriction site where the cloning of the ENT fragment 
was done. This transfection plasmid also expresses the blasticidin-S-deaminase (BSD) 
selectable marker, which is under the control of a 0.6-kb P. falciparum calmodulin 5′ 
untranslated region (UTR) and a 0.6-kb hrp2 3′ (UTR).  Re drawn from (Sidhu et al, 2005). 
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CTAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAG
GCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACA
AGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACG
TGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCC
CGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTA
GGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGC
GTCCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTG
GCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGA
CGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCCCATGGGAATTCTATATGTGATTAAT
TTTATATATTATCAATTTATATATTTTTAAATGCTTACTTAATTATCTTTTTTTTTTTTTTTTTTTTTTTTTCCCC
TCTTTTTATATTAATTTATTTTTGAAAAAATTGATATATATATATATATATAATATATATATATACATGTAGTAGT
ATTAAACAATGTATAATATATATAAATAATATATTTATATATTTCATTTCAATTTTAATTTTTTTTGGTTTTTTTT
TTTTTTCTTTTTGTCATATTTAAAAAAAATTATATTCATATAAGTTATGCATTTTTTATAAACATTATTCAATATA
TGTATAATATAATATATATATATATATTAATGTATTATTCCAATGTGCATGATAAAAGAAAAAAATAATATTTATA
AAAAAAAAGAAAAATAAAACAAAAAAAGAAAAAAAAAAAAAAAAAAAAAAAAATACAAAAATAAATAATATAATTT
ATAATTATATATTCTTGTCACAATAAAAATATATATATATATATATATATTTATAATATGTATATTTTAAACTAGA
AAAGGAATAACTAATATTTTATTTATTATCATTCAAGATTTATATTTTATAATAATAAATACCTAATAGAAATATA
TCAATGGTGCATGCCAAGCCTTTGTCTCAAGAAGAATCCACCCTCATTGAAAGAGCAACGGCTACAATCAACAGCA
TCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCATCTTCACTGGTGTCAATGT
ATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGGTGCTGGGCACTGCTGCTGCTGCGGCAGCTGGCAACCTG
ACTTGTATCGTCGCGATCGGAAATGAGAACAGGGGCATCTTGAGCCCCTGCGGACGGTGACGACAGGTGCTTCTCG
ATCTGCATCCTGGGATCAAAGCGATAGTGAAGGACAGTGATGGACAGCCGACGGCAGTTGGGATTCGTGAATTGCT
GCCCTCTGGTTATGTGTGGGAGGGCTAAGCTTTAATAATAGATTAAAAATATTATAAAAATAAAAACATAAACACA
GAAATTACAAAAAAAATACATATGAATTTTTTTTTTGTAATCTTCCTTATAAATATAGAATAATGAATCATATAAA
ACATATCATTATTCATTTATTTACATTTAAAATTATTGTTTCAGTATCTTTAATTTATTATGTATATATAAAAATA
ACTTACAATTTTATTAATAAACAATATATGTTTATTAATTCATGTTTTGTAATTTATGGGATAGCGATTTTTTTTA
CTGTCTGTATTTTTCTTTTTTAATTATGTTTTAATTGTATTTTATTTTTATTATTGTTCTTTTTATAGTATTATTT
TAAAACAAAATGTATTTTCTAAGAACTTATAATAATAATAAATATAAATTTTAATAAAAATTATATTTATCTTTTA
CAATATGAACATAAAGTACAACATTAATATATAGCTTTTAATATTTTTATTCCTAATCATGTAAATCTTAAATTTT
TCTTTTTAAACATATGTTAAATATTTATTTCTCATTATATATAAGAACATATTTATTAAACTGCAGCCCGGGGGAT
CCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCT
TGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGG
AAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCT
TTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTG
GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTC
AAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAG
GCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATC
GACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCT
CATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACT
GGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCT
AACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAG
AAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAA
GGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAA
TCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTG
TCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGC
CCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAA
GGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGT
AAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTT
GGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGG
TTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACT
GCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGA
GAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTT
TAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTC
GATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACA
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAAT
ATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAAT
AGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC 
 
 
Figure 2.7:DNA sequence of the 4519bp pCAM-BSD. 
The figure shows the restriction site for BamH1 (underlined bold blue colour), SacII 
(underlined red colour) and the forward (pCAM-BSD_ F2) and reverse primers (pCAM-BSD_ 
R2) that are highlighted purple and light green respectively. 
Neils Ben Quashie, 2008 Chapter Two  
 
65
 
2.3.10 Restriction digestion of ENT DNA or pCAM-BSD 
plasmid  
In order to create sticky ends, the plasmid and ENT fragments were digested with BamH1 
and SacII (Promega, USA). A 20µl digestion-mix was prepared containing 1µl of either 
1µg/µl plasmid (pCAM-BSD) or the purified DNA fragment of the ENT gene, 2µl ×10 
buffer C [100 mM Tris-HCl, (pH 7.9), 500 mM NaCl, 100 mM MgCl, and 10 mM DTT], 
0.5 µl Bam H1 (10u/µl), 0.5 µl Sac II (10u/µl) and 16.0 µl DNase/ RNase-free water. 
Sac II recognises the restriction site:   5′ …CC GC▼GG…3′ 
 3′ …GG▲CG CC…5′ 
 
Bam H1 recognises:     5′…G▼GATC C…3′ 
 3′…C CTAG▲G…5′. 
 
Digestion was performed overnight at 37°C for 5-6 hours and was terminated by heat 
inactivation of the enzyme at 70°C for 10 minutes. To confirm that digestion of both 
plasmid and the ENT fragment was successful, 2 µl of the digested product were run on 
1.5% agarose gel alongside the uncut DNA using the procedure described in section 2.3.6. 
 
2.3.11 Ligation of ENT fragment into pCAM-BSD   
The DNA fragments of ENT were subcloned into pCAM-BSD plasmid at the Bam HI and 
Sac II restriction sites (Figure 2.6) using T4 DNA ligase (Invitrogen). The T4 DNA ligase 
which was originally isolated from E. coli lambda lysogen can join DNA fragments with 
staggered or blunt ends (Invitrogen). Three different reaction-mixes containing the 
following ratio of insert and vector were set up:           
Tube A   1 part insert: 1 part vector          
Tube B   2.5 part insert: 1 part vector          
Tube C (control)  0 part insert: 1 part vector 
Each tube contains a 20 µl reaction mix made up of, vector: insert ratio (as stated above, 
with a total DNA concentration of 500 ng), 4 µl of ×5 ligase buffer (250mM Tris-HCl [pH 
7.6], 50 mM MgCl2, 5 mM ATP, 5 mM DTT and 25% [w/v] polyethylene glycol-8000), 
1U ligase (1U/µl) and top up with Dnase/RNase-free deionised water. The digest was 
incubated at 14°C overnight. The resultant DNA construct was denoted pCAM-BSD/ENT  
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2.3.12 Transforming DH5α cells with (pCAM-BSD/ENT) 
DH5-α chemically competent cells (Invitrogen) were transformed with the constructed 
plasmid (pCAM-BSD/ENT) using the heat-shock method (Sambrook et al., 1989). Briefly, 
50 µl of the stock DH5-α chemically competent cells were pre-incubated with 50 ng of 
pCAM-BSD/ENT construct on ice for 30 minutes followed by heat shock at 42°C for 45 
seconds. The suspension was placed on ice immediately for two minutes for the bacteria 
cells to recover. Two hundred and fifty micro litres of Super Optimal broth (SOC) medium 
(0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM Glucose) were added to the transformed bacterial cells. The transformants 
were incubated at 37°C for one hour in order for the antibiotic (ampicillin) resistance gene 
to be expressed. 100 µl of the transformed cells was spread under sterile condition on 
Luria-Bertani (LB) agar containing 1% bacto tryptone, 0.5% yeast extract, 1%NaCl 1 per 
cent, 0.1% glucose. The plate also contains ampicillin (100µg/ml) to allow for selection of 
transformed cells. The inoculated plate was incubated overnight at 37°C. A plate with 
untransformed bacteria cells was set up as a control. 
Success of the transformation was checked by PCR using the ENT-forward and reverse 
primers shown in Table 2.2. Single bacteria colonies were picked into 1× sterile PBS. The 
mixture was used as the DNA template in a PCR reaction set up using the method and 
cycling conditions described in section 2.3.7. 2 µl of the PCR product were run on 1.5% 
agarose gel along side a molecular size marker. The expected band sizes are as shown in 
Table 2.1. 
To obtain large copies of the pCAM-BSD/ENT construct, a single colony of the 
transformed bacteria cells on the plate was picked into 500ml liquid LB (containing 
100µg/ml ampicillin). The culture was incubated in a shaking incubator at 37°C, 225 rpm. 
Incubation was terminated when the OD600 of the culture reaches 0.5-0.75. 
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2.3.13 Retrieval and purification of pCAM-BSD/ENT  
Following propagation of the bacteria cells containing the pCAM-BSD/ENT construct, the 
culture was centrifuged at 6000 × g for 15 minutes (at 4°C) to pellet the cells. The 
construct was retrieved from the pellet and purified using a maxi DNA purification kit 
(Qiagen) following the manufacturer’s instructions. The purified DNA was re-dissolved in 
150 µl of DNase/RNase-free deionised water. The concentration of pCAM-BSD/ENT 
DNA was estimated using the spectrophotometric method described in section 2.3.5. The 
purified plasmid DNA was stored at –70oC until required. The presence of the ENT 
fragment within the construct was confirmed by PCR and restriction digest of pCAM-
BSD/ENT. Using the ENT forward and reverse primers shown in Table 2.2, the ENT insert 
was amplified by PCR. The PCR method used is as described in section 2.3.7. The PCR 
amplification was followed by gel electrophoresis of the PCR product. The expected band 
sizes are as shown in Table 2.1. 
A 10 µl enzyme digest-mix was also set up in order to confirm the presence of the ENT 
fragment in the construct. The digestion-mix consisted of 1µl of 10× buffer C, 2 µl purified 
pCAM-BSD/ENT construct, 0.2 µl Bam H1, 2 µl Sac II and 6.6 µl with DNase/RNase-free 
deionised water. Digest-mix was incubated at 37°C for 3 hours followed by electrophoresis 
of 5-8 µl of the digest-product on 1.5% agarose gel. 
ENTBSD
Bam H1 restriction site Sac II restriction site
pCAM
 
Figure 2.8: PCAM-BSD/ENT construct showing the restriction sites for Sac II and Bam H1. 
 
 
Neils Ben Quashie, 2008 Chapter Two  
 
68
2.3.14 Sequencing of pCAM-BSD/ENT 
In order to confirm the presence of the entire coding region of the ENT fragment in the 
construct and also to verify whether the sequences matches that enlisted in the PlasmoDB 
for the gene, an aliquot of the purified pCAM/BSD-ENT construct was sent for sequencing 
at the University of Dundee Sequencing Service (DSS). Purified pCAM/BSD-ENT 
construct at a concentration of 600 ng/30 µl H2O and 3.2 µM of the pCAM/BSD forward 
primer were sent. 
2.4  Transfection of P. falciparum by electroporation 
P. falciparum parasite, clone 3D7, was transfected with the PCAM-BSD/ENT construct 
using previously described methods (Sidhu and Fidock, 2005). Briefly, a 3 ml culture at 
around 5-6% parasitaemia (predominantly of ring-stage parasites) was washed with an 
incomplete cytomix (120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
K2HPO4/ KH2PO4, 25 mM Hepes, pH 7.6). The parasite pellets were then re-suspended to 
a final volume of 400µl in an incomplete cytomix containing 100 µg of the purified DNA 
construct. Electroporation of the parasites was performed in a 0.2 cm cuvette using a 
GenePulser (Bio-Rad) set at 0.33 kv and 950 µF. Control cells were treated similarly 
except that the cytomix did not contain any DNA construct. After electroporation, samples 
were mixed with fresh erythrocytes to give a 5% haematocrit in normal complete culture 
medium RPMI1640 with 10% human serum, supplemented with 1mM adenosine, 
hypoxanthine and inosine. The culture was maintained under standard conditions as 
described in section 2.1.4.  
 
 
2.4.1 Selection of transfected P. falciparum parasites 
Forty-eight hours after transfection, blasticidin (CALBIOCHEM, Merck Biosciences Ltd, 
Nottingham) was added to the culture to a final concentration of 2.5µg/ml in order to select 
for transfected cells containing the construct (PCAM-BSD/ENT). The culture was 
maintained under constant 2.5 µg/ml blasticidin drug pressures. The pCAM-BSD vector 
contains a cassette conferring resistance to blasticidin (BSD) as a positive selectable 
marker (Sidhu et al., 2005). As the parasite is haploid and ENT is a single copy gene, only 
one round of drug selection is necessary to obtain a null-mutant. Blasticidin-resistant 
parasites appeared after 3-4 weeks of selective culture.  
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2.4.2 Verification of integration by PCR 
Integration of the episome through homologous recombination into the parasite’s genome 
was verified by PCR examination of the genotype of blasticidin-resistant parasite 
populations at the ENT locus. This was done using different combinations of primers (see 
Table 2.4) which allow to distinguish between: (i) the wild-type locus, (ii) the 5’ 
integration event, (iii) the 3’ integration event, and (iv) the episomal form of the 
transfected plasmid (Figure 2.9).  
 
Genomic DNA from the control parasites (3D7 clones of P.falciparum) and the 
transfectant was extracted using previously published method (2.3.2). The DNA was 
subjected to amplification using the following PCR primer pairs: PfNT UP and PfNT 
DOWN; pCAM-BSD F2 and PCAM-BSD R2. Primers PfNT UP and PfNT DOWN 
correspond to PfNT sequences up and down stream the ENT gene respectively, while 
primers pCAM-BSD F2 and pCAM-BSD R2 correspond to pCAM-BSD vector sequences 
flanking the insertion site. Primers for the four ENT genes were designated with the prefix 
PfNT1, PfNT2, PfNT3 and PfNT4 corresponding to Pf13_0252, Pf14_0662, MAL8pl.32 
and Pfa0160c respectively. Parasites with disrupted ENT gene were designated 
3D7∆PfNT1, 3D7∆PfNT2, 3D7∆PfNT3 and 3D7∆PfNT4 for the corresponding Pf13_0252, 
Pf14_0662, MAL8pl.32 and Pfa0160c genes respectively. 
 
Primer Sequence 
PfNT1 Up 5′ TATGGAATACAGCCTTAGG 3′ 
PfNT1 Down 5′ CTAACATAGCCATACATACAC 3′ 
PfNT2 Up 5′ GGATACGTTTCATACAACAG 3′ 
PfNT2 Down 5′ CACAATTCTTACATGAACC 3′ 
PfNT3 Up 5′CACTACAGAATGGACGGAATTACA3′ 
PfNT3 Down 5′ATCCATAGCCTGTTAACAAGCCAA3′ 
PfNT4 Up 5′ GAGGAGATCCAGATAAAGGTTA′ 
PfNT4 Down 5′ TCTGATATTCTGGCATAACTAATA3′ 
pCAM-BSD_ F2 5′ ATTTATTAAACTGCAGCCC 3′ 
pCAM-BSD_R2  5′ AAGCTGGAGCTCCACCGC 3′ 
 
Table 2.3: Primers used to check integration of the episomes: PfNT1, PfNT2, PFNT3 and 
PfNT4. 
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Wild type ENT locus
BSD
× 
pCam-BSD/ENT
BSD 
ENT
1 4
2 3
1 3 2 4
Non  functional  ENT gene 
A 
 
 
Figure 2.9:Confirmation of integration in P. falciparum transfectant lacking the ENT gene. 
‘A’ is the entire ENT gene and the part in light blue colour (labelled ENT) represent the 
fragment used in preparing the construct. The primers for checking the various integration 
events are marked 1-4. Combination of 1 + 3: indicate integration at 5’end; 2 + 4: indicate 
integration at 3’end; 2 + 3: indicate the presence of the episome; 1 + 4: indicate the 
presence of the ENT Wild type locus. NB: 1 = PfNT Up; 2 = pCAM F2; 3 = pCAM R2; 4 = PfNT 
Down. 
Primer combination Cycling condition Expected product 
size (bp) 
PfNT1 UP+pCAM R2 (1+3) 731 
PfNT1Down+pCAM F2 (2+4) 840 
pCAM F2+pCAM R2 (2+3) 712 
PfNT1 Up+NT1 Down (1+4) 
94°C, 3min/ 94°C, 30sec/ 
55°C, 1min/ 62°C,2min/ 
25 cycles/ 62°C, 5min 
895 
PfNT2 UP+pCAM R2 (1+3) 942 
PfNT2Down+pCAM F2 (2+4) 1138 
pCAM F2+pCAM R2 (2+3) 818 
PfNT2 Up+NT2 Down (1+4) 
94°C, 3min/ 94°C, 30sec/ 
55°C, 1min/ 62°C,2min/ 
25 cycles/ 62°C, 5min 
1266 
PfNT3 UP+pCAM R2 (1+3) 1401 
PfNT3 Down+pCAM F2 (2+4) 1244 
pCAM F2+pCAM R2  (2+3 949 
PfNT3 Up+NT3 Down (1+4) 
94°C, 3min/ 94°C, 30sec/ 
55°C, 1min/ 62°C,2min/ 
25 cycles/ 62°C, 5min 
1696 
PfNT4 UP+pCAM R2 (1+3) 1196 
PfNT4Down+pCAM F2 (2+4) 1173 
pCAM F2+pCAM R2 (2+3) 963 
PfNT4 Up+PfNT4Down (1+4) 
94°C, 3min/ 94°C, 30sec/ 
55°C, 1min/ 62°C,2min/ 
25 cycles/ 62°C, 5min 
1408 
 
Table 2.4:Primer combinations used to check integration of the episome. 
The expected product size of the amplicons and the cycling conditions for their amplification 
is shown. The primer pair combinations represent the following: PfNT UP+pCAM R2 
=integration at 5′ end; PfNT Down+pCAM F2=integration at the 3′ end; pCAM F2+pCAM 
R2=presence of the episome; PfNT Up+NT4 Down=presence of the wild type. 
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2.4.3 Cloning of 3D7∆PfNT1 parasites  
Cloning of 3D7∆PfNT1 (parasites with disrupted Pf13_0252) was performed in a 96 well 
plate using the limited dilution method previously described (Rosario, 1981). A culture of 
about 1% parasitaemia was incubated in a shaking incubator at 37°C for 48 hours to ensure 
single parasite invasion of the erythrocytes. An accurate count of parasitaemia (by 
microscopy of Giemsa-stained thin films, section 2.1.6) and red blood cell densities (using 
a haemocytometer, section 2.1.9) were performed. The number of parasites per microlitre 
of culture was calculated by multiplying the red cell density by the parasitaemia. The 
culture was diluted with 5% blood suspension in complete RPMI 1640 to obtain a 
concentration range of 10000-0.5 parasites/0.1 ml aliquot. Twenty cultures of 0.5 parasites/ 
0.1ml in alternative wells of a 96-well plate were set up. Five other wells containing 
cultures with parasitaemia of 10000 parasites/0.1ml or 100 parasites /0.1 ml respectively 
were also set up on the plate.  
The culture medium contains blasticidin (2.5 µg/ml) and was supplemented with additional 
purines to a final concentration of 1mM hypoxanthine, 1mM adenosine and 1mM inosine. 
The plate with the cultures was placed in a Modular incubator chamber (MP, Cambridge, 
UK) and gassed with a gas mixture containing 1% O2, 3% CO2, and 96% N2. The chamber 
was place in an incubator set at 37°C.  
Medium was changed every 48 hours until day 4 when smears were prepared from the 
wells with parasitaemia at 10000 parasites/ 0.1ml. The smears were processed using the 
method described in section 2.1.6 and the presence of parasites verified. Once parasites 
were present, culturing was resumed otherwise plates were discarded. 0.1ml blood 
suspension (5% PVC) was added to each culture on day 6 and the culture split into two 
wells. Microscopic examination of the culture initially at 100 parasite/ 100ml was done on 
day 7 to determine the presence of parasites. If parasites were absent from these cultures 
till day 12 then the plate was discarded. Otherwise, culturing was continued. From day 12, 
cultures from wells with the starting parasitaemia of 0.5 parasites /100 ml were 
microscopically examined for the presence of parasites.  
Once parasites were seen in a well, the entire content of the well was transferred into a 
culture flask and made up to 2ml with blood/RPMI 1640 medium at 5% PCV containing 
blasticidin (100ug/ml) and cultured as previously described (section 2.1). Fresh 
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blood/RPMI 1640 mixture (5% PCV) was added to each well on day 12 and thereafter the 
medium was changed every 24 hours. Once the parasitaemia of the cultures in the flask has 
reached 5%, PCR analysis was carried out using the method described in section 2.4.2 in 
order to verify disruption of the ENT gene. Southern blot analysis was also carried out to 
confirm integration. Once integration is confirmed stabilates were prepared: parasite clones 
from the culture flask were cryopreserved as described in section 2.1.7.  
 
2.4.4 Confirmation of Integration by Southern blot analysis 
Southern blotting was performed as described by Fidock and Wellems to independently 
confirm homologous integration at the PfNT1 locus in the parasite clones and the absence 
of the wild type(Fidock & Wellems, 1997). Genomic DNA from the wild type and the 
clones was extracted using previously described method (section 2.3.2). 5 µg DNA was 
digested with XmnI. A 20 µl digestion mix consisting of 1× NEBuffer 2 (50 mM NaCl, 10 
mM Tris-HCl, 10 mM MgCl2, 1mM DTT), 1U Xmn 1, 0.2 µl and 100 µg/ml BSA was set 
up. The Digest-mix was incubated at 37°C overnight. 12 µl, of the digest-mix were loaded 
on 0.8% agarose gel and run at low voltage (22 V) overnight. After electrophoresis, the gel 
was photographed. 
 
The DNA was partially depurinated by immersing the gel in 0.25 M HCl for 15 minutes. 
Alkaline denaturation of nucleic acid was performed by agitating the gel in denaturation 
solution: (0.2 mM and 0.5 M NaCl). This was followed by neutralisation of the gel at room 
temperature for 1 hour in a solution containing, 0.025 MNaHPO4/NaH2PO4 (pH=6.5).  
 
Denatured DNA was transferred from the gel onto a positively charged nylon membrane 
(Hybond N+, Amersham Biosciences) by capillary action using 20× SSC (17.5% NaCl, 
8.8% sodium trisodium citrate, pH 7). The transfer was allowed to continue for up to 24 
hours at room temperature. The membrane containing the DNA was washed in 2 × SSC to 
remove residual agarose by placing it in a tray containing the solution and shaking it gently 
for 10 minutes at room temperature. The membrane was then air-dried at room 
temperature. The DNA was cross-linked to the membrane by exposure to UV illumination 
using the StrataLinker™ 2400 UV Crosslinker (Stratagene) set at optimium crosslink.  
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A PfNT1fragment was used as fluorescein- labelled ENT probe using the ‘Gene Images™ 
Random Prime Labeling Kit’ (Amersham Biosciences, USA,). The kit is designed to label 
nucleic acid by random prime labelling (Amersham Hand book). Nonamers of random 
sequence are used to prime DNA synthesis on a denatured DNA template in a reaction 
catalysed by the klenow fragment of E coli DNA polymerase. Fluorescein-11-dUTP (F1-
dUTP) partially replaces dTTP in the reaction so that a fluorescein labelled probe is 
generated (http://www.gelifesciences.co.jp/tech_support/manual/pdf/nadna/RPN3520.pdf). 
There is net synthesis of probe in this reaction, with up to 350ng probe synthesised from 
50ng template. The probe can be denatured and used directly in hybridisation. 
 
Detection of the hybridised gene of interest was done with the Gene Images CDP star 
detection module. Following hybridisation this detection module allows detection of 
hybrids by incubation with antifluorescein alkaline phosphatase (AP) conjugate. After 
washing off the excess conjugate, probe-bound AP is used to catalyse light production by 
enzymatic decomposition of a stabilised dioxetane substrate (Amersham Handbook). 
 
Following the instructions in the manufacturer’s handbook 50ng PFNT1 DNA was 
denatured by heating for 5 minutes in boiling water and used to prepare the probe. A 50 µl 
reaction-mix was prepared in 1.5ml microcenrifuge tube placed on ice bath. The reaction-
mix consist of the following: 50ng denatured PfNT1 DNA, 10 µl nucleotide mix (5× F1-
dUTP, dATP, dCTP, dGTP and dTTP in Tris-HCl, pH 7.8, mercaptoethanol and MgCl2), 5 
µl primers (random monomers in an aqueous solution), enzyme solution (5 units/µl 
exonuclease free Klenow in buffer, pH 6.5), top up to the final volume with water  
The reaction-mix was gently pipetted up and down followed by brief spin to ensure 
uniform mixture. The reaction-mix was incubated at 37°C for 1 hour. 
 
Following the manufacturer’s instructions the Southern blot was hybridized to the probe 
representing the same region of PfNT1 present in the plasmid pCAM/BSD-NT1. The probe 
hybridized to a 7.9kb fragment in wild type 3D7 parasites, representing the genomic copy 
of PfNT1. This was followed by detection using the Gene Images CDP-Star detection 
module. 
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2.5 Isotopic method for testing sensitivity to 
antimalarial drugs. 
Cultures used for the drug sensitivity assays contained predominantly ring forms of the 
parasites. In some cases cultures were naturally synchronous; otherwise they were 
synchronized by brief incubation with 5% aqueous D-sorbitol using standard method 
(Lambros & Vanderberg, 1979) [Section 2.1.5]. All drug sensitivity assays were performed 
in 96-well microtitre plates using the method described by Rieckmann and 
others(Rieckmann et al, 1978). Briefly, stocks of drugs were prepared by dissolving in 
DMSO.Chloroquine was prepared from chloroquine sulphate supplied by May and Baker, 
England. The Pyrimethamine used was a gift from Prof. David Walliker (University of 
Edinburgh, UK) to Dr Lisa Randford Cartwright (University of Glasgow, UK). Serial 
dilutions of the dissolved drugs were made with incomplete RPMI1640 medium to obtain 
five times the required final concentration range. Each well of a microtitre plate, except for 
the outermost rows and columns, was pre-dosed with 50 µl of the appropriate drug 
solution. Parasite cultures were diluted appropriately with fresh uninfected erythrocytes 
and RPMI 1640 culture medium to achieve a final parasitaemia in the wells of 0.5-1.0% 
and PCV of 2%. Two hundred microlitres of the diluted parasite culture were added to 
each well of the pre-dosed plates. Positive control wells consisted of: 50 µl culture medium 
without drug (but containing the same amount of DMSO as in drug wells) and 200 µl 
infected erythrocytes. Negative control wells contained 50 µl culture medium without drug 
(but containing the same amount of DMSO as in drug wells) and 200 µl uninfected 
erythrocytes respectively. Each assay point was done in triplicate on the same plate and 
each experiment was performed three times. 
The plates were incubated at 37°C for 42-48 hours in a modular incubator chamber (MP, 
Cambridge, UK), gassed with a mixture of 3% CO2, 1% O2, 96% N2. Cultures were 
incubated for an initial period of 24 hours followed by the addition of 10 µl of incomplete 
RPMI1640 medium containing 1.87 µM [3H]-hypoxanthine with a specific activity of 37 
GBq/mmol (Amersham Biosciences to each well. Incubation was resumed under the same 
conditions for a further 24 hours. At the end of incubation, cells were harvested from each 
well onto a single fibreglass filter paper using a Filtermate Harvester (Packard 
Instruments). The filter paper was dried, sealed in a plastic bag and 3 ml scintillation fluid 
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(OptiPhase HiSafe, Perkin Elmer) was added. Radioactivity incorporated into the parasites 
was counted with a Microbeta Wallac Trilux liquid scintillation and luminescence counter. 
The IC50 value, representing 50% inhibition of uptake of [3H]-hypoxanthine, was 
determined from a non-linear regression analysis of log drug concentration against 
radiolabel incorporated into the parasites using Prism version 4.0, using the equation for a 
sigmoidal dose-response curve with variable slope. Mean IC50 values and standard errors 
of the mean (s.e.m.) for each drug were determined from three independent drug sensitivity 
assays performed in triplicate on each plate.   
 
2.6 PicoGreen® Method for drug sensitivity assays 
PicoGreen® (Invitrogen-Molecular Probes) is a fluorochrome which selectively binds 
dsDNA by intercalation, resulting in an exceptionally high increase in fluorescence 
emission. PicoGreen® has been shown to detect as little as 25 pg/ml of dsDNA in the 
presence of ssDNA, RNA, and free nucleotides (Corbett et al, 2004). Corbett and co-
workers also demonstrated that replication of malaria parasites was directly proportional to 
the amount of PicoGreen® fluorescence, with a linear relationship between parasitaemia of 
0.1% and 15%. This property of PicoGreen® was used in this study to determine the 
susceptibility of malaria parasites to antimalarial drugs. 
 
P. falciparum parasites were cultured in the presence of different concentrations of test 
compounds. After 48 hours incubation in a 96-well microtitre plate, 150 µl of the culture 
from each well were transferred into a new, opaque, 96-well plate and centrifuged at 630 × 
g, 5 min to pellet the cells. The supernatant was removed and the cells resuspended in 
saponin (0.15%, w/v) to lyse the erythrocytes. Following centrifugation of the plate, the 
supernatant was removed and the plate washed with 200 µl of PBS. Freed parasite pellets 
in the wells were re-suspended in 150 µl of PBS.  
Fifty microlitres of lysis/fluorescence-mix consisting of PicoGreen® (1:200 in TE buffer, 
pH 7.5) and Triton X-100 (final concentration, 2%) in nucleic acid- and DNase-free water 
were added to each well. Plates were incubated in the dark at room temperature for 
between 5-30 minutes and fluorescence intensity measured at 485 nM (Excitation) and 528 
nM (Emission) using a Perkin Elmer LS 55 Luminescence Spectrophotometer. Positive 
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control wells consisted of parasites without drugs whilst the negative controls contained 
uninfected blood. Control wells were treated similarly. The mean background reading from 
the two control wells was subtracted from the test fluorescence reading to give the final 
fluorescence measurement. Fluorescence (arbitrary units ranging from 1 to 1000 units) was 
plotted against drug concentrations in a non-linear sigmoid plot using Prism version 4.0. 
All experiments were performed in triplicate for each drug concentration. 
 
 
2.7 Data analysis 
For any given permeant, the linear phase of uptake was first determined using the 
described time dependent assay. Linearity was assessed using linear regression, defined as 
a correlation coefficient >0.95 and significant difference from zero uptake (F-test; 
GraphPad Prism version 4). A graph of the initial rate of uptake of a permeant plotted 
against substrate concentration results in a curve that becomes asymptotic to a horizontal 
line, which represents “maximum rate of uptake” referred to as the Vmax (Figure 2.10). . 
The Km is the concentration of substrate that gives "half-maximal activity" i.e. 0.5 × Vmax. 
The relationship between Km and Vmax is defined by the Michaelis-Menten equation:   
v = Vmax / (1 + (Km/[S])),               
where [S] is the concentration of substrate and v = the rate of uptake at concentration S 
The Km denotes the affinity of the transporter for the permeant. A relatively low Km value 
signifies a high affinity of the transporter for the substrate and vice versa.  
 
The effects of different inhibitors on the uptake of radiolabeled permeants in this study 
were compared using the IC50 values. The IC50 value is the concentration of the inhibitor 
required to reduce the influx of the permeant by half (50%). A relatively low IC50 value 
will therefore mean a relatively strong inhibitor, but the IC50 is a function of the permeant 
concentration. The inhibition constant Ki, which is independent of the permeant 
concentration, was calculated from the equation Ki = IC50 /(1+(L/Km)), where L is the 
permeant concentration.  
 
Neils Ben Quashie, 2008 Chapter Two  
 
77
 
Figure 2.10: A typical Michaelis-Menten plot. 
Dependence of initial velocity on substrate concentration for a reaction obeying Michaelis-
Menten kinetics. The Km is the concentration of substrate that gives "half-maximal activity 
Whilst Vmax  is the maximum rate of uptake 
(http://www.ucl.ac.uk/~ucbcdab/enzass/substrate.htm). 
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CHAPTER THREE 
3 Purine transport into uninfected and P. falciparum 
infected human erythrocytes 
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3.1 Summary 
Transport of purine from an exogenous source into P. falciparum infected erythrocyte is an 
important event, necessary for the growth and development of the parasite. Up to now, 
three routes of purine transport into the infected erythrocyte have been identified: the 
human equilibrative nucleoside transporter (hENT1), the human facilitative nucleobase 
transporter (hFNT1), and the New Permeation Pathway (NPP). Although detailed studies 
of the hENT1, hFNT1 and NPP have been carried out, there is no information on the 
relative contribution of each of these salvage mechanisms to the overall uptake of purine 
into the P. falciparum infected erythrocytes. The effect of classical inhibitors, such as 
furosemide, on hFNT1 and hENT1 has not been studied although it has been demonstrated 
for the NPP. Using a standard uptake technique, the transport of adenosine, hypoxanthine 
and adenine into uninfected and P. falciparum-infected human erythrocytes in the presence 
or absence of inhibitors was measured. Kinetic values obtained from such experiments 
allowed for the assessment of the contribution of each of these transporters to the overall 
purine salvage in parasitized erythrocytes. Results from these investigations indicate that 
transport of exogenous purines into infected or uninfected erythrocytes occurred primarily 
through equilibrative transporters, rather than the NPP, which is non-saturable. 
Hypoxanthine and adenine appeared to enter erythrocytes mainly through the hFNT1 
whereas adenosine entered predominantly through the hENT1 nucleoside transporter. The 
rate of purine uptake was approximately doubled in infected cells compared to uninfected 
erythrocytes. Additionally, the rate of adenosine uptake into infected hRBC was 
comparably higher than that of hypoxanthine uptake. It was also observed that furosemide 
has similar inhibitory effects on purine transport through the hFNT1 and the NPP. This 
observation gives support to the hypothesis that the NPP evolved out of endogenous 
proteins. From observations made in this study, it can be firmly concluded that endogenous 
transporters are the major means of purine uptake into infected erythrocytes. 
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3.2 Introduction  
The mature non-infected human erythrocytes have numerous membrane transport systems, 
which are responsible for the uptake of essential nutrients and other compounds from 
external sources (Kirk, 2001). Though the importance of some of these transport systems is 
not clear at the moment, they are thought to have evolved from the cell from which the 
erythrocyte originated (Kirk, 2001).  Most of these endogenous transport systems, 
especially those responsible for purine salvage, have been characterized with regard to 
their kinetic properties (Kirk, 2001). It has been shown that hypoxanthine is rapidly 
transported across the non-infected red cell membrane by a facilitated diffusion through the 
human facilitative nucleobase transporter (Domin et al, 1988;de Koning et al, 2005). 
Similarly, Kraupp and colleagues reported that the transport of adenine and hypoxanthine 
in human erythrocytes occurs through two mechanisms (Kraupp et al, 1991). The first 
mechanism involves a common carrier for both nucleobases and the second is through an 
unsaturable permeation pathway in which uptake is 4–5-fold faster for adenine than for 
hypoxanthine (Kraupp et al, 1991). The group further demonstrated that adenine and 
hypoxanthine ‘share a common transporter and that their membrane transport is adequately 
described by the alternating conformation model of carrier-mediated transport’. In terms of 
nucleoside transport, it has also been shown that the non-infected erythrocyte takes up 
these nutrients through the equilibrative nucleoside transporter (hENT1), which is located 
in the erythrocyte membrane (Plagemann et al, 1988). While hFNT1 is inhibited by 
papaverin (Domin et al, 1988), hENT1 is potently blocked by 6-[(nitrobenzyl)-thio] 9-β-D-
ribofuranosylpurine (NBMPR) (Plagemann et al, 1988;Plagemann & Woffendin, 1988). 
 
During the intraerythrocytic stage of the parasite lifecycle, which involves a repeated cycle 
of red blood cell invasion by the parasite, followed by multiplication and release of 
merozoites (daughter cells), there is an increased demand for nutrients, particularly 
purines. Unlike pyrimidines, the malaria parasite is incapable of de novo synthesis of 
purines and therefore has to depend on exogenous sources for the supply of this essential 
nutrient (Divo et al, 1985). Despite the abundance of adenosine triphosphate (ATP) in the 
host erythrocyte cytosol, hypoxanthine rather than adenosine is the main purine precursor 
utilized by parasite (Webster & Whaun, 1981;Scheibel & Sherman, 1988). Indeed, it has 
been shown that supplementation of culture medium with 100-400 µM hypoxanthine 
increases parasite yields three- to fourfold (Zoig et al, 1982;Divo & Jensen, 1982;Freese et 
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al, 1988). Further evidence indicating that hypoxanthine is the preferred purine source was 
provided by Berman and colleagues (Berman et al, 1991). By depleting hypoxanthine in a 
parasite culture through the addition of xanthine oxidase, P. falciparum growth was 
reduced by about 90% (Berman et al, 1991). Based on this evidence and others, Berman 
and co-workers devised a model for the metabolism of purine in non-infected and infected 
erythrocytes, which is shown in figure 3.1 (Berman et al, 1991). In the model, 
hypoxanthine may enter or diffuse out of the erythrocyte through a non-concentrative 
purine base transporter located in the RBC membrane.  
 
 
Figure 3.1:The sources of hypoxanthine in infected erythrocyte, proposed by Berman and 
colleagues (Berman et al., 1991). 
Abbreviations: ADA, adenosine deaminase; PNP, purine nucleoside phosphorylase; HPRT, 
hypoxanthine phosphoribosyl transferase; XOD, xanthine oxidase; PRPP, 5-phosphoribosyl-l-
pyrophosphate; ASS, adenylosuccinate synthase; IMPD, inosine monophosphate 
dehydrogenase. (Reproduced with permission from (Berman et al, 1991). 
 
For nutrients to reach the parasite from an exogenous source they have to cross numerous 
membranes barriers including the host RBC membrane, the parasitophorus vacuole 
membrane and the parasite’s plasma membrane (Figure 3.2). In order to facilitate the rapid 
movement of nutrient from exogenous sources into the infected cell, the parasite induces 
an additional, NBMPR-insensitive uptake system in the host plasma membrane (Gero et al, 
1988). The induced uptake system, referred to as the New Permeation Pathway has been 
described in detailed in section 1.15.1. The pathway, which does not distinguish between 
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the D and L-enantiomers of nucleosides, particularly adenosine (Upston & Gero, 1995), 
exhibits the characteristic of an anionic channel, mediating the uptake of some anions. It is, 
therefore, inhibited by a range of anionic channel blockers such as furosemide and 5-nitro-
2- (3-phenylpropylamino) benzoic acid (NPPB) (Kirk et al, 1994). 
 
Human Nucleoside Transporter
Human Facilitative Nucleobase Transporter
New Permeation pathway
Parasite Nucleoside Transporter
Red cell Membrane
Parasite Plasma Membrane
Parasitophorous Vacuole Membrane
Parasite
RBC
 
Figure 3.2: Schematic presentation of an infected human erythrocyte showing location of 
purine transporters and the new permeation pathway. 
  
Given the continued presence of the hFNT1 and hENT1 in the infected erythrocyte, it is 
not completely clear what function the NPP plays with regard to purine salvage.  Although 
the purine-mediating role of the NPP as well as the other endogenous transporters has been 
studied, the relative contribution of each component to the overall purine salvage in an 
infected cell has not been clearly elucidated. The current study therefore sought to 
investigate the degree to which the overall purine salvage by the intraerythrocytic-stage P. 
falciparum-infected erythrocyte is attributable to the NPP. Using classical inhibitors that 
block the NPP and the endogenous transporter, hENT1, the kinetics of purine transport into 
infected and non-infected RBC was studied. Transport of 0.5 µM [3H]-adenosine or 1.0 
µM [3H]-hypoxanthine into P. falciparum-infected erythrocytes and uninfected 
erythrocytes in the presence of NBMPR, furosemide, and 1mM of unlabelled adenosine or 
hypoxanthine was investigated. The inhibitory effect of increasing concentrations of 
furosemide and unlabelled adenine on the uptake of 1.0 µM [3H]-adenine into uninfected 
erythrocytes was also investigated. 
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3.3 Adenosine uptake into Percoll™-enriched P. 
falciparum infected erythrocytes is not consistent 
with salvage through the NPP  
The extent to which the new permeation pathway contributes to adenosine salvage in P. 
falciparum-infected erythrocytes was investigated in this study. All experiments were 
carried out using the 3D7 clone of P. falciparum at the trophozoite-stage. The parasites 
were maintained in complete RPMI 1640 using the Trager and Jensen method, described in 
section 2.1.4 of this thesis. Prior to an experiment the culture was synchronized using 
standard method (Lambros & Vanderberg, 1979) (section 2.1.5).  Cell counts of the culture 
were made using an improved Neubauer counting chamber and the parasitaemia was 
determined on methanol-fixed, Giemsa-stained blood smears (section 2.1.6). 
 
Concentrated trophozoite-stage infected erythrocytes (60-90% parasitaemia) were obtained 
by density gradient sedimentation on Percoll™ (Amersham Biosciences) using previously 
described method (Gero et al, 1988;Kirk & Horner, 1995). Briefly, isotonic Percoll™ 
solution was prepared by mixing the stock Percoll™ solution (100%) with PBS and 
distilled water to give a working solution of density 1.090 and osmolality 320 mosm (kg 
H2O)-1. Concentration of the trophozoite-stage parasitized erythrocytes was achieved by 
layering an equal volume of culture at 10% haematocrit on top of the isotonic Percoll 
solution and centrifuging at 650 × g for 12 minutes. The trophozoite-enriched red blood 
cells were harvested from the interface. Pellets with up to 80% infected erythrocytes were 
obtained using this method. The concentrated cells were washed three times with 
incomplete RPMI 1640 and incubated in the same medium containing glucose (0.2%) for 
30 minute to allow for full recovery of the parasites before their use in uptake experiments.  
Results were similar when erythrocyte medium (140mM NaCl, 5mM KCl, 20mM 
Tris/HCl, (pH 7.4), 2mM MgCl2, and 0.1mM EDTA) was used as the assay buffer instead 
of incomplete RPMI 1640. 
Transport of 0.5 µM [3H]-adenosine into uninfected and P. falciparum infected 
erythrocytes was investigated using the uptake technique described in section 2.2. Briefly, 
a solution of radiolabeled adenosine at twice the intended final concentration was prepared 
in the presence (also at twice the final concentration) or absence of NBMPR or furosemide. 
An equal volume of the radio-labelled adenosine/inhibitor mixture and the Percoll-
concentrated parasitized erythrocytes were mixed together and at predetermined time 
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interval 200 µl of the mixture was dispensed into an ice-cold stop solution which had been 
carefully layered on an oil-mix (300 µl of 5 parts dibutylphthalate: 4 parts dioctyl 
phthalate, v/v) in a 1.5 ml microcentrifuge tube. The influx of the permeant was terminated 
by sedimenting the parasites below the oil using centrifugation at 13000 × g for 60 s. The 
stop solution used in this experiment contains 10 µM dilazep and 200 µM furosemide in 
erythrocyte medium (140 mM NaCl, 5 mM KCl, 20 mM Tris/HCl, (pH 7.4), 2 mM MgCl2, 
and 0.1 mM EDTA). Furosemide in the stop solution inhibits the parasite-induced new 
permeation pathway whilst dilazep is an inhibitor of the exogenous (erythrocyte) 
nucleoside transporter (Kirk, 2001). Uninfected erythrocytes were incubated in parallel 
with the infected erythrocyte culture under identical conditions for at least 24 hours before 
the start of the experiment and were also centrifuged through isotonic Percoll™. The 
uptake of permeant into these cells was investigated using the same procedure described 
for the infected cells. The samples were processed for scintillation counting using the 
procedure described in section 2.2.7. 
Non-mediated influx of adenosine into the cells was assessed by measuring the rate of 
uptake of the radiolabeled permeant in the presence of 1 mM unlabeled permeant. The rate 
of uptake of adenosine was obtained from a plot of permeant concentration against time. 
Experiments were performed in triplicate at room temperature.  
 
Observations made in these experiments indicate that 0.5 µM [3H]-adenosine was 
transported very rapidly into both P. falciparum-infected and uninfected human 
erythrocytes. A plot of permeant concentration against time indicates that the uptake was 
linear for at least 10 seconds, thus allowing for the determination of uptake rates by linear 
regression over this period. The results shows that [3H]-adenosine was taken up by 
uninfected human erythrocytes with a rate of 0.032 ± 0.006 pmol (107 cells)-1s-1 with 
complete inhibition of uptake in the presence of 1 mM unlabelled permeant (Figure 3.3). 
Uptake of 0.5 µM [3H]-adenosine by the uninfected erythrocyte was 95% inhibited by 100 
nM NBMPR (Figure 3.3). This observation is in line with the well-documented presence of 
the NBMPR-sensitive es/hENT1 adenosine transporter in human erythrocytes (Plagemann 
1988). An important observation made in this study is that adenosine uptake into infected 
or uninfected human red blood cells (hRBC) was not noticeably inhibited by 100 µM 
furosemide (Figure 3.4), suggesting that the NPP plays at best a limited role in the salvage 
of this purine.  
The uptake rate of 0.5 µM [3H]-adenosine into infected human erythrocytes (0.070 ± 
0.005) was observed to be more than twice as fast than into uninfected erythrocytes and 
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adenosine also accumulated two fold higher in P. falciparum-infected erythrocytes than in 
uninfected cells (Figure 3.4). This observation is consistent with a generally higher level of 
nutrient uptake in infected cells as discussed by Kirk and colleagues (Kirk et al, 1999). 
Since the uptake of this nucleoside, as observed in this study, was almost completely 
inhibited by NBMPR and also the salvage mechanism involved was fully saturable (which 
are inconsistent with the properties of the NPP), it may be concluded that the NPP plays 
only a minor role in the salvage of adenosine in infected erythrocytes.  
This conclusion was further strengthened by the observation that the rate of adenosine 
uptake in infected hRBC was identical in the presence or absence of 100 µM of the NPP-
inhibitor furosemide (0.054 ± 0.006 and 0.059 ± 0.003 pmol (107 cells)-1s-1, respectively), 
which indicates that hENT1 was not sensitive to furosemide (Figure 3.4).  
In conclusion, evidence gathered from these experiments indicates that adenosine transport 
in P. falciparum infected erythrocyte is overwhelmingly through hENT1.  
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Figure 3.3: Adenosine transport in P. falciparum-infected and uninfected human 
erythrocytes with inhibition by NBMPR. 
Uptake of 0.5 µM [3H]-adenosine in Percoll-enriched infected (closed symbols, dashed lines) 
and uninfected (open symbols, solid lines) erythrocytes without inhibitor (squares), in the 
presence of 0.1 µM NBMPR (circles) or 1 mM unlabelled adenosine (ADO) (triangles). 
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Figure 3.4: Adenosine transport in P. falciparum-infected and uninfected human 
erythrocytes with inhibition by furosemide. 
Uptake of 0.5 µM [3H]-adenosine in Percoll-enriched infected (closed symbols, dashed lines) 
and uninfected (open symbols, solid lines) erythrocytes without inhibitor (squares), in the 
presence of 100 µM furosemide (circles) or 1 mM unlabelled adenosine (triangles). 
 
 
3.4 Hypoxanthine uptake into uninfected erythrocytes 
and Percoll-enriched P. falciparum-infected 
erythrocytes occurs mainly through hFNT1 and is 
inhibited by furosemide 
Transport of hypoxanthine through hFNT1 following the blocking of the NPP with 
furosemide was investigated. Uptake of 1 µM [3H]-hypoxanthine into uninfected 
erythrocytes and into Percoll- enriched P. falciparum infected erythrocytes was performed 
in the presence or absence of 250 µM furosemide. The cell preparation and uptake 
techniques employed were as described for the experiment with adenosine (section 3.3). 
The stop solution used in these experiments consisted of 19 mM Papaverine (in 165 mM 
NaCl), which inhibits the exogenous nucleobase transporter, hFNT1 (Domin et al, 1988). 
Assessment of the non-mediated influx of permeant into the cells was performed by 
measuring the rate of uptake of the radiolabeled permeant in the presence of 1 mM 
unlabelled permeant, as well as with cells and permeant at 0 oC. Since increased 
phosphoribosylation of nucleobases occurs in phosphate-containing buffers (Capuozzo et 
al, 1986;Plagemann, 1986), a phosphate-free buffer was used in these transport 
experiments in order to minimize metabolism of the purine nucleobases that might 
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otherwise complicate the interpretation of the results. The rate of uptake of hypoxanthine 
was obtained from a plot of permeant concentration against time.Transport of 1 µM [3H]-
hypoxanthine into uninfected erythrocytes and into Percoll-enriched P. falciparum infected 
erythrocytes was saturable and linear for up to 10 seconds. Uptake of 1 µM [3H]-
hypoxanthine into uninfected erythrocytes hFNT1 was observed to occur at a rate of 0.012 
± 0.005 pmol (107 cells)-1s-1 and involved a fully saturable transporter (Figure 3.5). This 
rate was considerably lower than the uptake of 0.5 µM [3H]-adenosine. Transport of 1 µM 
[3H]-hypoxanthine was also saturable in Percoll-enriched P. falciparum-infected 
erythrocytes, at 0.029 ± 0.005 pmol(107 cells)-1s-1 (Figure 3.5). This represents a very 
similar increase in transport rates, of 2.3-fold and 2.1-fold, respectively, for hypoxanthine 
and adenosine in parasite-infected hRBC compared to uninfected hRBC. Hypoxanthine 
uptake by the uninfected and P. falciparum-infected hRBC was inhibited 65% and 67%, 
respectively, by 250 µM furosemide (Figure 3.5). The inhibition of hFNT1 by furosemide 
has not been reported previously. To further investigate the effect of furosemide on the 
hFNT1, hypoxanthine was replaced with adenine as the substrate (see section 3.5 below). 
The choice of adenine was based on the fact that it is reported to be the preferred substrate 
for this transporter and it is also stable after uptake (Wallace et al, 2002).  
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Figure 3.5:Transport of 1 µM [3H]-Hypoxanthine in P. falciparum-infected and uninfected 
human erythrocytes with inhibition by furosemide. 
Uptake of 1 µM [3H]-hypoxanthine (Hypox) in Percoll-enriched infected (closed symbols, 
dashed lines) and uninfected (open symbols, solid lines) erythrocytes without inhibitor 
(squares), in the presence of 250 µM furosemide (circles) or 1 mM unlabelled hypoxanthine 
(triangles). 
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3.5 Adenine transport into uninfected human 
erythrocytes is inhibited by furosemide 
To further investigate the inhibitory effect of furosemide on transport of nucleobases 
through hFNT1, the dose-dependent inhibition of uptake of [3H]-adenine into uninfected 
erythrocytes was investigated. Dose-dependent inhibition of uptake was investigated as 
described in section 2.2.6. Briefly, mature human erythrocytes were washed three times 
with erythrocyte medium (section 3.2) and re-suspended in the same medium to achieve a 
haematocrit of 25%. The cell suspension was allowed to equilibrate at room temperature 
for approximately ten minutes. The RBC concentration of the suspension was determined 
with the improved Neubauer counting chamber, to allow uptake to be expressed in terms of 
cell number. The cell suspension and different concentrations of furosemide or unlabelled 
adenine, containing [3H]-adenine at a final concentration of 1 µM were incubated on top of 
an oil-mix for 5 seconds. The concentration range for unlabelled adenine and furosemide 
was 0 – 1000 µM and 0 – 500 µM respectively. The flux of [3H]-adenine into the cells was 
terminated by the addition of 1 ml cold stop solution (19 mM Papaverine in 165 mM NaCl) 
followed by centrifugation at 13000 × g to pellet the cells and separate them from the 
aqueous layer through the oil-mix, thus preventing further uptake of radiolabeled 
permeant. The cell pellets were retrieved as previously described (Section 2.2.7) and the 
amount of radiolabeled adenine taken up into the cells was determined by scintillation 
counting. The IC50 value for the inhibition of uptake of 1 µM [3H]-adenine by unlabelled 
adenine and by furosemide was determined from a non-linear plot of [3H]-adenine uptake 
against log concentration of the inhibitor.  
  
The results of the dose-dependent uptake of 1µM [3H]-adenine into uninfected erythrocytes 
in the presence of unlabelled adenine and furosemide are shown in Figure 3.6. Furosemide 
was observed to competitively inhibit the uptake of [3H]-adenine into uninfected 
erythrocytes with a mean IC50 value of 5.6 ± 2.2 µM. High extracellular concentrations of 
unlabelled adenine similarly inhibited uptake of [3H]-adenine into the uninfected cells with 
a mean IC50 value of 3.7 ± 0.9 µM. 
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Figure 3.6: Adenine transport in uninfected human erythrocytes with inhibition by 
furosemide. 
Uptake of 1 µM [3H]-adenine by uninfected human erythrocytes over 5 seconds, in the 
presence or absence of various concentrations of unlabelled adenine (closed squares) or 
furosemide (open circles), as indicated. The experiment shown is representative of four 
independent experiments and was conducted in triplicate. Data points represent the mean 
of three samples and error bars for each point represent the standard errors of the mean. 
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3.6 Discussion  
The observations reported in this chapter provide compelling evidence that purine salvage 
in the trophozoite stage of P. falciparum infected erythrocyte occurs mainly through the 
hFNT1 and hENT1 endogenous transporters on the red cell surface. These observations 
contradict reports implicating the NPP as the main channel of purine uptake into P. 
falciparum trophozoite-stage infected erythrocytes. The results reported here clearly 
demonstrate that in P. falciparum infected erythrocytes, purine uptake occurs primarily 
through saturable transporters: adenosine appeared to be transported from exogenous 
sources into the cell through hENT1 whilst hypoxanthine uptake was through hFNT1. The 
equilibrative nature of the transporters observed here clearly suggests that the NPP, which 
is non-saturable and not inhibited by NBMPR, plays only a minor role in purine salvage 
and uptake into infected erythrocytes. Although the NPP is doubtless capable of mediating 
purine transport, our results show that this channel is not as important to purine uptake into 
infected cells as previously thought. However, there is strong evidence to show that the 
NPP generally plays a major role in the salvage of other nutrients such as pantothenic acid 
into the infected cells(Saliba et al, 1998). Not only are hFNT1 and hENT1 present in 
malaria parasite-infected erythrocytes, their activity appears to be increased and this can 
not be attributed solely to increased purine utilisation as initial transport rates and total 
uptake over 30 s were both increased. A similarly increased rate of uptake up into infected 
erythrocytes compared with the uninfected cell has also been reported for other 
compounds. The activity of the Na-K pump in uninfected erythrocytes was increased two-
fold after infection with P. falciparum (Staines et al, 2001). A significant increase in the 
rate of uptake of tryptophan (Ginsburg & Krugliak, 1983) and choline (Elford et al, 1990) 
into infected erythrocytes, compared to uninfected cells, has also been reported. The 
regulatory mechanism behind this general increase in transporter efficiency is not known. 
 
Notwithstanding our observation that the majority of adenosine and hypoxanthine uptake 
into infected erythrocytes was mediated by the hENT1 and hFNT1, others (Upston & 
Gero, 1995;Gero & Hall, 1997) have reported that nucleosides, at least, can be transported 
by the furosemide-sensitive New Permeation Pathways (NPP). Gero and co-workers 
clearly demonstrated the uptake of L-adenosine, which is not a substrate of hENT1, 
through the NPP (Upston & Gero, 1995;Gero & Hall, 1997). Our observations place some 
doubt on the pharmacological importance of the NPP as a conduit for selective entry of 
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toxic enantiomers into the infected erythrocytes only (Gero et al, 1999), although the 
selective uptake of even small amounts of the L-enantiomer, comparative to D-adenosine, 
could affect parasite viability. 
  
In line with findings from this study, it is being proposed that inhibition of the hENT1 may 
cause parasite death, most likely through purine starvation. This assertion is supported by 
reports showing that nucleoside transport inhibitors, such as NBMPR, dilazep and 
dipyridamole, all display intrinsic activity against P. falciparum in vitro (Plagemann, 
1986). It is therefore most likely that inhibitors of hENT1 would have at least a growth-
delaying effect on P. falciparum , and perhaps more so if used in combination with an 
inhibitor of the hFNTl. However, it must be emphasised that blocking both endogenous 
transporters would also deprive the uninfected erythrocytes of a purine source. While 
erythrocytes, unlike the Plasmodium parasites that infect them, do not need purines for 
nucleic acid synthesis, their energy balance would be affected as they require adenosine for 
synthesis of ATP (Komarova et al, 1999). However, it is anticipated that infected 
erythrocytes will be far more quickly affected as their intracellular purine stores would be 
rapidly depleted by the highly efficient P. falciparum purine salvage system. 
A further observation made in this study is that the rate of adenosine uptake is considerably 
higher than the rate of hypoxanthine uptake in infected hRBC even though hypoxanthine is 
the preferred purine for P. falciparum (Berman et al, 1991;Berman & Human, 1991). An 
explanation for this observation could be that due to the presence of adenosine deaminase, 
adenosine is rapidly converted to hypoxanthine in the cytosol of the infected erythrocyte, 
as reviewed by De Koning and colleagues (de Koning et al, 2005). 
  
A final notable observation made in this study is the inhibition of transport through hFNT1 
by furosemide. The inhibition by furosemide of [3H]-hypoxanthine and [3H]-adenine 
uptake reported here was definitely not through inhibition of the NPP, as it was observed 
equally in infected and uninfected hRBC. The similar inhibitory effect of furosemide on 
hFNT1 and NPP increase the suspicion that the NPP is a modification of endogenous 
protein as suggested by (Egee et al, 2002) and (Verloo et al, 2004). However it must be 
emphasised that furosemide is not a very specific agent, as it blocks several other 
transporters and channels in the host erythrocytes including the Na+/K+ co-transporter 
(Dunham et al, 1980;Garcia-Romeu et al, 1991).  
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3.7 Conclusions  
Nucleobases and nucleosides present at very low levels in the host plasma gain entry into 
the parasite-infected erythrocyte predominantly through equilibrative transporters rather 
than the parasite-induced New Permeation Pathway, which is reported not to be saturable. 
The process of uptake is efficiently driven by the rapid salvage of purines from the cytosol 
by the intracellular parasite, which maintains a concentration gradient across the hRBC 
plasma membrane. This study also showed a faster uptake rate of adenosine into parasite-
infected cells compared with hypoxanthine. The rate of purine uptake was also found to be 
approximately doubled in parasite-infected cells compared to uninfected cells. 
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CHAPTER FOUR 
4 Purine transport in saponin-freed P. falciparum 
trophozoites 
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4.1 Summary 
The malaria parasite P. falciparum lacks the capability to synthesise the purine ring de 
novo and has to salvage this important nutrient from the host milieu through transporters. 
Although the potential of these transporters as target for novel antiplasmodial compounds 
has been recognised, compared to other protozoa such as Trypanosoma brucei and 
Leishmania donovani little is known about their kinetic properties. Yet such knowledge 
would inform any rational design strategy for purine-based antimalarial drugs. It was 
therefore an objective of this study to systematically investigate and characterise the 
parasite’s purine transporters in terms of their substrate affinity, selectivity, and the role 
they play in the salvage of purine from the host. Using classical uptake techniques, four 
transporters were identified in saponin-freed P. falciparum-infected erythrocytes. Three 
separate and novel transport activities were identified:  a high affinity hypoxanthine 
transporter with a secondary capacity for purine nucleosides, which was named PfNT1, a 
separate high affinity transporter for uptake of adenine (named PfADET1) and a low 
affinity/high capacity adenine carrier (denoted PfADET2). Additionally, a low affinity 
adenosine transporter with kinetic properties similar to that previously reported by other 
research groups was also characterised. The kinetic data obtained in this study 
demonstrated that hypoxanthine was taken up with 12-fold higher efficiency than 
adenosine, confirming assertions that hypoxanthine is the preferred source of purine for the 
growing parasite. A hypoxanthine analogue, JA-32, was found to exhibit promising 
antimalarial activity. These findings re-emphasise the importance of purine transporters as 
targets for novel antimalarial drugs. A new model for purine salvage in P. falciparum is 
presented, based predominantly on the highly efficient uptake of hypoxanthine by PfNT1 
and a high capacity for purine nucleoside uptake by a lower affinity carrier. 
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4.2 Background 
P. falciparum parasites require purine for the synthesis of DNA and other important bio-
molecules needed to sustain life, growth and reproduction. Like the other members of the 
parasitic protozoa studied to date, P. falciparum are unable to synthesize purine de novo 
and have to depend on salvage mechanisms for the supply of this essential nutrient from 
the host. To date, all transporters of purine nucleosides in protozoa have been found to 
belong to the Equilibrative Nucleoside Transporters (ENT) family. The characteristics of 
ENT transporters have been described in detail in section 1.20 of this thesis.  
 
Four putative Equilibrative Nucleoside Transporters (ENT) genes, denoted PFA0160c, 
MAL8P1.32, PF14_0662 and PF13_0252 have been identified within the P. falciparum 
genome database (Martin et al, 2005). However, only one gene PF13_0252, has been 
characterised and was believed to encode a moderate to low affinity adenosine transporter 
(Parker et al, 2000;Carter et al, 2000). The two groups independently cloned a P. 
falciparum gene of the equilibrative nucleoside transporter family, which they termed 
PfENT1 or PfNT1. The protein was expressed in Xenopus laevis oocytes and the kinetics 
of transport was assessed. However, the two groups reported significantly different kinetic 
properties for the same protein. Carter and colleagues described PfNT1 as a broad 
specificity nucleoside transporter with Km values of 13.2 µM and 253 µM for adenosine 
and inosine, respectively, and no affinity for nucleobases (Carter et al, 2000). In contrast, 
Parker and co-workers reported a purine nucleoside/nucleobase transporter with a similar, 
but low, affinity for adenosine, adenine and hypoxanthine (Km values 320 – 410 µM) 
[(Parker et al, 2000)].  
 
One reason for the observed difference could be linked to the type of system in which the 
protein was expressed. It has been documented that endogenous proteins present in vectors 
such as Xenopus laevis are able to interact with foreign expressed proteins, which affect 
their functional properties and thereby confound the results obtained from studies using 
such proteins (Wagner et al, 2000).  
 
The work presented in this chapter was designed to address the large discrepancy observed 
in the two available studies of purine transport, both of which used exogenous expression 
systems. To avoid the potential problems of variable expression levels associated with 
Xenopus oocytes, purine transport was studied in the parasite itself, using saponin-freed P. 
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falciparum parasites. This work was started in 2004, and was in the process of finalisation 
when a third group, led by Kirk, published data on the kinetic properties of a purine 
transporter in the parasite, similarly using saponin-freed P. falciparum parasites (Downie 
et al, 2006). The outcome of their investigation showed the presence of a low affinity 
adenosine transporter, similar to that described by (Parker and Carter) with Km estimates of 
13 and 320 µM (Parker et al, 2000;Carter et al, 2000). However, despite using the same 
system as that presented here, the conclusions reported were completely different. A major 
short coming of the published studies is that they all used micromolar concentrations of 
radiolabelled substrate in their assays, which would result in the saturation of any 
transporters with sub- or lower-micromolar Km values. Thus the presence of high affinity 
purine transporters could not be detected. The current studies used radiolabeled substrate 
concentrations in the sub-micromolar range (0.1-0.5 µM), allowing detection of any high 
affinity transporters if present.  
 
 
4.2.1 Mechanism of permeabilisation of P. falciparum infected 
erythrocytes 
 
P. falciparum parasites with a permeabilised red cell membrane were prepared using the 
saponin permeabilisation method. The plant-derived detergent, saponin, interacts with 
cholesterol in the cell membrane, causing ‘disruption of the barrier properties of 
cholesterol-containing membranes’ (Ansorge et al, 1996). Although the ghost of the red 
cell membrane remains present (Figure 4.1), it no longer acts as barrier to the entry of 
compounds from external sources (Siddiqui et al, 1979).  
 
The parasitophorous vacuole membrane is also not a barrier to the inward movement of 
nutrients as studies show that it is permeable to small solutes (Desai et al, 1993). Since the 
parasite plasma membrane is not significantly affected by the saponin treatment (Saliba et 
al, 1998;Allen & Kirk, 2004), initial rates of transport measured in this system reflect 
uptake by the Plasmodium- encoded transporters located in the parasite’s plasma 
membrane. 
 
 
 
 
Neils Ben Quashie, 2008 Chapter Four  
 
97
 
Parasite plasma 
membrane
Red cell membrane 
(RCM)
Ghost of RCM
Pores
Parasite Nucleoside Transporter
 
 
Figure 4.1: A P. falciparum-infected erythrocyte showing the presence of the different 
membranes before and after saponin permeabilsation of the RBC. 
The blue arrows represent the purine transporter. Although fragments of the RBCM are 
present, they do not hinder the movement of nutrients into the parasite.  
 
 
 
4.2.2 Hypoxanthine, the preferred purine source for P. falciparum 
It is well documented that hypoxanthine is the preferred purine source for the malaria 
parasites. For example, very high activities of hypoxanthine-guanine 
phosphoribosytransferase and inosine phosphorylase have been measured in the parasite, 
whereas adenine phosphoribosyltransferase and adenosine kinase activities were low or 
absent (Reyes et al, 1982). Adenosine is metabolised through rapid deamination to inosine 
and thence to hypoxanthine (Reyes et al, 1982), and this process mostly occurs 
extracellularly, as discussed in chapter three of this thesis. This explains the observation of 
Hansen and co that inhibition of adenosine deaminase with deoxycoformycin potently 
reduced [3H]-adenosine uptake by P. berghei (Hansen et al, 1980). The importance of 
hypoxanthine in the growth and development of Plasmodium was also shown in the study 
of Berman and his colleagues (Berman et al, 1991). 
 
While it is clear that hypoxanthine is fundamental for the survival and multiplication of the 
malaria parasite, most of the available information on Plasmodium purine transporters has 
been concerned with the uptake of adenosine. It was, therefore, an objective of this study to 
investigate the salvage of purines in saponin-isolated P. falciparum trophozoites with 
particular emphasis on the uptake of hypoxanthine. 
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4.3 Preparation of saponin-freed P. falciparum (clone 
3D7) trophozoites for uptake studies 
P. falciparum (clone 3D7) was maintained in continuous culture using standard methods, 
described in section 2.1.4. Synchronised P. falciparum culture was obtained by treatment 
of the cultured parasites with sorbitol (section 2.1.5). Permeabilised P. falciparum infected 
erythrocytes were prepared by incubating the synchronised culture (trophozoite stage) with 
0.15% saponin as described in section 2.2.2. The classical uptake method described in 
section 2.2.4 was used to study the flux of radiolabeled purine compounds into saponin-
permeabilised P. falciparum trophozoites. The permeants studied were hypoxanthine, 
adenine and adenosine. The inhibitory effect of guanine, guanosine, inosine, the 
pyrimidines (cytosine, cytidine, uridine, uracil, thymidine, thymine) and some purine 
analogues on the transport of hypoxanthine, adenine and adenosine was also investigated. 
Two types of assays were conducted in this part of the study: (i) the time dependent uptake 
assay, which allows the linear phase of the uptake and thus the transport rate to be 
determined, and (ii) the concentration-dependent assay that assesses the ability of a non-
radiolabeled compound to inhibit uptake of a radiolabeled purine.  
For the time course, 200 µl of a suspension of saponin-permeabilised, parasite-infected 
erythrocytes (usually at 2-6 × 107 cell/assay) were mixed with the same volume of 
radiolabeled permeant which was at twice the final intended concentration. At pre-
determined times, uptake was terminated by adding 1 ml ice-cold, 2 mM stop solution 
(unlabelled permeant at saturating concentrations). The mixture was immediately 
centrifuged at 13000 × g for 30 s through an oil-mix (300 µl of 5 parts dibutylphthalate: 4 
parts dioctyl phthalate, v/v) to pellet the cells and separate them from the aqueous 
radiolabeled permeant.  
 
When uptake was too rapid to provide a reliable linearity of transport at room temperature, 
it was reassessed at 6 °C, using a ThermoStat plus (Eppendorf, Germany) temperature 
controlled microfuge rack to maintain a reduced temperature during the incubation, thus 
reducing the uptake rate. 
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For the dose dependent assay, radiolabeled permeant was mixed with the same volume and 
concentration of an inhibitor. Two hundred microlitres of the mixture were carefully 
layered onto 300 µl oil-mix in a 1.5 ml microfuge tube. The tube was centrifuged briefly at 
13000 × g to collect the mixture into a single bubble on top of the oil layer. An equal 
volume of saponin-freed P. falciparum trophozoites (isolated parasites), suspended in 
hypoxanthine-free, RPMI 1640 usually at about 3-6 x 107 parasites/assay, was incubated 
with the radio-labelled/inhibitor mixture on top of the oil-mix for a pre-determined time. 
The uptake of radiolabel was terminated by adding 1 ml cold stop solution (2 mM of 
unlabelled permeant) prior to centrifugation at 13000 × g for 30 s. 
Inhibition studies were always performed within the linear phase of uptake, and thus reflect 
true initial rates of transport across the P. falciparum plasma membrane rather than rates of 
metabolism or sequestration. 
 
After uptake, the samples were processed for scintillation counting using the method 
described in section 2.2.7 of this thesis. Non-mediated influx of the respective permeant 
was assessed by determining the rate of uptake of the radiolabeled permeant in the 
presence of 1 mM unlabelled permeant as well as with cells and permeant at 0°C.  
 
4.4 Data analysis 
For any given permeant, the linear phase of uptake was first determined using the 
described time dependent assay. The curve of best fit through the points was assessed for 
linearity using linear regression. Linearity is defined as a correlation coefficient >0.95 and 
significant difference from zero uptake (F-test; GraphPad Prism version 4). 
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4.5 High affinity hypoxanthine transport in saponin-
freed P. falciparum trophozoites 
Studies of the uptake of hypoxanthine into saponin-permeabilised P. falciparum infected 
erythrocytes were performed at room temperature. 
 
 
4.5.1 Time dependent uptake of hypoxanthine into saponin-freed 
P. falciparum trophozoites 
 
The time dependent assays revealed that uptake of 0.25 or 0.1 µM [3H]-hypoxanthine was 
rapid and followed a hyperbolical curve, which was linear up to 120 s at both permeant 
concentrations (Figure 4.2). The correlation coefficients (r2) determined by linear 
regression over the first 120 s were 0.99 and 0.98 for permeant concentrations at 0.25µM 
and 0.1 µM respectively. Rates of 0.62 ± 0.04 and 0.40 ± 0.03 pmol (107 cells)-1s-1 were 
determined at permeant concentrations of 0.25µM and 0.1 µM respectively, and the uptake 
was completely inhibited by 1 mM unlabelled hypoxanthine (Figure 4.2(A and B)).  
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Figure 4.2: Hypoxanthine transport in saponin-freed P. falciparum trophozoites. 
Representative graphs showing uptake of (A) 0.25 µM [3H]-hypoxanthine and (B) 0.10 µM 
[3H]-hypoxanthine into saponin-freed P. falciparum trophozoites in the presence (closed 
squares) or absence (open squares) of 1 mM unlabeled hypoxanthine at 20 °C. Data points 
are the mean of 3 experiments and error bars indicate SEM. Uptake was expressed as 
pmol(107 cells)-1 
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4.5.2 Determination of Km and Vmax values for the high affinity 
hypoxanthine transporter 
 
Analysis of the results from the dose-dependent uptake of [3H]-hypoxanthine at sub-
micromolar concentrations revealed the presence of a very high affinity transporter for 
oxopurines, with a mean Km value for hypoxanthine of 0.34 ± 0.05 µM, a Vmax of 0.36 ± 
0.12 pmol(107 cells)-1s-1 (n = 6; Figure 4.3) and a mean Ki value of 0.11 ± 0.01 µM for 
guanine (n=3);. inosine also displayed affinity in the low micromolar range for this 
transporter (Ki = 1.99 ± 0.20 µM; n=3) (Figure 4.3). 
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Figure 4.3: Characterization of a high affinity P. falciparum hypoxanthine transporter. 
Uptake of 30 nM [3H]-hypoxanthine in the presence or absence of various concentrations of 
unlabelled hypoxanthine (□), guanine (●) or inosine (▲). Inset: conversion of hypoxanthine 
inhibition data to Michaelis-Menten plot for determination of Km and Vmax. Data points are the 
mean of triplicate determinations and error bars show the standard error of the mean (SEM). 
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4.5.3 Inhibitory effect of other purines on the high affinity 
hypoxanthine transporter 
 
Adenosine and guanosine (Figure 4.4) displayed affinity in the low micromolar range for 
the hypoxanthine transporter (Table 4.1). However, adenine did not inhibit the transport of 
0.03 µM [3H]-hypoxanthine into the saponin-freed trophozoites at concentrations close to 1 
mM (Figure 4.4).  
 
In order to avoid confusion later on, this high affinity purine transporter will hereafter be 
referred to as the P. falciparum Nucleoside Transporter 1 (PfNT1) in this thesis. 
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Figure 4.4: Characterization of a high affinity P. falciparum hypoxanthine transporter. 
Uptake of 30 nM [3H]-hypoxanthine in the presence or absence of various concentrations of 
unlabelled adenine (■), guanosine (∆) or adenosine (●). Representative experiments are 
shown, conducted in triplicate. Data points are the mean of triplicate determinations and 
error bars indicate SEM. 
 
In summary this work has demonstrated the presence of a transporter with a high affinity 
for hypoxanthine (Km=0.34 ± 0.05 µM) which also has affinity for guanine, adenosine and 
guanosine in the low micromolar range, but which does not bind adenine.  
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4.6 Inhibitory effect of purine analogues on the high 
affinity hypoxanthine transporter 
The effect of purine analogues received from Dr. Daniel Brown (MRC, Cambridge, UK) 
was tested against the uptake of [3H]-hypoxanthine through PfNT1. It was observed that 
the uptake of 0.30 nM [3H]-hypoxanthine into saponin permeabilised P.falciparum infected 
erythrocyte was inhibited by the purine analogue, JA-32 with a Ki of 14 ± 3 µM (Figure 
4.6). Two other analogues, JA-23 and JA-24, had little (Ki = 320 ± 80 µM for JA-24) or no 
effect (JA23) on high affinity hypoxanthine transport (Figure 4.5). From the chemical 
structures of the analogues shown in figure 4.6, it can be deduced that the strong inhibitory 
effect of JA-32 was probably due to its ‘hypoxanthine-like’ conformation. Apparently, the 
amino substitution at the N6 position prevents proper binding of the adenosine analogues, 
the amine substitution at position 2 is shared with guanosine and thus unlikely to prevent 
high affinity binding. 
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Figure 4.5: Uptake of 30 nM [3H]-hypoxanthine in the presence or absence of purine 
analogues JA-23, JA-24 and JA 32. 
The figure shows the uptake of 30 nM [3H]-hypoxanthine in the presence or absence of JA23 
(■), JA24 (∆), JA32 (●). Data points are the mean of 3 experiments and error bars indicate 
SEM. Chemical structures of the JA-compounds are also shown. 
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4.7 Inhibition of high affinity hypoxanthine transport by 
Pyrimidines 
 
In general, pyrimidines had little effect on the uptake of sub micromolar concentrations of 
[3H]- hypoxanthine. Only uridine, uracil and thymidine, at a concentration of 1 mM 
inhibitor, appreciably inhibited transport of 30 nM [3H]-hypoxanthine by 36 ± 9% 
(P<0.03), 49 ± 6% (P<0.005) and 57 ± 6% (P<0.02) respectively (Paired Student’s t-test 
against no-inhibitor control, based on four independent experiments in duplicate). 
Cytosine, thymine and cytidine did not significantly inhibit the transport of 30 nM [3H]-
hypoxanthine.  
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Figure 4.6: Effect of pyrimidines on the transport of 30 nM [3H]-hypoxanthine by saponin-
freed P. falciparum trophozoites. 
Inhibitor concentrations were 1 mM and transport was measured at 20 °C over 60 s. Data 
shown are the means and SEM of four independent experiments, each performed in 
duplicate. Control values (100%) were taken as the uptake of [3H]-hypoxanthine in the 
absence of inhibitor. Statistical significance was determined using a paired Student T-test 
with the mean rate of uptake in the presence of each inhibitor paired with the mean control 
rate of uptake of the same experiment. *, indicates significant inhibition, P<0.05.Shown in 
the table on the right are the p-values of the paired student’s t-test against no-inhibitor 
control, based on four independent experiments in duplicate. 
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4.8 High affinity adenosine transport into saponin-freed 
P. falciparum trophozoites 
Observations made in the current studies indicate that the transport of [3H]-hypoxanthine 
through PfNT1 was inhibited by adenosine with a Ki of 4.0 ± 0.67 µM. To investigate 
whether adenosine is a true ligand for the high affinity hypoxanthine transporter, rather 
than an inhibitor, high affinity uptake of [3H]-adenosine in saponin-freed trophozoites was 
investigated using the uptake techniques described earlier (section 2.2). All the 
experiments were performed at room temperature. The results of these investigations are 
shown in section 4.8.1 to section 4.8.2. 
 
4.8.1 Time dependent uptake of adenosine 
Uptake of 0.25 µM [3H]-adenosine proceeded with a rate of 0.015 ± 0.002 pmol(107 cells)-
1s-1 over the linear phase (at least 30 s), and was completely inhibited by 1 mM adenosine 
(Figure 4.7). At the end of linear phase, cells had transported approx. 0.55 pmol [3H]-
adenosine/107 cells, which would correspond to ~8-fold the extracellular concentration if 
unmetabolised [based on intracellular volume of 2.8×10-7 l/107 parasites isolated by 
saponin treatment; (Saliba et al, 1998)]. 
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Figure 4.7: Uptake of low concentrations of [3H]-adenosine in isolated P. falciparum 
trophozoites. 
Uptake of 0.25 µM [3H]-adenosine () was linear over 30 s (r2 > 0.99; inset). Uptake in the 
presence of 1 mM adenosine () was not significantly different from zero (F-test, P = 0.67). 
Data points are the mean of 3 experiments and error bars show the standard error of the 
mean (SEM). 
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4.8.2 Determination of the Km and inhibition profile for the high 
affinity adenosine transport 
When kinetic values obtained from the uptake of 0.25 µM [3H]-adenosine were fitted into a 
Michaelis-Menten plot, a mean Km value of 2.0 ± 0.2 µM and Vmax 0.18 ± 0.08 (107 cells)-
1s-1 (n=3; Figure 4.8, inset) were obtained. From the dose-response uptake assay it was 
clear that transport of 0.25 µM [3H]-adenosine was inhibited by unlabelled adenosine as 
well as by hypoxanthine (mean Ki = 0.75 ± 0.18 µM; n=3), but not by adenine (Figure 4.8). 
An important observation made in this experiment is that the inhibition by hypoxanthine in 
three independent assays was not quite complete at 100 µM (6.1 ± 0.2%; P<0.05, paired 
Student’s t-test). A possible reason for this observation could be that there is a minor 
contribution to the 0.25 µM [3H]-adenosine flux from a second, low affinity adenosine 
transporter that is insensitive to hypoxanthine.  
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Figure 4.8: Uptake of low concentrations of [3H]-adenosine in saponin-freed P. falciparum 
trophozoites. 
Transport of 0.25 µM [3H]-adenosine was measured over 30 s in the presence or absence of 
various concentrations of unlabelled adenosine (□), adenine (▲) and hypoxanthine (●). Inset: 
conversion of the adenosine inhibition data to a Michaelis-Menten plot. The adenine IC50 
value was obtained by extrapolation to 100% inhibition. Data points are the mean values 
from representative experiments performed in triplicate; error bars represent SEM.  
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Combining results from this experiment with that from the uptake of hypoxanthine (section 
4.5.3), it can be concluded that PfNT1 took up both adenosine and hypoxanthine. Meaning 
that hypoxanthine and adenosine have reciprocal inhibition on the high affinity transporter. 
This assertion is based on the fact that the Ki value for adenosine on hypoxanthine 
transport is similar to the Km for adenosine; and the Km for hypoxanthine is similar to the 
Ki value for hypoxanthine with [3H]-adenosine transport. 
 
 
4.9 Transport of adenine into saponin-freed P. 
falciparum trophozoites 
Since adenine did not appear to be transported by PfNT1, further investigations were 
conducted to assess whether a separate transporter exists for the uptake of adenine into 
saponin-permeabilised parasites. Time course and dose dependent uptake experiments of 
1µM of [3H]-adenine were therefore performed using the procedure described in section 
2.2.4. 
 
 
4.9.1 Uptake of adenine is mediated by a separate high affinity 
transporter 
Uptake of 1 µM of [3H]-adenine was rapid and was almost completely saturated by 1 mM 
unlabelled adenine. This observation was suggestive of an uptake process mediated by a 
high-affinity transporter (Figure 4.9). The rate of transport was estimated as 0.0091 ± 
0.0025 pmol (107 cells)-1s-1 by linear regression over the linear phase (6 s; r2 = 0.93).  
 
Comparatively, the measured rate of uptake of [3H]-adenine was two orders of magnitude 
lower than for [3H]-hypoxanthine, again confirming hypoxanthine as the preferred purine 
source by the growing malaria parasites. The novel adenine transport activity observed 
here was designated P. falciparum adenine transporter 1 (PfADET1).  
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Figure 4.9: Characterization of a high affinity adenine transporter in P. falciparum 
trophozoites (Transport of 1 µM [3H]-adenine). 
Transport of 1 µM [3H]-adenine in saponin-freed P. falciparum trophozoites over a period of 
8 minutes, in the presence (○) or absence (■) of 1 mM unlabelled adenine. Data points are 
the mean of 3 experiments and error bars indicate SEM.  
 
 
 
4.9.2 Determination of Km and Vmax for PfADET1 
The Km value for the high affinity adenine transporter was estimated through uptake of 50 
nM [3H]-adenine. The results, shown in Figure 4.10, indicate that uptake was linear for up 
to 240 s, allowing inhibition experiments at an incubation time of 150 s. In the absence of 
inhibitor the transport rate was estimated as 3.9 ± 0.2 × 10-5 pmol (107 cells)-1s-1 as 
calculated by linear regression (r2 = 0.98). At 240 s, uptake was inhibited 70% by 1 mM 
adenine. 
 
 Using a Michaelis-Menten plot, a Km of 0.23 ± 0.07 and Vmax of 0.0004 pmol (107 cells)-
1s-1 was estimated for this transporter (Figure 4.11). Combining the high Km value, which 
was similar to the hypoxanthine Km for PfNT1 with the very low Vmax measured here, 
PfADET1 can be said to be a high affinity/low capacity transport system (see Table 4.1 for 
Vmax/Km ratio).  
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Analysis of the results clearly show that there was a substantial uptake component that was 
not sensitive to 1mM adenine, as indicated by the positive gradient of uptake observed in 
the presence of 1mM unlabelled adenine in Figure 4.10. Uptake through PfADET1 
represents approximately 70-80% of total uptake at this [3H]-adenine concentration, 
leaving approximately 20-30% of adenine uptake through an alternative pathway. One 
explanation for this observation could be that this proportion of adenine uptake is 
occurring by diffusion: adenine is known to have the highest diffusion component among 
all the purine compounds, and is accumulated by the related parasite T. gondii solely 
through passive diffusion (de Koning et al, 2003). An alternative explanation may be the 
presence of a second, as yet uncharacterised, adenine transporter (see section 4.9). 
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Figure 4.10: Characterization of a high affinity adenine transporter in saponin-freed P. 
falciparum trophozoites (Transport of 0.05 µM [3H]-adenine). 
Transport of 0.05 µM [3H]-adenine over 240 s, in the presence (○) or absence (■) of 1 mM 
unlabelled adenine. Data points are the mean of 3 experiments and error bars indicate SEM.  
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Figure 4.11: Characterization of a high affinity adenine transporter in P. falciparum 
trophozoites (Michaelis-Menten plot). 
Transport of 0.05 µM [3H]-adenine was inhibited by increasing concentrations of unlabelled 
adenine. Inset: conversion of the inhibition data to a Michaelis-Menten plot. Data points are 
the mean of 3 replicates and error bars indicate SEM. 
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4.9.3 Inhibition profile of PfADET 1  
Observations made in this study indicate that, unlike PfNT1, the adenine carrier 
(PfADET1) detected here was not inhibited by the oxopurines, hypoxanthine (Figure 4.12), 
guanine (data not shown) and inosine (data not shown), though it was sensitive to 
adenosine, with a Ki value of 2.0 ± 0.2 µM (Figure 4.12). 
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Figure 4.12: Uptake of 0.05 µM [3H]-adenine into saponin-freed P. falciparum trophozoites 
in the presence of varying concentrations of other purines. 
The figure shows the uptake of 0.05 µM [3H]-adenine in the presence of hypoxanthine (∆), 
adenosine (■) or 1 mM adenine (○). Data points are the mean of 3 experiments and error bars 
indicate SEM.  
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4.10 A very low affinity/high capacity transporter of 
adenine exists in saponin-freed P. falciparum 
trophozoites 
Since the uptake of 0.05 µM [3H]-adenine was not fully inhibited by 1 mM unlabelled 
adenine, the possible presence of a low-affinity adenine transport activity in P. falciparum 
trophozoites was investigated. The uptake of adenine described above was repeated using a 
higher concentration of radiolabeled permeant (10 µM [3H]-adenine). As shown in Figure 
4.13, uptake of 10 µM [3H]-adenine was linear for up to 12 s, with a rate of 0.13 ± 0.01 
pmol (107 cells)-1s-1  (r 2 = 0.96). This could not be entirely attributed to simple diffusion as 
it was partly inhibited (~60%) by 1 mM adenine. Attempts to establish a Km value for [3H]-
adenine uptake on this transporter were unsuccessful due in part to the high rate of 
diffusion of adenine at high concentrations, and also because the limitations of adenine 
solubility prevented the determination of a complete inhibition curve. However, the Km for 
adenine was estimated to be in excess of 1 mM, and the Ki value for adenosine on this 
transporter was observed to be >2.5 mM. There was no clear inhibition by up to 1 mM 
hypoxanthine. This low affinity but high capacity transport activity was provisionally 
designated PfADET2.  
0 5 1 0 1 5 2 0 2 5 3 0
0
1
2
3
Tim e  (s )
Ad
en
in
e 
up
ta
ke
(p
m
ol
(1
07
 c
el
ls
)-1
)
 
Figure 4.13: Uptake of 10 µM [3H]-adenine by P. falciparum trophozoites. 
Saponin-freed trophozoites were incubated for up to 30 seconds with 10 µM [3H]- adenine, in 
the presence (○) or absence (■) of 1 mM unlabelled adenine. Data points are the mean of 3 
experiments and error bars indicate SEM The straight dotted red line shows the linear 
regression line fitted over the first 15 seconds of uptake.  
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4.11 Low affinity transport of adenosine in saponin-
freed P. falciparum trophozoites 
The low affinity adenosine transport activity in P. falciparum, which was previously 
described by the groups of Ullman and Baldwin (Parker et al, 2000;Carter et al, 2000), was 
re-investigated in the current study using concentrations of the radiolabeled permeant that 
would saturate the high affinity transporter. The outcome is reported in sections 4.11.1-
4.11.2. 
 
 
4.11.1 Existence of a low affinity adenosine transporter in P. 
falciparum trophozoites confirmed 
 
At room temperature (22 °C) 25 µM [3H]-adenosine was rapidly taken up by saponin-freed 
P. falciparum trophozoites (Figure 4.14). This observation is consistent with the report of 
Downie and colleagues (Downie et al, 2006). In order to slow down the uptake rate and 
allow for accurate determination of the linear phase of uptake, the experiment was repeated 
at 6 °C. It was consistently observed that uptake of 25 µM [3H] - adenosine at this 
temperature was linear over a period of 4 – 6 s (Figure 4.15), and that initial rates of 
transport could therefore be assessed over a three second interval. Whether uptake was 
conducted at 22 °C or 6 °C, it was observed that the transporter was almost completely 
saturated by the presence of 1 mM unlabelled adenosine, although this never inhibited 
100% of transport (Figure 4.14 and Figure 4.15). This clearly confirms the presence of a 
low affinity transporter for adenosine. At 6 °C the rate of uptake of 25 µM [3H]-adenosine 
was 0.041 ± 0.004 pmol (107 cells)-1s-1, less than 10% of the estimated rate at room 
temperature. The transport activity was designated P. falciparum Low Affinity Adenosine 
Transporter (PfLAAT). 
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Figure 4.14: Low affinity transport of adenosine in saponin-freed P. falciparum trophozoites 
(at room temperature). 
Uptake of 25 µM [3H]-adenosine (at room temperature) was determined at various time 
points in the presence (□) or absence (■) of 1 mM unlabelled adenosine. Curves were 
calculated by non- linear regression using a hyperbolic fit. Data points are the mean of 3 
experiments and error bars indicate SEM.  
 
 
Figure 4.15: Low affinity transport of adenosine in saponin-freed P. falciparum trophozoites 
(at 6 °C). 
Uptake of 25 µM [3H]-adenosine (at 6 °C) was determined at various time points in the 
presence (□) or absence (■) of 1 mM unlabelled adenosine. Curves were calculated by non- 
linear regression using a hyperbolic fit. The dotted line was calculated by linear regression 
(r2 = 0.97). Data points are the mean of 3 experiments and error bars indicate SEM.  
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4.11.2 Determination of Km and Vmax of PfLAAT 
 
The Km and Vmax values were measured at 6 °C for the flux of 25 µM [3H]-adenosine over 
a three second interval (Figure 4.16). The mean Km value under these conditions was 197 ± 
20 µM, with a Vmax of 0.19 ± 0.03 pmol (107 cells)-1s-1 (n=3). The Km value obtained here 
confirms the presence of a transporter with low affinity for adenosine as reported by others 
(Parker et al, 2000;Carter et al, 2000;Downie et al, 2006).  
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Figure 4.16: Transport of 25 µM [3H]-adenosine into saponin-freed P. falciparum 
trophozoites (Michaelis-Menten plot). 
Transport of 25 µM [3H]-adenosine was determined over a three second interval at 6 °C, in 
the presence of various concentrations of unlabelled adenosine as indicated. Inset: 
conversion to a Michaelis-Menten plot. Data points are the mean of 3 experiments and error 
bars indicate SEM.  
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4.12 Effect of dipyridamol on the low affinity 
adenosine transporter 
Dipyridamol (N, N´ (4, 8-Dipiperidinopyrimido [5,4-d] pyrimidine) [Figure 4.7], a 
cardiovascular agent reported to be a potent inhibitor of nucleoside transport (Shi & 
Young, 1986), was tested for its inhibitory effect on the low affinity adenosine transporter. 
A dose dependent uptake of 1-25 µM dipyridamol on the transport of 25 µM [3H]-
adenosine into saponin-freed P. falciparum trophozoites was performed at 6 °C using 
previously described method (section 2.2.6). Incubation time for the uptake was 3 seconds.   
 
Result (Figure 4.18) indicates that dipyridamol at up to 25 µM has little effect on the 
uptake of high concentrations of adenosine (low affinity adenosine transporter). This 
observation is consistent with the report of Parker and co workers (Parker et al, 2000).  
However, it contrasts that of Carter and colleagues, who showed that adenosine uptake was 
inhibited (up to 85%) by 10 µM dipyridamole [(Carter et al, 2000)]. 
 
 
 
 
 
Figure 4.17: Structure of Dipyridamol. 
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Figure 4.18: Effect of dipyridamole (1-25 µM) on the uptake of 25 µM [3H]-adenosine at 6 °C 
by saponin-freed P. falciparum trophozoites. 
Incubation time was 3 seconds. Dipyridamole was used from a stock solution in ethanol – the 
solvent did not exceed 1% during the final incubation with the parasites. This experiment is 
representative of three identical experiments each performed in triplicate. Data shown are 
means and SEM. 
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4.13 Summary of results: Profile of purine transport 
in P. falciparum trophozoites. 
Findings from this part of the study strongly suggest that isolated trophozoites express: 
(i) a high affinity hypoxanthine transporter with a secondary capacity for purine 
nucleosides (designated PfNT1), 
(ii) a separate high affinity transporter for adenine (designated PfADET1)  
(iii) a low affinity adenosine transporter (designated PfLAAT) and 
(iv) a low affinity/high capacity adenine carrier (designated PfADET2).  
Summary of the kinetic properties of PfNT1, PfADET1 and PfLAAT is shown in Table 
4.1. For technical reasons (see section 4.10) the kinetic properties of PfADET2 could not 
be measured. It was clear that the high affinity transport activity observed here is encoded 
by the previously reported PfNT1, which by the kinetic properties reported by the group of 
Kirk (Downie et al, 2006) suggests that it is a low rather than a high affinity transporter. 
 
High affinity [3H]-
hypoxanthine 
uptake (PfNT1) 
High affinity 
[3H]-adenosine 
uptake (PfNT1) 
Low affinity [3H]-
adenosine uptake 
(PfLAAT) 
Affinity [3H]-
adenine uptake 
(PfADET1) 
 
Ki or Km 
value (at 
22°C, µM, 
SE) 
N Ki or Km 
value (at 
22°C, µM, 
SE) 
N Ki or Km value 
(at 6°C, µM, 
SE) 
N Ki or Km value 
 (at 22°C, µM, 
SE) 
N
Vmax 0.36 ± 0.12 6 0.18 ± 0.08 3 0.19 ± 0.03 3 .0004 ± .0002 3
Vmax/Km 1.1  0.090  0.00096  0.0019  
Hypoxanthine 0.34 ± 0.05 6 0.75 ± 0.18 3 ND  >1000 3
Guanine 0.11 ± 0.01 3 ND  ND  >50 3
Inosine 2.0 ± 0.2 3 ND  ND  >1000 3
adenosine 4.0 ±0.67 3 2.0 ± .02 3 197 ± 20 3 2.0 ± 0.2 3
Guanosine 11.6 ± 2.7 3 ND  ND  ND  
Adenine >500 3 240 ± 70 3 ND  0.23 ± 0.07 3
Table 4.1: Summary of the kinetic studies of saponin-freed P. falciparum trophozoites. 
Values in bold are Km values obtained with radiolabeled substrate; other values are Ki values, 
obtained from dose-dependent inhibition of radiolabeled substrate. All values were 
determined using non-linear regression from experiments in duplicate or triplicate with a 
minimum of 8 points over the relevant range. Zero values were taken to be radiolabel 
associated with the cell pellet in the presence of saturating concentrations of unlabelled 
permeant. Units for Vmax are pmol (107 cells)-1s-1. ND= not determined.
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4.14 Proposed model for purine transport in 
saponin-freed P. falciparum trophozoites 
From evidence gathered in this study a new model for transport of purine in isolated P. 
falciparum trophozoites is proposed (Figure 4.19), where uptake is predominantly reliant 
on a high affinity nucleoside transport activity, designated PfNT1. This transporter, which 
has a high affinity for hypoxanthine, also salvages adenosine, guanosine, inosine and 
guanine. The model also includes a low affinity/high capacity PfLAAT, which presumably 
contributes significantly to adenosine uptake only when high levels of extracellular purine 
are present. The two adenine transporters proposed in this model, PfADET1 and PfADET2 
may not be important in the salvage of the parasite’s purine requirement for synthesis of 
bio-molecules as adenine is not believed to be an important purine source for the parasite 
due to the reported absence of the genes encoding adenine phosphoribosyltransferase 
(APRT) and methylthioadenosine phosphorylase in any of the Plasmodium spp 
(Chaudhary et al, 2004;Ting et al, 2005). Whilst the capacity of PfADET2 may be high, it 
is unlikely that sufficiently high adenine concentrations are present at the parasite plasma 
membrane to allow much uptake by this low affinity transporter. Conversely, the affinity 
of PfADET1 is high enough to salvage traces of adenine undoubtedly present in the 
infected erythrocytes (because of the presence of hFNT1 on the red cell plasma membrane, 
see Chapter 3), but its capacity is so low that its contribution to purine uptake, compared to 
PfNT1, is almost negligible. It is certainly conceivable that these transporters have a more 
prominent role in other parts of the complex Plasmodium life cycle. 
Hypoxanthine
Adenosine
Guanine
Inosine
Adenine 
Adenosine
Parasite
Adenine
PfLAAT
PfNT1
PfADET 2
PfADET 1
 
Figure 4.19: Proposed model of purine transport systems in P.falciparum trpohozoites. 
The substrates for each transporter are indicated. PfNT1=High affinity 
hypoxanthine/nucleoside transporter; PfADET1=adenine transporter 1 (high affinity); 
PfLAAT= low affinity adenosine transporter; PfADET 2=adenine transporter 2 (low affinity). 
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4.15 Discussion 
From observations made in this study, it can be concluded that saponin-freed P. falciparum 
trophozoites exhibit four transport activities for the uptake of purines. These are; (i) PfNT1 
for the uptake of predominantly hypoxanthine and also guanosine, adenosine, inosine, 
guanine but not adenine (ii) PfADET1 for the uptake of adenine at low concentrations of 
the nutrient, (iii) PfADET2 for the uptake of adenine when levels of adenine are high (iv) 
PfLAAT for uptake of adenosine when the exogenous concentration of the purine is high.  
 
Homology searches of the P. falciparum genome database have shown four genes 
encoding transporters of the equilibrative nucleoside transporters family in the parasite, 
each of which is expressed during the intraerythrocytic stage of the parasite’s life cycle 
(Martin et al., 2005). It is very tempting to conclude that each of the transporters identified 
in this study is encoded for by one of the identified genes. However until each of these 
genes has been investigated using a gene disruption strategy followed by kinetic study of 
the resultant phenotype it would be erroneous to draw conclusions on this issue. At present, 
only one of the four genes encoding for an ENT homologue in P. falciparum has been 
cloned and characterized: PfNT1 (PF13_0252) mRNA was expressed in the oocytes of 
Xenopus laevis by two groups of researchers working independently (Parker et al, 
2000;Carter et al, 2000). The kinetic properties and other characteristics described by the 
two groups clearly fit a low affinity transporter. Recently, a follow up to these studies 
using saponin-freed P. falciparum trophozoites, carried out by the group of Kirk (Downie 
et al, 2006), also showed the presence of a low affinity adenosine transporter.  
When the kinetic data obtained in this study was compared with that obtained by the group 
of Kirk in saponin-freed tropnozoites, it was clear that the transporter designated PfLAAT 
in this study is the closest to that described by that group. Apart from the slightly lower Km 
value of 197 ± 20 µM obtained in this study, other observations such as the rapidity of 
equilibration and insensitivity to dipyridamole were very similar to that reported by the 
group of Kirk. On the basis of the earlier studies by groups of Carter and Parker (Parker et 
al, 2000;Carter et al, 2000), as well as their own analysis of PfNT1 in Xenopus oocytes, 
Kirk’s group (Downie et al, 2006) concluded, that PfNT1 encodes the low affinity 
adenosine transporter. Data presented in the current chapter do not corroborate or disprove 
this assertion, but it will be demonstrated in Chapter 6 that PfLAAT activity is completely 
unaltered after disruption of the PfNT1 gene. 
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Since hypoxanthine is the preferred purine source for P. falciparum. (Berman et al, 1991), 
an efficient transporter for its uptake during the intraerythrocytic stages of the parasite was 
expected. A high affinity hypoxanthine transporter, was identified in this study, and 
designated PfNT1 on the basis of gene disruption studies (Chapter 5) and kinetic studies 
(chapter 6). This transporter demonstrated the highest affinity for the oxopurine 
nucleobases, guanine and hypoxanthine, with low, if any, affinity for adenine. This 
transporter also showed high affinity for purine nucleosides, apparently not discriminating 
between aminopurine and oxopurine nucleosides. The transporter appeared to display a 
preference for oxopurine nucleobases over aminopurine bases. It is possible that the 
selectivity of PfNT1 relies on the sugar moiety present in nucleosides, but not in the 
nucleobases (i.e. a different orientation for the two classes of purines within the transporter 
binding pocket). Alternatively, the nucleobases or nucleosides may not be true substrates 
for PfNT1 and may act to inhibit hypoxanthine transport allosterically.  
In order to practically address this last issue, transport of micro-molar concentrations of 
[3H]-adenosine into isolated P. falciparum trophozoites was investigated (section 4.8). A 
high affinity adenosine transporter that was inhibited by hypoxanthine but not adenine with 
compellingly similar reciprocal Km and Ki values was observed (i.e. Ki value for adenosine 
on hypoxanthine transport was similar to the Km for adenosine; and the Km for 
hypoxanthine was similar to the Ki value for hypoxanthine with [3H]-adenosine transport). 
This strongly suggests that PfNT1 is able to transport hypoxanthine and adenosine. 
However, the value of the calculated Vmax/Km ratio suggests an 11.9-fold higher efficiency 
of translocation for hypoxanthine compared to adenosine, which gives further support to 
the assertion that hypoxanthine is the preferred purine source to the parasite. The basis for 
the selectivity of hypoxanthine over, for example, inosine, may indeed be a different 
orientation in the transporter-binding pocket, or limited steric hindrance of the ribose 
moiety within the translocation pathway. A combination of the two factors would account 
for both the selectivity profile and the reduced translocation efficiency for nucleosides. 
 
Adenine did not appear to be a substrate for PfNT1, suggesting that a separate transporter 
may exist for its uptake. Further investigation revealed the presence of a separate saturable 
adenine transporter, designated PfADET1, which is distinguishable from PfNT1 by its 
insensitivity to inhibition by the oxopurines hypoxanthine, guanine and inosine. PfADET1 
displayed very high affinity for adenosine and adenine, though the Vmax was two to three 
orders of magnitude lower than that measured for the high affinity transport of 
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hypoxanthine and adenosine through PfNT1. This observation implies that adenine is a far 
less important purine source for Plasmodium compared to hypoxanthine or adenosine.  
A second adenine transporter, PfADET2, with low affinity for the nucleobase, was also 
demonstrated in this study. The role of this transporter is not immediately known but can 
be postulated to play at best a limited role in purine salvage, at least in the intraerythrocytic 
stages of P. falciparum investigated here, as argued above. Some of the transporters 
characterised in the trophozoite stages of the parasite, and thought to play limited role in 
the uptake of purine, could be important at a different stage of the life-cycle, when purine 
uptake is required from a different external milieu. 
 
A compound with the ability to prevent or reduce the replication of deoxyribonucleic acid 
(DNA) and the synthesis of ribonucleic acid (RNA) in the nucleus of the malaria parasite 
should be a good antimalarial drug. Since DNA replication requires purine and pyrimidine 
nucleotides, blockage of their supply may prevent parasite multiplication, as shown by El 
Bissati and colleagues(El Bissati et al, 2006). Purine antimetabolites have thus received 
consideration in the search for novel antimalarial drug to combat the surge in drug 
resistance parasites. In this study, purine analogues JA-23 (2-Amino-N6-amino-N6-
methyladenosine), JA-24 (2-Amino-N6-amino-adenosine) and JA-32 (N6-Hydroxy-9H-
purin-6-amine), donated by Daniel Brown and David Loakes of the MRC Laboratory of 
Molecular Biology, Cambridge, UK, were tested for their antiplasmodial activities. These 
compounds showed moderate antiplasmodial activity in vitro and in vivo (Too et al, 2007). 
The compound with the chemical structure closest to hypoxanthine, JA-32, displayed 
moderately high affinity for PfNT1, whereas JA-23 and JA-24 had very low affinity for 
PfNT1, indicating that, for nucleosides, substitutions at N6 result in low affinity for this 
carrier. However, it is possible that these analogues are accumulated instead through 
PfLAAT, as this was not tested.  
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4.16 Conclusions 
This study identified four transporters for the uptake of purine nucleobases and nucleosides 
in saponin-freed P. falciparum-infected erythrocytes. The transporters and their substrate 
according to the test performed in this study is listed below: 
PfNT1 - hypoxanthine, adenosine, guanine, inosine 
PfLAAT - adenosine 
PfADET1 - adenine 
PfADET2 - adenine. 
Finding from this study is consistent with studies involving other Plasmodium species 
which show a transport system for hypoxanthine with secondary capacity for purine 
nucleosides and a separate uptake system for adenine [reviewed by de koning and co (de 
Koning et al, 2005)]. The high affinity purine transporter, PfNT1 in the parasite’s plasma 
membrane could be a target for anti-purine based drugs. Inhibition of the uptake of 
hypoxanthine through the PfNT1 transporter by an antiplasmodial purine analogue, JA-32, 
provides support for the further investigation of purine analogues as potential antimalarial 
drugs. 
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CHAPTER FIVE 
5 Generation of P. falciparum clones with disrupted 
Equilibrative Nucleoside Transporter- encoding genes 
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5.1 Summary 
Four genes with homology to the Equilibrative Nucleoside Transporter (ENT) family are 
present in the P. falciparum genome. In order to gain proper understanding of the exact 
role played by each of these genes in purine salvage by the parasites, clones of P. 
falciparum with a disrupted ENT locus were generated for each of the four genes using the 
insertion-gene disruption method. P. falciparum malaria parasites were transfected by 
electroporation with plasmids containing a fragment of each of the genes encoding the 
putative ENT proteins. Transfected parasites, selected using the selectable marker 
blasticidin, emerged in culture approximately 21 days post-transfection. A single crossover 
homologous recombination at the ENT locus was expected to generate a pseudo diploid 
configuration, with both truncated copies lacking some of the transmembrane domains of 
the protein predicted to be essential for the function of the protein. Parasites with the 
disrupted genes were designated ∆PfNT1, ∆PfNT2, ∆PfNT3 and ∆PfNT4; corresponding to 
genes listed in PlasmoDB as PF13_0252, MAL8P1.32, PFA0160c and PF14_0662 
respectively. Parasites with ∆ENT were observed to grow relatively better when the culture 
medium was supplemented with extra purine such as adenosine inosine and hypoxanthine. 
A clone designated 3D7∆PfNT1 (locus listed as PF13_0252 in PlasmoDB) was generated 
using the limiting dilution method from parasites transformed with a plasmid containing 
the central region of this gene. Molecular analysis of the clone using PCR and southern 
blot confirmed that the ENT gene PfNT1 had indeed been disrupted. Generation of 
3D7∆ENT clones for each of the four genes combined with kinetic assessment should pave 
the way for proper understanding of the functions of these transporter proteins.   
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5.2 Introduction 
Earlier in this study, four separate transporter activities were observed to be responsible for 
purine salvage in saponin-freed P. falciparum infected erythrocytes (see chapter four). 
Homology searching of the P. falciparum genome database by Martin and co-workers had 
revealed the existence of four genes with homology to the equilibrative nucleoside 
transporter protein family in the parasite (Martin et al, 2005). It was therefore speculated 
that a link exists between the four genes listed in the genome database and the four purine 
transporters found in the current study. In order to verify this, parasite lines with a 
disrupted locus for each of the four putative ENT genes were generated using a previously 
described gene targeting strategy (Fidock et al, 2000). The kinetic characteristics of the 
generated phenotypes lacking the genes encoding the ENTs were then determined using 
the classical uptake techniques (see chapter six).  
 
Gene targeting in P. falciparum involves the alteration of a chosen gene in a predetermined 
way by homologous recombination (Menard & Janse, 1997). Two commonly used 
methods are the replacement and insertion methods. In this study, the insertion method was 
employed to disrupt genes encoding ENT-family proteins in P. falciparum. The method 
involves homologous recombination between the gene of interest (listed as PF13_0252 in 
the genome database) and a DNA construct comprising the target DNA that had been 
subcloned into a plasmid. The plasmid, pCAM/BSD, used in this study to prepare the 
construct, contains a cassette that confers resistance to blasticidin (BSD) as a positive 
selectable marker (Sidhu et al, 2005). P. falciparum can support the replication of circular 
plasmid DNA molecules. It was anticipated that a single crossover homologous 
recombination at the ENT locus would generate a pseudo-diploid configuration, with both 
truncated copies lacking some of the transmembrane domains of the protein predicted to be 
essential for the function of the transporter (Figure 5.1). As the parasite is haploid and each 
ENT gene is present as single copy gene, only one round of drug selection is necessary to 
produce a null-mutant. 
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Wild type locus 
pCAM-BSD
PfNT1
BSD 
BSD
X 
Non functional gene product
Recombined locus 
1 
1 
4
4 
3
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2 
2
 
Figure 5.1: Strategy for disruption of the ENT locus. 
The wild-type PfNT1 chromosomal locus is shown at the top including the construct pCAM-
BSD/ENT used to disrupt the ENT gene. The insert excludes the transmembrane domains, 
considered to be essential for the functioning of the transporter. Single crossover 
homologous recombination results in a pseudo-diploid configuration with two truncated 
copies, each of which lacks some of the essential transmembrane domains, shown at the 
bottom. Adapted from (Fidock et al, 2000). 
 
 
5.2.1 Four genes encode Equilibrative Nucleoside Transporters in 
P. falciparum 
Martin and his colleagues identified numerous genes in the P. falciparum genome database 
encoding proteins involved in membrane permeability (Martin et al, 2005). The principle 
was ‘based on the theory that polypeptides comprising transporter proteins typically 
possess multiple hydrophobic transmembrane domains (TMDs) and hydrophilic extra-
membrane loops that are detected as peaks and troughs respectively in a plot of the 
hydrophobicity index of the polypeptide’ (Martin et al, 2005). Four genes were identified 
that putatively encode for nucleoside and/or nucleobase transporters in P. falciparum. One 
of the four genes had been isolated and cloned earlier on by the groups of Ullman and of 
Baldwin (Parker et al, 2000;Carter et al, 2000). The four genes identified are listed in 
PlasmoDB with the accession numbers PF13_0252, MAL8P1.32, PFA0160c and 
PF14_0662 (Martin et al, 2005). Search of the GeneDB indicate that, PF13_0252, 
MAL8P1.32, PF14_0662 and PFA0160c are on chromosomes 13, 8,14 and 1 respectively 
of the P. falciparum genome.  
 
Neils Ben Quashie, 2008 Chapter Five  
 
128
Despite their conserved structure, ‘the four ENT genes share limited sequence similarities 
with each other and are only weakly related to ENT proteins from other organisms’ 
(Martin et al, 2005). Details of their expression during the parasite’s asexual lifecycle, 
reported in the same study, revealed that the genes listed as PFA0160c, MAL8P1.32 and 
PF13_0252 had similar expression profiles. Transcription was observed to start early 
during the parasite development in the erythrocyte, increasing rapidly in abundance 
between 16 and 24 hours post invasion. The level of transcript reached a maximum 32 
hours after invasion and then declined slowly (Figure 1.18). Transcription of the gene 
identified as PF14_0662 was reported to start between 8-20 hours and peaked at 
approximately 36 h post invasion. 
 
 
5.2.2 Alignment of amino acids of the four ENT proteins 
Before disruption of the four genes encoding equilibrative nucleoside transporters in P. 
falciparum was performed, multiple alignments of the predicted amino acid sequences of 
the four genes encoding for ENT were performed using ClustalX program. The alignment 
revealed limited similarities in the predicted amino acid sequences for the four genes (see 
Figure 5.2) and only six amino acids conserved in all four genes. The predicted amino acid 
sequences of the Pf(E)NT1 clones used by Parker and colleagues (Parker et al, 2000) and 
Carter and colleagues (Carter et al, 2000) respectively were also compared. The alignment 
of the sequences indicated a single amino acid difference at position 385; with leucine 
reported for Parker and co (Parker et al, 2000) and Phenylalanine for Carter and co (Carter 
et al, 2000). It is possible that this small difference could explain some of the discrepancies 
observed in the two studies. The Phe385 polymorphism is unusual: in a multiple alignment 
of 28 protozoan ENT family genes plus the four human ENT sequences, the equivalent 
amino acid residue was conserved in so far as it was never aromatic, amide, charged, 
cysteine or proline (alignment not shown). 
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                1                                                         60 
PFA0160c    (1) --------------------------MLKKSEEIQI-------KVIFFFIG---LLLSLP 
PF13_0252   (1) --------------------MSTGKESSKAYADIES-------RGDYKDDGKKGSTLSSK 
PF14_0662   (1) -------MSDSQSKDTFHTTVGGLYEKPNKVRDIECLYPCDIEKVDTFEEDRYKKLLCAA 
MAL8P1.32   (1) MSNSNSKEHYRMDGITENKIINEDDESLLNMKKEEIILNGKFEEEPKLDLTENKIDIEEK 
 
                 61                                                       120 
PFA0160c    (25) SHILINVS-----FLINHIYKEEIAITVMG---------FLSGFMIISSFLQLTFEFTSF 
PF13_0252  (34)  QHFMLSLT-----FILIGLSSLNVWNTALGLNINFKYNTFQITGLVCSSIVALFVEIPKI 
PF14_0662   (54) YALMAIIADAPYFMIVSMADYFKSTFNVNDVMINEFALMESLILIVVCSLLHLIGSYRLK 
MAL8P1.32   (61) NNNMSEFTNIFPNITLCLMGMSSVLMYNCVLNTTPHIHALLNKNIVVSSTFFLYFSILVI 
 
                 121                                                      180 
PFA0160c   (71)  KWIMICNGLNVFNLLLLLIFVCVMKCS-------------KYYIYGISGIIGFFIGYLYS 
PF13_0252  (89)  MLPFLLGGLSILCAGFQISHSFFTDTQF------------DTYCLVAFIVIGVVAGLAQT 
PF14_0662  (114) WNLLMPIFMTMILVVLNFVVYFKLDYIG------------HKIIIFSAIPLGLVSCISKM 
MAL8P1.32  (121) VSLLSSLFIEVKTRTYDVCFILSFILQMIYPFIIKYFYDKTVFFYVLVALIGATCSMMKT 
 
                 181                                                      240 
PFA0160c   (118) SCTKYSLLFPLKVNGYMVTGISFSSLFFFAINLIMSYFSIEDGNISSYYNTIYLSIGTIV 
PF13_0252  (137) IAFNIGSTMEDNMGGYMSAGIGISGVFIFVINLLLDQFVSPE---KHYGVNKAKLLYLYI 
PF14_0662  (162) TTMKICVLFKNAYCSAYVCGLSFSGFIVFIIYMLGAYVFFPNDEMKFFKMFTFFCLIICS 
MAL8P1.32  (181) MIFSISSIVVNDSKVICLSYGLTGIYSLFITSTFFYFVIKINKDIQKLMLSLFITSAINC 
 
                 241                                                      300 
PFA0160c   (178) FIEFIILVCIIFIQYNSPYFKEQKEKIESAQNKKCIEYNGSNDLCEVEKGKNKSSENIQS 
PF13_0252  (194) ICELCLILAIVFCVCNLDLTNKNNKKDE--ENK---ENNATLSYMELFKDSYKAILTMFL 
PF14_0662  (222) LALTCFSILYRLYKKRFVKILEEKYKDKGLKINRKIFYDSIKSMKILWPYMLISYFTSLL 
MAL8P1.32  (241) IFILVSFLCYTVLKRTNNFKEKFKIYTEERKNNKNSRDDSYKYYESITEKKSQNISYPIN 
 
                 301                                                      360 
PFA0160c   (238) NNVSMISKCKNKIK---------------------------------------------- 
PF13_0252  (249) VNWLTLQLFPG------------------------------------------------- 
PF14_0662  (282) TYQIYPSIFPT------------------------------------------------- 
MAL8P1.32  (301) INSIIYESKTENTESKYSLTKNDSNSVGIKSSSNNTNNMTSNEIGDHKILQESHSKNKKF 
 
                 361                                                      420 
PFA0160c  (252)  -----NVGKMFNCANIIEGACLIRYYYLCLIPIFFSFFVTSIIYPHMIPNKLKKNVYYKY 
PF13_0252  (260) ----------VGHKKWQESHNISDYNVTIIVGMFQVFDFLSRYPPNLTHIKIFK------ 
PF14_0662  (293) -------------F-----MDVSKELKGTLAGFLLFGDSMAHLLVHYRRNEFLK------ 
MAL8P1.32  (361) NDILLNENKTLSLTHSKKEDNIDDENKNHKNQFFLFNINKKNLIKQAKIKAFLYKKSFIF 
 
                 421                                                      480 
PFA0160c  (307)  LFMFLYQLSDLIFHIIVTVYYSAFN----------------------------------F 
PF13_0252  (304) ------------------------N----------------------------------F 
PF14_0662  (329) ------------------------------------------------------------ 
MAL8P1.32  (421) LFCSFYNIFLKILLFPVVCPEMWTNNVDERYILIGIVQFADCISRVFPSLAGTFPVFKIF 
 
                 481                                                      540 
PFA0160c  (333)  FKQKYVAILCLSRILLLLLSFKIKNLTEASFLYSNTFLSFLIFVIGGTNGSLINISYARI 
PF13_0252 (306)  TFSLNKLLVANSLRLLFIPWFILNACVDHPFFKNIVQQCVCMAMLAFTNGWFNTVPFLVF 
PF14_0662  (329) -TDFSTLVFCTLFRIFFVPIFLFLPKLHYIYNFSYFMLTSFSFLFGLMNGLVNNLIFLKA 
MAL8P1.32  (481) LLTQKKVLIYSLLRTILSVIGLIIPLTQDTFINNFLFKCALIFLNIYLNGWFVIMSFINV 
 
                 541                                                    598 
PFA0160c  (393)  SDCFEESNKKTKQIAVASSFCALCLLMSFALAPWFCNAIIHL---------------- 
PF13_0252  (366) VKELKKAKK-KKEIEIISTFLVIAMFVGLFCGIWTTYIYNLFNIVLPKPDLPPIDVTQ 
PF14_0662  (388) PETCKEKSK-YEYIQLTPNILYLCLIFGITSGCLISKVHVRIVNIIAVILK------- 
MAL8P1.32  (541) PEILKPINS-MSNVAIVSSFGSTLLRVGLLTGYGCSTLYKYIISKM------------ 
 
Figure 5.2: Alignment of the predicted amino acid sequences from the four ENT encoding 
genes in P. falciparum. 
Similarity in all four genes is highlighted in yellow. Similarity in two or three of the 
sequences is shown in bright blue. The point where the difference between sequence 
reported by (Parker et al, 2000) and (Carter et al, 2000) (i.e. Leucine 385) is highlighted 
with a red box. 
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5.3 Alignment of the nucleotides of the four genes 
encoding for ENT in P. falciparum 
To ascertain similarity between the four genes encoding for equilibrative nucleoside 
transporter in P. falciparum, multiples alignment of the genes was performed using the 
ClustalX program. The outcome of the alignment shown in Figure 5.3 indicates limited 
similarity between the four genes. 
 
 
PfNT1 ------------------------------------------------------------ 
PfNT2 ------------------------------------------------------------ 
PfNT3 ATGAGCAATTCTAATAGCAAGGAGCACTACAGAATGGACGGAATTACAGAAAATAAAATA 60 
PfNT4 ------------------------------------------------------------ 
 
PfNT1 ------------------------------------------------------------ 
PfNT2 ------------------------------------------------------------ 
PfNT3 ATTAATGAAGATGATGAAAGTCTCTTGAACATGAAAAAAGAAGAAATAATTTTAAATGGA 120 
PfNT4 ------------------------------------------------------------ 
 
PfNT1 ------------------------------------------------------------ 
PfNT2 ------------------------------------------------------------ 
PfNT3 AAATTTGAAGAAGAGCCAAAGCTTGATTTAACCGAAAACAAAATTGATATTGAAGAGAAG 180 
PfNT4 ------------------------------------------------------------ 
 
PfNT1 ------------------------------------------------------------ 
PfNT2 ------------------------------------------------------------ 
PfNT3 AATAATAACATGAGTGAGTTTACAAATATTTTTCCAAATATAACATTATGTTTAATGGGA 240 
PfNT4 ------------------------------------------------------------ 
    
PfNT1 -------------------------ATG-AGTACCGGTAAAGAGTC-ATCTAAAGC--TT 31 
PfNT2 -----------------------------ATGAGTGACAG----TC-AGAGTAAGG--AT 24 
PfNT3 ATGTCATCTGTATTAATGTATAATTGTGTATTAAATACAACACCTC-ATATACATGCATT 299 
PfNT4 ----------------------ATGTTGAAGAAAAGCGAGGAGATCCAGATAAAGG--TT 36 
    
PfNT1 ATGCTGATATAGAATCCAGGGGTGATTATAAGGACGATGGAAAGAAAGGATCTACATTAA 91 
PfNT2 A--CGTTTC-ATACAACAGTGGG---T-GGA----TTATATGAGAAGCCTAACAAAGTTC 73 
PfNT3 AT-TAAATA-AGAATATAGTAGTATCT-TCAAC-CTTTTTTCTATATTTTTC--TATTTT 353 
PfNT4 AT-CTTTTT-TTT-TATAG--GT---T-TG----CTTTTGAGTTTACCCTCCCATATTTT 83 
    
PfNT1 GCAGTAAAC-AACATTTCATGTTATCTTTAACCTTTATAT-TAATAGGTTT-AAGTTCT- 147 
PfNT2 G-AGATATTGAATGTTTAT--A--TCCTTGTGATATTGAA--AA-AG-TAGATACTTTTG 124 
PfNT3 --AGTTATTGTATCATTGTTAAGTTCCTTAT-TTATAGAAGTAA-AGACAAGAACATATG 409 
PfNT4 --AATAAATGTATCTTTTTTGA-TTAATCAC-ATATACAAGGAAGAGATAGCTATAACGG 139 
    
PfNT1 TTGAATGTATGGAATACAGCCTTAGGATTA-AA-T-ATAAATT--TTAAATATAA--TAC 200 
PfNT2 AAGAA-GATAGGTAT-AAGAAGT--TATTATGTGCAGCATATGCATTAATGGCTA--TAA 178 
PfNT3 ATGTGTGTTTTATAT-TATCATTCATATTACAAATGATATATCCATTTATTATAAAATAT 468 
PfNT4 TTATGGGTTTTTTAT-CAGGATT--TATGATAA-T-ATC-ATC-ATTT-TTACAAT-TAA 190 
    
PfNT1 CTTTCAGAT--TAC--AGGTTTAGTATG--TTCCTCAATTGTAGCT--T--TATTTG-T- 248 
PfNT2 -TAGCTGATGCTCCATATTTTATGATTGTATCGATGGCTGATTATT--TTAAAAGTACT- 234 
PfNT3 TTTTATGATAAAACCGTTTTTTTTTATGTACTAGTAGCAT-TAATTGGTGCTACGTGCTC 527 
PfNT4 CTTT-TGAATTTAC--ATCTTTTAAATGGATTA-TGATATGTAACGGAT--TAAATG-TT 243 
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PfNT1 TGAGATTCCCAAAATAATGTTACCATTTCTTTTGGGTGGTTTATCAATTTTATGTGCAGG 308 
PfNT2 TTTAATGTAAATGACGTTATGATAAATGAATTTGCCT---TAATGGAAAG-TTTAA---- 286 
PfNT3 TATGATGAAAACCATGATATTTTCCAT-ATCTTCCAT-TGTTGT-AAATGATTCAAAAGT 584 
PfNT4 TTTAATTTAT--TAT--TATTATTAAT--TTTTGTATGTGTAATGAAATG-TTCAAAA-- 294 
    
PfNT1 TTTTCAAATATCTCACAGTTTTTTTACAGATACACAATTTGATACATATTGTTTAGTAGC 368 
PfNT2 TATTG----AT--TGTTGTTTGTTCAT-TAT-TA-CATTTAATT-GGAA----------- 325 
PfNT3 TATTTGTTTATCATATGGTTTGACTGG-GATATATTCTTTATTT-ATAACATCCACATTT 642 
PfNT4 TATTA---TAT-ATATGGTATATCCGG-GAT-TATCGGTT-TTT-TTA----------TT 336 
    
PfNT1 TTTTATT--GTTATTGGTGTAGTGGCAGGATTAGC------TCAAAC-CAT--TGCATT- 416 
PfNT2 -GTTATC--GT--TTAAAA-TGGA-----ATTTAC-----TT-ATGCCTAT----ATTTA 364 
PfNT3 TTTTATTTTGTTATTAAAA-TAAATAAAGATATACAAAAGTTGATGT-TATCATTATTTA 700 
PfNT4 GGTTATTT-GT-ATTCATCGTGTACAAA-ATATTC-----TT--TGC-TAT--TTCCTT- 382 
   
PfNT1 TAAT-AT-AGG-ATCAACCAT-GGAAGATAATATGGGT---GGTTATATGT--CAGCAGG 467 
PfNT2 TGACGAT--G--AT-ATTAGT--TGTG-TTAAATTT-TGTTGTTTATTT-T-AAACTTGA 413 
PfNT3 TAAC-ATCAGCCATCAATTGT-ATAT--TTATATTAGTGTCTTTTCTATGTTACACTGTA 756 
PfNT4 TAA--A--AG---TCAATGGTTATATGGTTACAGGAAT-TAGTTTCTCT-T--CATTATT 431 
    
PfNT1 T---ATTGG-----TA--TATCA-GGAGTATT-TATT--TTTGT-TATT-AATTTAT--- 508 
PfNT2 CTACATTGGACATAAGATTATCATCTTCAGTGCTATACCTTTAGGTTTAGTATCTTG--- 470 
PfNT3 TTAAAGAGAACAAATAATTTTAAAGAAAAATTTAAAA--TTTA--TACAGAAGAGAGAAA 812 
PfNT4 TTTTTTTG--CTA-TAAATTTAA--TAATGTCGTATT--TTTC--TATCGAAGATGG--- 479 
    
PfNT1 ---TACTTGATCAATTCGTAT--C--TCCCGAAAAACATTATGGT--GTTAA-TAAAGCA 558 
PfNT2 ---TATAT-CTAAAATGAC-T-ACTATGAAAATATGTGTTTTG----TTTAA--AAACGC 518 
PfNT3 AAATA-AT-AAAAATTCACGTGATGATTCTTATAAATATTATGAAAGTATAACTGAAAAA 870 
PfNT4 ---TA-AT-ATAAGTTCATATTACAACACA-ATATAT-TTATC----CATAG--GAACTA 526 
   
PfNT1 AAGTTAT----TATATTTATAT--ATAATCTGTGA-ACTTTGTTTAATAT-T-AGC-TAT 608 
PfNT2 CTATTGTAGTGCTTATGTATGTGGATTATCTTTTTCAGGTTTTATAGTGTTT-A---TAA 574 
PfNT3 AAATCACAAAATATATC-ATATCCAATAAATATT---AATAGTATAATATATGAAAGTAA 926 
PfNT4 TAGTT------TTTATC-GAATTCATTATAC-TT---GTTTGTATAATTTTT-A---TAC 571 
    
PfNT1 AGTAT---TTTGTGTATGTA-ATTTAGATTTAACAAACAAGAA--TAA---------TA- 652 
PfNT2 TATATATGTTAGGG---GCATATGTGTTTTTTCCGA--ATGAT--GAA----------AT 617 
PfNT3 AACAGAAAATACGGAATCCAAATATTCATTAACAAAAAATGATTCTAACTCAGTTGGTAT 986 
PfNT4 AATATA--ATTC----TCCATAT-TTCAAGGAGCAAAAA-GAG---AA---A------AT 611 
    
PfNT1 AAAAAGATG-A---AGAAAATAAAGAAAACAA--TGCCACATTATCTTATATGGA-ATTA 705 
PfNT2 GAAATTTTTTA---AGATGTTTACTTTTTT---TTGTTTGATTATTTGT--TCATTAGCA 669 
PfNT3 AAAAAGTAGTAGTAATAATACTAATAATATGACTAGTAATGAAATAGGAGATCAT-AAAA 1045 
PfNT4 AGAAAGT-GCAC--AGA--ACAAAAAATGT-A-TTG-AATATAAT-GGA--TCGA-ATGA 659 
    
PfNT1 T-TTA-AAGATAG---TTACAAAGCTATATTA-------ACTATGTTTCTTGT--AAACT 751 
PfNT2 T-TAACATGTTT----TTCTA----TCCTATA--------C-CGAC-T-ATAC--AAAA- 706 
PfNT3 TATTACAAGAATCTCATTCAAAAAATAAAAAATTTAATGAC-ATACTTCTTAATGAAAAT 1104 
PfNT4 T-TTATGTGAAG----TTGAAAAAGGAAAAAA--------C-AAA--TCATCA-GAAAAT 702 
    
PfNT1 GGTTAACTTTACAATTATTTCCAGGTGTTGGACACAA---AAAATGGCA-A-GAA--AGT 804 
PfNT2 AACGAT-TTGTGAA--AAT---ATT-GGAAGAAA--AG-TATAA-AGAT-A--AAGGATT 752 
PfNT3 AAA-ACATTATCACTTACT-C-ATA-GTAAAAAAGAAGATAACATAGATGACGAA--AAT 1158 
PfNT4 ATCCAGAGTAATAATGTCT-CTATG-ATAAGTAA-ATG-TAAAA---AT-A--AA--ATT 750 
   
PfNT1 CATAATATCTCCGATTATAATGTTACCATTATTGTTGGTATGTTTCAAG--TTTTTGATT 862 
PfNT2 AAAAATTAATA-GA--AAAATATTTTATGACTCTATAAAATCAATGAAA-ATATT--GTG 806 
PfNT3 AAAAATCA-T---A--AAAATCAATTCTTTCTATTTAATATAAATAAAAAAAATTTAATA 1212 
PfNT4 AAAAATGT-TG-GA--AAAATGT-TTAATTGTGCT-AATATAATTGAGGGAGCTT--GTT 802 
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PfNT1 TTCTCAGTAGATATCCACCAAATCTTACACATAT----TAAAATCTTTAAAAATTTTACT 918 
PfNT2 ------GCC---AT------AT----ATGTTGA-----TTTCATATTTTACAAGTTTATT 842 
PfNT3 AAACAAGCCAAAATTAAAGCATTCTTATATAAAAAATCGTTCATATTTT-TATTTT--GT 1269 
PfNT4 TAATAAG---ATATTATT--AT--TTATGTTTAATACCTATATTCTTTT-CATTTTTCGT 854 
    
PfNT1 TTCTCTTTAAATAAATT-AT----------TGGTTGCC------------A-ATTCATTG 954 
PfNT2 GACTTATCAAATATATCCATCTA-----TAT--TTCCAACTTTT------ATGGATGTTA 889 
PfNT3 AGCTTTTATAATATTTTTCTCAAAATATTATTATTCCCGGTTGTTTGTCCAGAAATGTGG 1329 
PfNT4 GACCTCTATAATATATC-CTCAC------ATGATTCC-----G-------A-ATAAGCTG 894 
    
PfNT1 A-GATTATTATTCATTCCA--TG---GTTTATTTTAAATG--C-ATGTGTTGATCATCCA 1005 
PfNT2 GTAAAGAATTAAAAGGAACACTAGCTGG--ATTTTTATT-----ATTTGGTGATTCTATG 942 
PfNT3 ACTAATAATGTTGATGAAAGATATATATTAATTGGAATTGTGCAATTTGCTGATTGTATA 1389 
PfNT4 AAGAAGAACGTATATTACAAATACCTGTTTATGTTTCTTTACCAACTCAGTGATCTTATA 954 
    
PfNT1 -----TTTTTCAAAAACATTGTACAACAATGTGTAT--GTA-TGGCTA-TGTTAGCTTT- 1055 
PfNT2 -------------GCTCACT-TATTAGTTCAT-TAT-AGAAGAAACGAATTTT----TAA 982 
PfNT3 AGTCGTGTTTTCCCATCCCT-TGCAGGAACAT-TTCCAGTA-TTTAAAATTTTCCTCTTG 1446 
PfNT4 --------TTTCATATCATTGTGACTGTTTAT-TAT-AGTGCTTTTAACTTTT----TT- 999 
    
PfNT1 -TACAAATGGTTGGT--TTAATACTGTACCATTCCTT--GTA------TT---TGTTAA- 1100 
PfNT2 AAACAGATTTTTCTACATTAGTCTTTTGCACATTGTTCAGAA--TATTTT-T-TG-TACC 1037 
PfNT3 ACACAAAAAAAAGTA--TTAAT-TTATTC--TTTATTAAGAA-CTATCTTATCTG-TAA- 1498 
PfNT4 AAACAAAAATATGTT--GCCATATTATG---TTTAAGCAGAATCCTTCTT-T-TGCTAT- 1051 
    
PfNT1 -AGAATTAAAAAAAGCCAAGAAAAAGAAAGAAATCGAAATTATATCCACATTCTTAGTTA 1159 
PfNT2 TAT-ATTTTTATT---C--TT-GCCA-AAG--CTTCATTATATATA-TAACT-TTAGTTA 1085 
PfNT3 TAGGATTGATAAT--ACCATT-AACACAAG--ATACATTT-AT-TAATAA-T-TTCCTTT 1549 
PfNT4 TATCCTTTAAAATTAAGAATTTAACTGAAGC-ATCCTTTTTATATTCTAA-T---ACTTT 1106 
   
PfNT1 TTGCTATGTTTGTT-GGAT--TATTCTGTGGTAT-ATGGACTACATACATTTATAACTTA 1215 
PfNT2 TTT-TATGTTGACTAGCTTTTCATT-TTTATTCGGACTAATGA-ATGGATTG--GTGA-A 1139 
PfNT3 TTA-AATGTGCACT--CAT--TTTT-TTAAATAT-ATATTTAA-ATGG-TTGGTTTGTTA 1600 
PfNT4 TT----TGT-CATT--CCTAATATT-TGTAATAGGAGGTACGA-ATGG-TTC-TTTG--A 1153 
   
PfNT1 TTCAATATAGTTTTACC-AAAG--CCAGATT--TACCACCC----ATC-GATGT----A- 1260 
PfNT2 T-AA-TTTAATTTTTTTGAAAGCACCAGAAACGTGTAAAGAAAAAAGCAAATATGAATAT 1197 
PfNT3 T-CA-TGT-CTTTTATT-AATGTTCCAGAAAT-TCTCAA------ACC-TAT-T----A- 1642 
PfNT4 T-CA-----ATATTAGT-TATG--CCAGAA---TATCAG------ACTGTTT-TGAAGA- 1193 
     
PfNT1 ACACAAT-AA-------------------------------------------------- 1269 
PfNT2 ATTCAATTAACTCCAAATATACTTTACTTATGTTTAATTTTTGG---AATAACCAGTGGG 1254 
PfNT3 ATTCAAT-GAGT--AATGTTGCAATAGTTA-GT---AGTTTTGGTTCAACACTCCTTC-G 1694 
PfNT4 ATCAAAT-AAGA--AAAC---CAA-ACA-A-AT---CGCTGTGG--CATCA-TCCTTCTG 1238 
 
PfNT1 ------------------------------------------------------------ 1269 
PfNT2 TG-TTT---AATATCCA-AGGTTCATGTAA--GAATTGTGA-ATATAATTGCAGTTATTT 1306 
PfNT3 AG-TTG--GCTTGTTAACAGGCT-ATGGAT--GTTCCACACTATATAAATATA-TCATAT 1747 
PfNT4 TGCTTTATGTCTATTAATGAGTT-TTGCATTAGCACCATGGTTTTGTAATGCAATAAT-T 1296 
 
PfNT1 ----------- 1269    
PfNT2 TAAAA---TAA 1314   
PfNT3 CAAAAATGTGA 1758   
PfNT4 CATT--TGTAA 1305   
     
 
Figure 5.3: Alignment of the four genes encoding for equilibrative nucleoside transporter in 
P. falciparum. 
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5.4 Phylogenic tree of the four genes encoding for ENT 
in P. falciparum 
Using the ClustalX program, a phylogenetic tree of the four genes encoding for the 
equilibrative nucleoside transporter was generated. TbAT1, which encodes for the 
adenosine transporter in T. brucei was included for comparison as an outgroup. The tree, 
which is shown in Figure 5.4 indicates that there is limited similarity between all five 
genes. However there appears to be a more recent ancestral link between PfNT1 and 
PfNT4. 
 
0.1 
Tb AT1 
PfNT3 
PfNT1 
PfNT4 
99.04 
PfNT2 
92.2 
 
Figure 5.4:Phylogenic tree, with bootstrap values, of the four genes encoding for ENT in P. 
falciparum and TbAT1 of T. brucei.  
The scale bar represents the distances as numbers of substitutions per site.  
 
Neils Ben Quashie, 2008 Chapter Five  
 
134
 
 
 
5.5 Sequencing of PfNT1 (PF13_0252) in P. falciparum 
clone 3D7 
To ensure that the sequence of the wild type PfNT1 is exactly as indicated in the 
PlasmoDB, a 1254 bp portion of parasite clone 3D7 was amplified and sequenced. This 
included the entire coding region of PF13_0252 gene plus regions up- and downstream 
from this segment. Three sets of primers were designed for amplification of overlapping 
portions of the gene. The primer sets are: 
PfNT1 SEQ1FOR=5′ AATGAGTACCGGTAAAGA 3′ 
PfNT1 SEQ1REV= 5′AATATTAAACAAAGTTCACAG 3′; 
 
PfNT1 SEQ2FOR=5′ TATTTCCAGGTGTTGGACAC 3′,  
PfNT1 SEQ2REV= 5′ GATGGGTGGTAAATCTGGC 3′; 
 
PfNT1 F=5′ TTACAGGTTTAGTATGTTCCTC 3′ 
PfNT1 R=5′ ATTTGGTGGATATCTACTGA G3′). 
 
The entire gene and the subgroups are shown in Figure 5.5. The amplicons was then 
shipped to the University of Dundee for sequencing.  
 
Outcome of the sequencing showed that the PfNT1 gene from the 3D7 clones of P. 
falciparum used in this study is 100% identical to the entry in PlasmoDB for PF13_0252.  
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TATATATATATATATATTTATTTAATAAATATATTTTGTAAAATTTAAAGAATATATATATATTAATATTATG
TATATATATTATATAATTAATATAGTAAATAAATAAATATACATATAAATATAATATTATATATATAATATTT
TTAGGTATTTATAAAATATATATATATATATATATATATATTTATATATATGTGCTGTTTACATATATATTAA
TAGGTTAATATATATATATATTTATTTATATTTATATGAATATATAAATATATTATATATTTATTTTGTTTAT
TTATCTATTATTATTTTATAAAGTAAAAATGAGTACCGGTAAAGAGTCATCTAAAGCTTATGCTGATATAGAA
TCCAGGGGTGATTATAAGGACGATGGAAAGAAAGGATCTACATTAAGCAGTAAACAACATTTCATGTTATCTT
TAACCTTTATATTAATAGGTTTAAGTTCTTTGAATGTATGGAATACAGCCTTAGGATTAAATATAAATTTTAA
ATATAATACCTTTCAGATTACAGGTTTAGTATGTTCCTCAATTGTAGCTTTATTTGTTGAGATTCCCAAAATA
ATGTTACCATTTCTTTTGGGTGGTTTATCAATTTTATGTGCAGGTTTTCAAATATCTCACAGTTTTTTTACAG
ATACACAATTTGATACATATTGTTTAGTAGCTTTTATTGTTATTGGTGTAGTGGCAGGATTAGCTCAAACCAT
TGCATTTAATATAGGATCAACCATGGAAGATAATATGGGTGGTTATATGTCAGCAGGTATTGGTATATCAGGA
GTATTTATTTTTGTTATTAATTTATTACTTGATCAATTCGTATCTCCCGAAAAACATTATGGTGTTAATAAAG
CAAAGTTATTATATTTATATATAATCTGTGAACTTTGTTTAATATTAGCTATAGTATTTTGTGTATGTAATTT
AGATTTAACAAACAAGAATAATAAAAAAGATGAAGAAAATAAAGAAAACAATGCCACATTATCTTATATGGAA
TTATTTAAAGATAGTTACAAAGCTATATTAACTATGTTTCTTGTAAACTGGTTAACTTTACAATTATTTCCAG
GTGTTGGACACAAAAAATGGCAAGAAAGTCATAATATCTCCGATTATAATGTTACCATTATTGTTGGTATGTT
TCAAGTTTTTGATTTTCTCAGTAGATATCCACCAAATCTTACACATATTAAAATCTTTAAAAATTTTACTTTC
TCTTTAAATAAATTATTGGTTGCCAATTCATTGAGATTATTATTCATTCCATGGTTTATTTTAAATGCATGTG
TTGATCATCCATTTTTCAAAAACATTGTACAACAATGTGTATGTATGGCTATGTTAGCTTTTACAAATGGTTG
GTTTAATACTGTACCATTCCTTGTATTTGTTAAAGAATTAAAAAAAGCCAAGAAAAAGAAAGAAATCGAAATT
ATATCCACATTCTTAGTTATTGCTATGTTTGTTGGATTATTCTGTGGTATATGGACTACATACATTTATAACT
TATTCAATATAGTTTTACCAAAGCCAGATTTACCACCCATCGATGTAACACAATAAATAAATAAAAATTGAAG
AGAAATAATGAATAATATATATATATATATATATTTACATATATATATTTATTTATTTATATATTTATTCATT
TTTACATTTATAAGTATTATGTAAATTTCGTATATATCTCCTCAATTTTCTTAAAATAAATTTAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAATTTATATATATAAATGTGTGTACATATCATTTATATGTTGTATT
AAAATTTTTAAAAACTTTTACCATTTTAAAAAAATAAAAAAAAAATAAATACAAGTTATAAAACTTAATATAT
AAATATATATATATATATATATATTTATATATTTATATGTATTATTTATTTTTGATGAGGTTCCTCTATATTT
TATACCAAG 
 
Figure 5.5: Sequencing of PfNT1. 
The figure is Part of P. falciparum genome showing the entire 1269 bp ENT1 (PF13_0252) in 
yellow colour. The under lined nucleotides constitute the 676 bp insert that was cloned into 
pCAM/BSD and used to disrupt the gene .The three pairs of primers used to amplify the 
entire ENT1 in order to sequence are shown in bold pink, red and blue (PfNT1 
SEQ1FOR=5′AATGAGTACCGGTAAAGA3′, PfNT1 SEQ1REV= 5′AATATTAAACAAAGTTCACAG3′; 
PfNT1 SEQ2FOR=5′TATTTCCAGGTGTTGGACAC3′, PfNT1 SEQ2REV= 
5′GATGGGTGGTAAATCTGGC3′; PfNT1 F=5′TTACAGGTTTAGTATGTTCCTC3′ PfNT1 
R=5′ATTTGGTGGATATCTACTGAG3′). Three overlapping segments of the gene were amplified 
and sequenced independently at the university of Dundee sequencing service.   
 
 
 
5.6 Preparation of plasmid constructs for disruption of 
the equilibrative nucleoside transporter genes 
Four DNA fragments were prepared for insertion into the vector pCAM/BSD for 
disruption of the genes encoding for the equilibrative nucleoside transporter proteins in P. 
falciparum, as described in section 2.3.7. The DNA sequences of the four genes encoding 
ENTs in P. falciparum and the target DNA chosen for disruption of gene functionality are 
shown in section 2.3.7. The fragments were chosen to ensure maximum disruption of the 
portion responsible for solute translocation in the parasite. Generally, the fragments chosen 
included the sequence encoding the transmembrane domains 3-6, as well as a portion of 
transmembrane domain 2, that are predicted to be responsible for solute translocation 
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(Hyde et al, 2001;de Koning et al, 2005). In order to increase the probability of 
recombination after integration, particular attention was given to the size of fragment 
chosen as detailed in section 2.3.7. Fragments sizes of 676 bp, 913 bp, 1171 bp (includes 
243 bp intron) and 778 bp were therefore chosen for PF13_0252, MAL8P1.32, PFA0160c 
and PF14_0662 respectively. 
 
Gel electrophoresis (section 2.3.6) confirmed that the expected size of PCR fragment for 
each gene was obtained with the gene-specific primers used, as shown in section 2.3.7. The 
PCR product was purified as described in section 2.3.8 and the concentration of the 
purified PCR product was determined as described in section 2.3.5. 
 
0    M   1   2  
200 
600 
1000 
bp 
676 bp
 
 
 
Figure 5.6: Amplification of PfNT1 (PF13_0252). 
Polymerase chain reaction of PfNT1 fragment (676 bp) separated on 1.5% agarose gel stained 
with ethidium bromide. Lanes marked 1 and 2 contain the 676 bp fragment, lane 0 is the 
blank and Lane M is the SMART molecular weight marker. 
 
 
 
M 1 2 3 4
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Figure 5.7: Amplification of PfNT2 and PfNT3 DNA fragments. 
Amplified fragments of PfNT2 and PfNT3 separated on 1.5% agarose gel stained with 
ethidium bromide.  PfNT2 shown in lane 1 had a band size of 778 bp whilst PfNT3 (lane 3) 
was 913 bp. Lanes marked 2 and 4 are the negative controls (no DNA) and the lane marked M 
is the molecular weight marker. 
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Figure 5.8: Amplification of PfNT4 DNA fragment. 
PfNT4 amplified fragment was separated on 1.5% agarose gel stained with ethidium bromide. 
The fragment, which is in lane 1, has a size of 938 bp. Lanes marked 2 and M are negative 
control and molecular weight markers respectively. 
 
1
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5.7 Preparation of pCAM/BSD-ENT construct  
Each of the purified PCR products prepared above was ligated into the expression vector, 
pCAM/BSD, as described in section 2.3.11. The constructs were designated pCAM/BSD-
PfNT1, pCAM/BSD-PfNT2, pCAM/BSD-PfNT3 and pCAM/BSD-PfNT4 for fragments 
targeting the ENT encoding genes, PF13_0252, PF14_0662, MAL8P1.32 and PFA0160c 
and respectively. Plasmids were purified as described in section 2.3.3. 
 
 
 
5.8 Transformation of DH5α competent cells with 
pCAM/BSD-ENT construct 
DH5-α chemically competent cells (Invitrogen, UK) were transformed with each of the 
four constructed plasmids (pCAM-BSD/ENT) using the standard heat-shock methods as 
described in section 2.3.12. There was an average growth of 30 single bacteria colonies per 
plate. Single colonies were subcultured into 500ml liquid bacterial culture as described in 
section 2.3.12. Plasmid was prepared from the liquid overnight bacterial cultures, as 
described in section 2.3.13 and plasmid DNA was purified using the maxi DNA 
purification kit (Qiagen, UK).  
The presence of the ENT inserts in each of the four pCAM/BSD-ENT constructs was 
verified by PCR using the forward and reverse primers designed for amplifying the ENT 
fragments.  PCR conditions described in section 2.3.7 were used for the amplifications. 
Four microlitres of the amplicon were then run on a 1.5% agarose. The insert amplified 
from each of the four pCAM/BSD NT plasmids was confirmed as being of the expected 
size (Table 2.1). Figure 5.9 shows verification of PfNT1 in pCAM/BSD-PfNT1 plasmid. 
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Figure 5.9: Verification of presence of PfNT1 insert in plasmid pCAM/BSD-PfNT1 by PCR. 
Each lane is from a culture prepared with a single colony as discussed above (section 5.5). 
The construct retrieved from the bacteria cells was subjected to PCR amplification using the 
forward and reverse primers PfNT1 F and PfNT1 R. The figure shows separation of the 
amplicon on 1.5% agarose gel stained with ethidium bromide. The lane marked M represents 
the molecular weight marker. The lanes with the 676 bp band show the colonies from the 
bacteria that were successful transformed with the construct, pCAM/BSD-NT1. 
 
Presence of the insert in the purified pCAM/BSD-ENT constructs was also verified by 
restriction digest with BamH1 and SacII. The enzymes are expected to cut the construct at 
the 5′ and 3′ end respectively of the insert, resulting in two bands (insert and vector). 
 
The fragments obtained from restriction of the four construct with BamH1 and SacII 
indicate that ligation of each of the ENT fragments into pCAM/BSD-NT was successful. 
Figure 5.10 is a picture of the gel showing the resultant fragments after restriction digest of 
the construct, pCAM/BSD-PfNT1. 
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Figure 5.10: Verification of the presence of PfNT1 inserts in the plasmid pCAM/BSD-PfNT1 
by restriction digestion with BamHI and SacII. 
The digested product was separated on 1.5% agarose gel stained with ethidium bromide. 
Lane 1: molecular weight marker. Lanes 2 and 3: Digested (cut) product (showing the 676bp 
PfNT1 and the 4519 pCAM/BSD fragments). Lanes 4 and 5:undigested (uncut) product. 
 
The sequence of each of the four inserts was verified through sequencing. Each of the four 
pCAM/BSD-ENT plasmids was purified as described in section 2.3.3and sequenced using 
the appropriate pCAM/BSD forward primer at the University of Dundee Sequencing 
Service (DSS). The results of the sequencing confirmed that each plasmid construct 
contained the exact sequence of the gene fragments for PfNT1 PfNT2, PfNT3, and PfNT4. 
 
5.9 Transfection of P. falciparum by electroporation 
Asexual parasites of P. falciparum clone 3D7 were cultured as previously described 
(section 2.1.4). Predominantly ring stage of the parasites were transfected with each of the 
purified pCAM/BSD-NT plasmids using the methods described in section 2.4. Blasticidin-
resistant parasites appeared in each of the four experiments after 3-4 weeks of selective 
culture, indicating successful transformation of parasites with the plasmids conferring 
resistance to Blasticidin. The plasmids could replicate episomally, which would confer 
blasticidin resistance but would not result in disruption of the PfNT loci. Therefore, PCR 
analysis was used to verify that the episome had integrated into the parasite’s genome 
through homologous recombination. 
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5.10 Confirmation of integration of 3D7∆PfNT1, 
3D7∆PfNT2 and 3D7∆PfNT3 in uncloned parasite 
cultures 
Different combinations of primers (see Table 2.3) specific to the PfNT gene allow 
discrimination of (i) the wild-type locus, (ii) a 5’ integration event, (iii) a 3’ integration 
event, and (iv) the episomal form of the transfected plasmid. Pictures of the gels showing 
integration of the pCAM/BSD-PfNT construct, verified with with various primer 
combinations are shown inFigure 5.11 to Figure 5.13. It was clear from the results that 
integration was achieved for all the four genes under investigation. 
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Figure 5.11: PCR analysis of uncloned PfNT1 transfectants, pCAM/BSD-PfNT1 and wild type 
3D7 parasites. 
Genomic DNA from PfNT1 transfectants, pCAM/BSD-PfNT1 and wild type 3D7 parasites were 
subjected to PCR analysis. Primer pairs were used to detect the presence of the episome, 
using pCAM F2 and pCAM R2 (1-4), integration at the 5’ end of the insert using primers 
PfNT1 up and pCAM R2 (lanes5-8), integration at the 3’ end of the insert, using PNT1 
Down+pCAM F2 (9-12), the wild type gene using PfNT1 Up+PfNT1 Down (13-16) and presence 
of the PfNT1 fragment (lane 17-20) as detailed in section 2.4.2. Lanes1, 5,9,13 and17: 
amplifications using DNA from the transfectant. Lanes 2,6,10,14 and 18: amplifications using 
DNA from pCAM/BSD PfNT1; lanes 3,7,11,15 and 19: amplifications using DNA from wild type 
parasite; lanes 4,8,12,16 and 20: negative control (water as template). Lanes marked M are 
molecular weight markers. See Table 2.4 for the expected band sizes. 
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Figure 5.12 PCR analysis of uncloned PfNT2 to verify integration of pCAM/BSD-PfNT2 into 
parasite’s genome. 
Lanes1,7,13,17 and 23 contains DNA from the transfectant; Lanes 2,8,14,18 and 24 contain 
DNA from the construct; lanes 3,9,15,19 and 25 contain DNA from wild type parasite; lanes 
4,10,16,20 and 26 are negative controls (water as template). Lanes marked M are molecular 
weight markers. Primer pairs used were pCAM F2 and pCAM R2 (lanes1-4), primers PfNT1 up 
and pCAM R2 (lanes7-10), PNT1 Down+pCAM F2 (13-16), PfNT1 Up+PfNT1 Down (17-20) and 
presence of the PfNT2 fragment (lane 23-26).see Table 2.4 for detail of expected band sizes. 
The figure shows integration at the 5′ end (lane 7) and 3′ end (lane13).  
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Figure 5.13: PCR analysis of uncloned PfNT3 to verify integration of pCAM/BSD-PfNT2 into 
parasite’s genome.  
Lanes1, 5,9,13 and 17 contain DNA from the transfectant; Lanes 2,6,10,14 and 18 contain 
DNA from the construct; lanes 3,7,11,15 and 19 contain DNA from wild type parasite; lanes 
4,8,12,16 and 20 are negative controls (water as template). Lanes marked M are molecular 
weight markers. Primer pairs used were pCAM F2 and pCAM R2 (lanes1-4), primers PfNT1 up 
and pCAM R2 (lanes 5-8), PNT1 Down+pCAM F2 (9-12), PfNT1 Up+PfNT1 Down (13-16) and 
presence of the PfNT3 fragment (lane 17-20). The figure shows integration at the 5′ end 
(lane 5:1401 bp) and 3′ end (lane 9:1244 bp).  
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5.11 Cloning of parasites with disrupted PfNT1  
Once integration of pCAM/BSD PfNT into parasite’s genome had been confirmed, the 
parasites were frozen down into liquid nitrogen (section 2.1.7). To proceed with further 
characterisation of the gene-disrupted parasites it was necessary to clone the transfected 
lines to obtain homogeneous parasite populations.  
 
The work presented in this section of the thesis describes the cloning and subsequent 
analysis of parasite clones with a disrupted PfNT1 gene. Cloning of the 3D7 parasite line 
with a disrupted PfNT1 (Pf13_0252) was performed in a 96 well plate using the limited 
dilution method described in section 2.3.19. Four parasite clones were obtained by this 
method and were designated 3D7 ∆PfNT1-D6, 3D7 ∆PfNT1-B9 and 3D7 ∆PfNT1-
B11.PCR confirmation in three of the clones is shown in Figure 5.14. 
 
Due to time constraints, clones could not be prepared for the other three disrupted ENT 
genes (PfNT2, PfNT3 and PfNT4). However, the frozen parasites would be cloned in the 
future and the kinetic properties of the phenotype lacking the ENT gene determined. 
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Figure 5.14: PCR analysis of the three clones of PfNT1 transfectants, pCAM/BSD-PfNT1 and 
wild type 3D7 parasites. 
Genomic DNA from cloned ∆PfNT1 transfectants, pCAM/BSD and wild type 3D7 parasites were 
subjected to PCR analysis. Primer pairs were used to detect the presence of the episome, 
using pCAM F2 and pCAM R2 (1-4), integration at the 5’ end of the insert using primers NT1 
up and pCAM R2 (lanes6-9), integration at the 3’ end of the insert, using NT1 Down+pCAM F2 
(11-14) and the wild type gene using NT1 Up+NT1 Down,  (15-18) and presence of the PfNT1 
fragment (lane 21-24) as detailed in section 2.4.2. Lanes1, 6,11,15 and21: amplifications 
using DNA from the transfectant. Lanes 2,7,12,16 and 22: amplifications using DNA from 
pCAM/BSD; lanes 3,8,13,17 and 23: amplifications using DNA from wild type parasite; lanes 
4,9,14,18 and 24: negative control (water as template). Lanes marked M are molecular 
weight markers. The size of the molecular weight marker is shown at the bottom right 
corner. Presence of the bands in lanes 6 (731 bp) and 11 (840 bp) confirmed integration at 
the 5’ and 3’ end respectively. Integration appears to have occurred in all the three ∆PfNT1 
clones. The episome was still observed to be present (lane 1; 712 bp). See Table 2.4 for the 
expected band sizes. 
. 
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5.12 Molecular characterisation of 3D7∆PfNT1 clones 
5.12.1 PCR characterisation of 3D7∆PfNT1 clones 
 
The four 3D7∆PfNT1 parasite clones were characterised by PCR as described in section 
2.4.2 using combinations of primers. The outcomes of this analysis for clones 
3D7∆PfNT1-B11 and 3D7∆PfNT1-D6 are shown in Figure 5.15. The results indicate that 
(i) the parasites have lost their wild-type gene (lane 4) indicating that the PfNT1 gene has 
been interrupted, (ii) amplicons with expected sizes for 5’ and 3’ integration events were 
recovered (lanes 1 and 2), and (iii) a band arising either from the episome or from an 
integrated concatemer of the plasmid was still present in the cloned parasites (lane 3). 
Similar results were obtained with clones 3D7∆PfNT1-B7 and 3D7∆PfNT1-B9.  
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Figure 5.15: PCR analysis of genomic DNA from the wild-type 3D7, uncloned pCAM/BSD-
PfNT1 transfected parasite population and two of the 3D7∆PfNT1 clones (B11 and D6). 
Lane 1 in each box contains the products of amplification with primers I and III, and a 
product of 1088 bp. indicates integration at 5’end of the locus. Lane 2 contains the products 
of amplification with primers II and IV, and a product of 908 bp. indicates integration at the 
3’ end. Lane 3 contains the products of amplification with primers II and III, and a product of 
850 bp. indicates the presence of the episome. Lane 4 contains the products of amplification 
with primers I and IV, and a product of 1174 bp indicates the intact PfNT1 gene.  
 
 
5.12.2 Southern blot analysis of 3D7∆PfNT1 clones  
Southern blotting was performed as described (Fidock and Wellem, 1997) to confirm 
homologous integration at PfNT1 in the 3D7∆PfNT1 clones and the absence of the wild 
type intact PfNT1 in the culture, as detailed in section 2.4.4 and section 2.4.2. 
 
The Southern blot was hybridized to a probe representing the same region of PfNT1 
present in the plasmid pCAM/BSD-PfNT1 (Fig. 5.20). The probe hybridized to a 7.9kb 
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fragment in wild type 3D7 parasites, representing the genomic copy of PfNT1 (Figure 
5.17). This fragment was absent in the four 3D7∆PfNT1 clones B11, B9, B7 and D6, being 
replaced by two fragments of 7.1kb and 5.9kb, representing the interruption of PfNT1 by 
the integrated plasmid sequence. Episomal plasmid with an expected size of 5.2kb was not 
detected by southern blotting (see Figure 5.16), whereas it was detected by PCR (Figure 
5.15). This is likely to be a reflection of the lower sensitivity of southern blotting method 
compared with PCR for the detection of episomes present in a minority of parasites in the 
culture. Alternatively, the PCR product observed may represent amplification from 
multiple copies of the plasmid inserted into the locus. It is not possible to differentiate 
between multiple copies of the plasmid integrating into a locus and circular episomes by 
Southern blot analysis, as any of these digests would merely drop out the extra plasmid 
copies from the locus and appear the same as circular episomes. 
 
M   1   2  3   4   5   6 M  8   9 10 11 12 13  M  
 
Figure 5.16: Separation of 12 µl of restriction digested DNA with Xmn1 of wild type (3D7 of 
P. falciparum) and DNA from four 3D7∆PfNT1 clones on 0.8% agarose gel prior to Southern 
blotting. 
Lanes 1 and 8 contain the wild type DNA, lanes 2 and 9 contain 3D7∆PfNT1-B11 DNA; Lanes 3 
and 10 contain 3D7∆PfNT1-B9; lanes 4 and 11 contain 3D7∆PfNT1-B7: Lanes 5 and 12 
contain 3D7∆PfNT1-D6, lanes 6 and 13 contain the plasmid (pCAM/BSD). Lanes marked M 
contain the SMART DNA ladder. 
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Figure 5.17: Gene disruption strategy. 
Primers used to detect integration of the construct into the wild type locus are shown by 
arrows labeled I, II, III and IV which correspond to the text descriptions as follows: I: 
PfNT1_UP; II: pCAM-BSD_F2; III: PCAM-BSD_R2; IV: PfNT1_DOWN.The restriction sites of the 
endonuclease, Xmn1, in the wild-type locus, construct and the integrants are as indicated.  
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Figure 5.18: Southern blot showing the wild type locus and the digested products of the 
clones by Xmn1. 
The blot was probed with a fluorescein labeled-PCR product representing nucleotides 210 to 
885 of PfNT1 gene. The sizes of the bands are as shown. 
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5.13 Discussion 
Gene targeting by homologous recombination, allows disruption of specific genes and 
consequently the interruption in the function of the proteins they encode (Menard & Janse, 
1997). In this study, the technique was used to disrupt the genes that encode for 
equilibrative nucleoside transporters (ENT) in P. falciparum. Employing the gene 
manipulation techniques described in this chapter in combination with the classical uptake 
technique (chapter two), the true kinetic properties of PfNT1 were uncovered (see chapter 
six). 
 
All the four genes predicted by Martin and his colleagues (Martin et al, 2005) to encode 
for the equilibrative nucleoside transporters in P. falciparum were successfully disrupted 
by homologous recombination. The four genes targeted and disrupted were designated 
PfNT1, PfNT2, PfNT3 and PfNT4, corresponding to the loci with PlasmoDB accession 
numbers PF13_0252, PF14_0662 MAL8P1.32, and PFA0160c respectively. Single 
crossover homologous recombination at each PfNT locus was expected to produce a 
pseudodiploid configuration, with both truncated copies lacking some of the 
transmembrane domains of the protein necessary for transport activity. In most cases 
blasticidin-resistant parasites (transfectants) emerged 21 days post-electroporation. Parasite 
growth under drug pressure confirmed successful transfection. In the absence of an 
antibody to confirm changes in the transporter protein, the disruption of the ENT genes 
could only be confirmed through Southern blot and PCR analysis.  
 
The observation that the parasites with a disrupted PfNT1 gene could only grow normally 
when the medium was supplemented with extra purines also indicated the loss of transport 
activity by this protein and emphasized the essentiality of this transporter. This observation 
also throws the spotlight on purine transporters as a possible target for novel antimalarial 
drugs.  
 
As the transfected lines went through numerous growth cycles it was expected that the 
episomal copies of the plasmid would disappear, because replication of the plasmid is not 
regulated with that of the parasite, and it is likely that some merozoites of a schizont would 
segregate without any episomal copies. Therefore over time the number of parasites with 
episomal copies should decrease. It is therefore most likely that the PCR product observed 
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using primers, which would amplify, an episome, most likely represent multiple copies of 
the plasmid inserted into the locus. It is well documented that by a single crossover event 
several copies of the plasmid can integrate into the malaria genome (McCoubrie et al, 
2007)). While plasmid rescue can be used to rescue episomes from parasites, the presence 
of rescued plasmids does not necessarily infer the presence of replicating episomes in 
parasites. This is because homologous plasmid sequences in the genomic DNA of parasites 
containing multiple plasmid copies will naturally recombine in E. coli upon transformation 
to yield plasmids.  
 
From the Southern blot, no wild type band was observed in any of the 3D7∆PfNT1 clones, 
indicating that all parasites after cloning harboured the integration event. This was 
confirmed by PCR, where only bands representative of integration at 5’ and 3’ ends were 
obtained, whereas no band representative of a wild-type locus (as would be the case in 
parasites that only harbour episomes) was observed.  
  
Taken together, the PCR and the Southern blot analyses confirmed that integration into 
PfNT1 had occurred and the PfNT1 locus had been disrupted. It was not possible to verify 
whether this gene disruption resulted in the complete loss of the PfNT1 protein, as no 
antisera were available. It is possible that a truncated form of PfNT1 could be produced, 
consisting of domain 1 and part of domain two (excluding the domain thought to be 
responsible for solute translocation). However this truncated protein is highly unlikely to 
be able to perform the same function of a wild-type PfNT1 with eleven trans-membrane 
domains. The 3D7 clone (control) was sequenced to confirm that its PfNT1 sequence was 
100% identical to the entry in PlasmoDB as PF13_0252. 
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5.14 Conclusions 
All four of the genes thought to encode for ENT in P. falciparum were successfully 
disrupted by homologous recombination. For each of the four disruptions, parasites with 
non-functioning ENT gene recovered after transfection and selection, indicating that none 
of the four ENT genes are essential to asexual P. falciparum parasites growing under in 
vitro culture conditions [although it was necessary to supplement the culture medium with 
additional purines to ensure growth]. Parasite clones were made by limiting dilution from 
one of the transfectant (PfNT1). Uncloned parasites from the other three transfection 
experiments were stored to await analysis at a later date, since time did not allow their 
further analysis for this thesis. The resultant 3D7∆PfNT1clones were analysed by PCR and 
Southern blot, confirming the absence of the intact, wild-type PfNT1 gene and the 
integration of the pCAM/BSD-PfNT1 plasmid into the PfNT1 locus.  
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CHAPTER SIX 
6 Characterisation of purine transport parameters in P. 
falciparum parasites lacking the gene encoding the 
Equilibrative Nucleoside Transporter 1 protein (PfNT1). 
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6.1 Summary 
 
The kinetic properties of nucleoside and nucleobase transport in parasite clones with a 
disrupted gene, coding for one of the four Equilibrative Nucleoside Transporter proteins in 
P. falciparum were determined. The technique employed for disruption of PfNT1 gene was 
described in chapter five of this thesis. In the present chapter, classical uptake techniques 
were used to assess the difference in purine salvage between parasites clones lacking the 
PfNT1 gene (3D7∆PfNT1) and the parental clone 3D7 of P. falciparum (wild type). It was 
clearly demonstrated in this study that in 3D7∆PfNT1 clones the high affinity 
hypoxanthine/ nucleoside transport activity observed in the wild type parasites was 
completely abolished, whereas the low affinity adenosine transport activity remained 
unchanged. Adenine transport in the 3D7∆PfNT1 clones appeared to be slightly increased. 
We conclude that the gene with PlasmoDB accession number PF13_0252 (PfNT1) encodes 
a high affinity hypoxanthine/nucleoside transport activity in P. falciparum.  
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6.2 Introduction 
In order to ascertain the link between the four P. falciparum genes encoding proteins of the 
Equilibrative Nucleoside Transporter (ENT) family and the four apparently distinct purine 
transport activities reported in chapter four of this thesis, an assessment of purine 
transporters in clones with a disrupted ENT gene was performed. The outcome of this 
investigation is expected to reveal the exact contribution of at least one ENT protein in 
purine salvage into P. falciparum and address some of the controversies surrounding 
purine uptake in P. falciparum. Parasites with a disrupted PfNT1 gene, whose generation 
was described in chapter five, were used in this investigation.  
 
A purine uptake profile was prepared for one of the 3D7∆PfNT1 clones, 3D7∆PfNT1-D6, 
using the uptake techniques described in chapter two. Non-transformed 3D7 parasites 
(wild-type) that had undergone the same electroporation process as the genetically 
modified clones, but were not transfected with the pCAM/BSD-PfNT1 construct, were 
used as controls. Transport of hypoxanthine, adenine and adenosine at high or low 
concentrations was assessed exactly as described in chapter four for the saponin-freed P. 
falciparum trophozoites. For any given permeant, the linear phase of uptake was 
determined, with a constant permeant concentration incubated with the cells for different 
time periods to generate a plot of uptake versus time. Linearity was assessed using linear 
regression and defined as a correlation coefficient >0.95 and significant difference from 
zero uptake (F-test; GraphPad Prism version 4). When uptake was too rapid to obtain 
linearity of transport at room temperature, it was reassessed at 6 °C. Only the linear part of 
the uptake was used for estimation of the uptake rate as it reflects true rates of transport 
across the P. falciparum plasma membrane rather than rates of metabolism or 
sequestration. 
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6.3 Kinetic characterisation of parasites- summary of 
procedure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1:. Flow diagram for the production of 3D7∆PfNT1 clones and wild-type control 
parasites used to assess purine transport in P. falciparum. 
Kinetic characterisation of parasites
using classical uptake technique 
P .falciparum 3D7 clone 
Parasites transfected by 
electroporation with pCAM/BSD-
PfNT1 construct 
In culture predosed with blasticidin 
Transfectant appears in culture 
21 days post-electroporation 
Integration of pCAM/BSD-PfNT1 
and disruption of PfNT1 check by 
PCR and Southern blot 
Cloning of 3D7∆PfNT1 line 
Parasites with disrupted PfNT1 freed 
from PfNT1 infected erythrocytes by 
saponin treatment of infected RBC 
P. falciparum 3D7 clone 
Electroporation of parasites in the 
absence of pCAM/BSD-PfNT1 construct 
Surviving parasites designated 
control (wild type) 
Parasites maintained in 
culture without blasticide
Parasites freed from P. falciparum 
erythrocytes by treatment with 
saponin 
Molecular analysis of PfNT1 gene to 
ensure that it is the same as that 
enlisted in PlasmoDB as PF 13_0250
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6.4 High affinity Adenosine transport is abolished in 
clone 3D7∆PfNT1-D6 
Time dependent uptake of 0.25 µM [3H]-adenosine into saponin-freed P. falciparum 
trophozoites of 3D7∆ PfNT1, lacking PfNT1, or wild type clone 3D7 (control) was carried 
out using the method developed and described in Chapter 4.  
 
Comparison of adenosine transport in control (wild type) parasites and in 3D7∆PfNT1-D6 
indicates that uptake of 0.25 µM [3H]-adenosine was reduced by 97 – 100% in the latter (n 
= 3; Figure 6.2). This observation clearly demonstrates the loss of high-affinity adenosine 
transport in the mutant line. The lack of high affinity adenosine transport activity was 
specific rather than a general reduction in transport rates as demonstrated below. 
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Figure 6.2: Purine transport in P. falciparum trophozoites of clone 3D7∆PfNT1-D6 lacking 
PfNT1 (Transport of 0.25 µM [3H]-adenosine at 22 °C). 
Transport of 0.25 [3H]-adenosine at 22 °C in 3D7∆PfNT1-D6 is indicated with open symbols and 
in wild-type3D7 parasites with closed symbols. Insert shows the linear phase of the uptake 
obtained by linear regression. Data points shown are the mean of duplicate determinations 
and the experiment shown is typical of three identical determinations. 
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6.5 High affinity Hypoxanthine transport in clone 
3D7∆PfNT1-D6 is abolished  
 
Uptake of 0.4 µM [3H]-hypoxanthine into saponin-freed 3D7∆PfNT1 or into wild-type 
control parasites was also assessed. The result, which is shown in Figure 6.3, indicates a 
reduction by 82 – 98% in hypoxanthine uptake into 3D7∆ PfNT1 when compared with the 
wild-type (n = 3).  
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Figure 6.3: Purine transport in P. falciparum trophozoites lacking PfNT1 (transport of. 0.4 
µM [3H]-hypoxanthine at 22 °C). 
Transport of 0.4 µM [3H]-hypoxanthine at 22 °C in 3D7∆PfNT1-D6 is indicated with open 
symbols and in wild-type 3D7 parasites with closed symbols. Insert shows the linear phase of 
the uptake. 
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6.6 High affinity adenine transport is not abolished in 
clone 3D7∆PfNT1-D6 
 
Uptake of 1 µM [3H]-adenine was not greatly affected in the 3D7∆PfNT1 parasites (Figure 
6.4): the initial rates of transport over 12 s were not significantly different in clone 
3D7∆PfNT1-D6 and wild-type 3D7 control parasites (n = 3; Paired t-test). However, in 
each of three independent experiments the maximum level of [3H]-adenine transport in 
clone 3D7∆ PfNT1-D6 was double that of the wild-type control (0.16 ± 0.06 vs. 0.077 ± 
0.022 pmol (107 cells)-1s-1; n=3, non-linear regression).  
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Figure 6.4: Purine transport in P. falciparum trophozoites lacking PfNT1 (Transport of 1 µM 
[3H]-adenine at 22 °C). 
Transport of 1 µM [3H]-adenine at 22 °C in 3D7∆PfNT1-D6 is indicated with open symbols and 
in wild-type 3D7 parasites with closed symbols. Insert displays the linear phase of uptake (r2 
= 0.99 for 3D7∆PfNT1-D6 and 0.98 for wild-type 3D7). 
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6.7 Low affinity adenosine transporter is not abolished 
in clone 3D7∆PfNT1-D6 
Time dependent uptake of 25 µM [3H]-adenosine into saponin-freed P. falciparum 
trophozoites of clone 3D7∆PfNT1-D6, lacking PfNT1, or into wild-type 3D7 (control) 
parasites was also investigated. The high concentration of the permeant used in this 
experiment was supposed to saturate the high affinity transporter and thus permit the 
uptake rate of the low affinity adenosine transporter to be measured. Since previous 
experiments with wild-type parasites (chapter four) revealed a very rapid uptake rate of 
this transporter, and a very short period of linear uptake these experiments were performed 
at 6°C in order to slow down the rate of uptake and make it measurable.  
 
The outcome of this experiment clearly shows that uptake of 25 µM [3H]-adenosine at 6 °C 
was not affected by the disruption of PfNT1 in the parasite as identical rates of uptake were 
measured in clone 3D7∆PfNT1-D6 and the wild-type 3D7 (Figure 6.4). In contrast to the 
observations with the high affinity adenine transport activity, very similar overall uptake 
rates were achieved after 20 seconds in both parasite clones. 
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Figure 6.5: Purine transport in P. falciparum trophozoites lacking PfNT1 (Transport of 25 µM 
[3H]-adenosine at 6 °C). 
Transport of 25 µM [3H]-adenosine at 6 °C in 3D7∆PfNT1-D6 is indicated with open symbols 
and in wild-type 3D7 parasites with closed symbols. Insert shows the linear phase of the 
uptake. 
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6.8 Sensitivity of parasites lacking PfNT1 to JA- and NA- 
compounds 
 
Using an improved PicoGreen® method (see Chapter seven for details of the method), 
purine analogues, JA-32, JA-23, NA-130 and NA-137 were tested for activity against 
parasites of clone 3D7∆PfNT1-D6 and wild-type (3D7). Chloroquine was included in the 
assays as positive control. The assay was performed exactly as described in section 2.6. 
The compounds were tested over a concentration range of 0-500 µM.  
 
The result of the tests, which is presented in Table 6.1, shows apparent differences in 
sensitivity between wild-type parasites and parasites with a disrupted PfNT1 for each of the 
compounds tested; the mean IC50 values appear to be higher for the 3D7∆PfNT1 clone, 
compared to the wild-type 3D7 control. However statistical analysis (unpaired t-test) of the 
results shows that with the exception of N-130, there was no significant difference between 
the two parasite types. Thus, the absence of the high affinity hypoxanthine/nucleoside 
transporter had no effect on the activity of these antiplasmodial purine analogues. Clearly, 
their activity did not primarily rely on entry through PfNT1. One trivial explanation would 
be that they are not substrates of the transporter. However, as their hydrophilicity is not 
compatible with passive trans-membrane diffusion at significant rates, they would have to 
be transported by one of the lower-affinity transporters. The fact that the in vitro 
antimalarial activity of the compounds is relatively low and, for NA-130 and NA-137, 
three orders of magnitude less than against T. brucei, is indeed consistent with an efficient 
uptake by P. falciparum. Overall, the JA-compounds had lower IC50 values than the NA-
compounds indicating a higher antimalarial activity in vitro in the former. There were 
some variability in the IC50 values and this may probably account for the failure to observe 
a significant difference. Though statistical analysis shows a significant difference in the 
response of 3D7∆PfNT1 clone and the 3D7 P. falciparum control to NA-130, the 
difference may not be biologically relevant as the difference is small. 
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Compound Result 3D7∆PfNT1-
D6 
3D7 (wild type) P value (paired 
student’s t-test) 
Assay 1 (µM) 3.62 0.84 
Assay 2 (µM) 2.46 - 
Assay 3 (µM) - - 
Mean IC50 (µM) 3.0 0.84 
JA-23 
SEM 0.6 ND 
0.300631 
Assay 1 (µM) 1.8 1.72 
Assay 2 (µM) 3.3 4.27 
Assay 3 (µM) 4.86 1.66 
Mean IC50 (µM) 3.3 2.6 
JA-32 
SEM 0.9 0.9 
ND 
Assay 1 (µM) 102 64 
Assay 2 (µM) 93.3 44.2 
Assay 3 (µM) 169 155 
Mean IC50 (µM) 121.4 87.7 
NA-130 
SEM 23.9 34.1 
0.041447 
Assay 1 (µM) 98.5 77.5 
Assay 2 (µM) 208 91.7 
Assay 3 (µM) 196 199 
Mean IC50 (µM) 167.5 122.7 
NA-137 
SEM 34.7 38.4 
0.172057 
Assay 1 (nM) 9.8 2.29 
Assay 2 (nM) 11.6 11.0 
Assay 3 (nM) 11.6 12.10 
Assay 4 (nM)   
Mean IC50 (µM)  8.5 
Chloroquine 
 
 
SEM 3.3 2.2 
0.104576 
 
Table 6.1 : Sensitivity of P. falciparum clones 3D7∆PfNT1-D6 and wild type (3D7 clones of P. 
falciparum) to JA- and NA-compounds. 
The values shown are the mean IC50  (µM) from triplicate. The SEM represents standard error 
of mean, P values shown are from paired t-tests for each compound. ND=not done.  
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6.9 Discussion 
The high affinity transport of adenosine and hypoxanthine present in the wild-type 
parasites was found to be completely absent in 3D7∆PfNT1 parasites, whereas the low 
affinity transport of adenosine remained unchanged. Initial rates of transport for [3H]-
adenine uptake in the clone with a disrupted PfNT1 and the wild-type 3D7 clone were also 
similar. These results strongly suggest that the disruption of the PfNT1 gene only affected 
the high affinity hypoxanthine/nucleoside transport activities.  
This finding is in agreement with a recently published independent report that disruption of 
the PfNT1 gene renders the parasite incapable of completing the intraerythrocytic life cycle 
under standard purine level culture conditions (El Bissati et al, 2006). The report states that 
the ∆ PfNT1 parasites (produced independently of this study, but using the same parental 
clone 3D7) could only grow in a medium supplemented with >10 µM hypoxanthine, 
adenosine or inosine whilst the wild-type P. falciparum were able to grow in very low 
levels of purines (El Bissati et al, 2006). Observations reported in that study therefore 
provided indirect evidence that PfNT1 is most likely to encode a high affinity purine 
transporter. Unfortunately, El Bissati and colleagues (El Bissati et al, 2006) did not 
perform studies to determine any kinetic characteristics, or the substrate selectivity profile 
of this important transporter. 
 
The conclusion from our study, that PfNT1 encodes a high affinity 
hypoxanthine/nucleoside transporter, is at odds with the previous reports of others that 
PfNT1, when expressed in Xenopus laevis oocytes, is a relatively low affinity transporter of 
hypoxanthine/nucleoside (Parker et al, 2000;Carter et al, 2000;Downie et al, 2006). It must 
however be stressed that the previous reports differed substantially from each (the reported 
Km for the uptake of adenosine by the three groups ranges from 13µM to 1860µM) which 
appears to suggest that the Xenopus expression system produces inconsistent results when 
expressing Plasmodium transporters, perhaps as a result of interference by the vector’s 
endogenous proteins, or the extremely high AT-content of the Plasmodium genome 
(Goman et al, 1982;Pollack et al, 1982;McCutchan et al, 1984;Musto et al, 1997) and the 
resultant different codon preferences of Plasmodium and Xenopus. Having said this, it 
must be added that the single amino acid difference observed between the two groups (phe 
vrs leu) could also have contributed to the significant difference in their results and 
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probably in addition to the difference in clones of parasites used in the two experiment 
(Carter and co used 3D7 and W2 whilst Parker and co used only 3D7).  
 
In work published subsequent to the findings presented here, Downie and colleagues 
(Downie et al, 2006) studied adenosine transport using saponin-freed P. falciparum-
parasites, rather than Xenopus laevis oocytes. However, they failed to detect the presence 
of a high affinity transport activity for adenosine. This can be explained if the high level of 
permeant (more than 10µM) used in the uptake assays saturated the high affinity 
transporter. Since low affinity transporters are functional even at high permeant 
concentrations, this became the sole transporter detected in that study. 
 
To avoid making a similar mistake in this study, the concentration of the permeant used in 
the uptake assays (less than 0.5µM) was carefully chosen to prevent saturation of any high 
affinity transporter. In addition, to remove all ambiguity surrounding the outcome of 
investigations conducted in this study, the PfNT1 gene of clone 3D7 (wild-type) was re-
sequenced and was found to be 100% identical to the entry in PlasmoDB (PF13_0252).  
On the basis of the evidence gathered in this study, it is proposed that purine salvage in P. 
falciparum is based predominantly on the highly efficient uptake of hypoxanthine and 
purine nucleosides by PfNT1.  
 
The related apicomplexan parasite T. gondii also expresses a high affinity transporter, 
TgAT2, with a Km value of 0.49 µM for adenosine and 0.77 µM for inosine (de Koning et 
al, 2003). However unlike P. falciparum, T. gondii expresses a separate high affinity 
transporter for oxopurine nucleobases, TgNBT1, which, in direct parallel with P. 
falciparum, does not transport adenine (de Koning et al, 2003). For both apicomplexan 
parasites, the expression of a high affinity purine transporter would seem essential, as their 
environment, within the host cell, is unlikely to contain a high level of free purine (Ngo et 
al, 2000) and nucleotides cannot be directly salvaged across the parasite plasma 
membrane. 
 
An interesting observation made in this study is the relatively high uptake of 1 µM [3H]-
adenine into 3D7∆PfNT1 parasites compared with wild-type 3D7 parasites after the linear 
phase; the difference in uptake during this phase was approximately doubled in 
3D7∆PfNT1 parasites. This phenomenon may reflect an adaptation by the 3D7∆PfNT1 
parasites to compensate for the loss of the high affinity hypoxanthine/nucleoside transport 
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activity. As the initial rates of [3H]-adenine transport were identical in the wild-type and 
gene-disrupted clones, this would seem to reflect increased metabolism of adenine rather 
than an upregulation of purine transport activity induced by lack of a purine source, as 
documented for other protozoan species including Crithidia fasciculata and T. brucei 
[reviewed by de Koning and co-workers (de Koning et al, 2005)]. 
 
 
6.10 Conclusion 
Data gathered in this study provide compelling evidence that the protein encoded by PfNT1 
is responsible for the high affinity uptake of hypoxanthine/nucleoside in isolated P. 
falciparum trophozoites. There was an apparent increase in the uptake of adenine into P. 
falciparum clones lacking PfNT1, presumably to compensate for the loss of high affinity 
hypoxanthine salvage. 
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CHAPTER SEVEN 
7 Development of an improved microfluorimetric 
method for in vitro assessment of the susceptibility of 
P. falciparum to purine antimetabolites 
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7.1 Summary 
A major objective of this study was the assessment of purine analogues for antiplasmodial 
activities using an appropriate in vitro drug sensitivity method. For various reasons, 
discussed below, the traditional microscopic assay and the [3H]-hypoxanthine 
incorporation methods are unsuitable for use in such experiments. A published 
microfluorimetric assay that used PicoGreen®
 
dye to stain parasite DNA followed by 
fluorimetric analysis for assessment of parasite growth in vitro was thought to be more 
appropriate for drug sensitivity assays of purine analogues. However, in an attempt to 
validate the published PicoGreen® method, it was discovered that the haemoglobin present 
in cultures of P. falciparum-infected erythrocytes quenched the fluorescence signal, 
thereby dramatically reducing the sensitivity of the assay and thus limiting its usefulness. 
In order to resolve this problem, a new procedure was developed, which incorporates 
additional steps to remove the interfering haemoglobin. Lysing of the red blood cells in the 
culture with saponin, followed by washes with PBS led to the restoration of PicoGreen® 
fluorescence. Susceptibility to chloroquine and pyrimethamine of 3D7 and K1 laboratory 
lines of P. falciparum were tested using the improved PicoGreen® method in parallel with 
the traditional [3H]-hypoxanthine incorporation method. The IC50s obtained with both 
methods were observed to be similar, indicating that the new improved PicoGreen® 
method could be a good substitute for the  [3H]-hypoxanthine uptake method for the 
assessment of parasite susceptibility to purine antimetabolites. With the improved 
PicoGreen® method, the antimalarial activity of a small library of purine analogues was 
evaluated. The outcome of this screening suggests that some purine analogues could serve 
as lead compounds towards the development of a purine-based antimalarial therapy. 
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7.2 Introduction  
The recent upsurge in drug resistant P. falciparum malaria has necessitated the search for 
safe and effective antimalarial drugs (Rieckmann, 1983), particularly those that would 
exploit the unique metabolic pathways of the parasite. In view of this, the purine salvage 
system in the parasite was considered an important drug target. This is because the 
parasites lack the ability to synthesise purines de novo and have to salvage the nutrients 
from the host through transporters (Sherman, 1979). It was therefore expected that 
blockage of purine salvage would adversely affect parasite growth. With the purine salvage 
activities in P. falciparum fully characterized in this study (see chapter four), the available 
information on the kinetic properties of the transporters should facilitate the development 
of rational purine–based chemotherapy of malaria. The main objective of this part of the 
study was therefore to develop a high-throughput in vitro method to be used to evaluate 
purine-based analogues as potential antimalarial drugs. 
 
Various methods exist for screening novel compounds for antimalarial activities. The ‘gold 
standard’ microscopy method is often laborious and needs an experienced microscopist 
(WHO, 1990). Another popular method is the radio-isotopic test, which measures the 
incorporation of 3H-hypoxanthine into the nucleic acids of viable parasites (Desjardins et 
al, 1979). The obvious disadvantage of this method is the requirement for the use and 
disposal of radiolabelled material. Additionally, the isotopic method is not suitable for 
assessing purine antimetabolites because of the presence of the nucleobase in the radiolabel 
compound, which may impact directly on purine metabolism in the parasites and thus 
compromise the results. Due to the shortcomings of these methods other methods for 
assessing purine-based compounds were considered. This led to the identification of a 
novel microfluorimetric method using PicoGreen® dye to stain parasite DNA (Corbett et 
al, 2004). The authors demonstrated that PicoGreen® was able to detect as little as 25 
pg/ml of dsDNA in the presence of ssDNA, RNA, and free nucleotides (Corbett et al, 
2004). Replication of malaria parasites in culture was found to be directly proportional to 
the amount of PicoGreen® fluorescence, with a linear relationship observed between 0.1% 
and 15% parasitaemia.  
 
The microfluorimetric method was therefore considered as the most appropriate for the 
evaluation of purine antimetabolites. However, in an attempt to use this method as 
published (Corbett et al, 2004), it was observed that the presence of blood in the parasite 
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culture quenched the fluorescence of PicoGreen®. Even at a low haematocrit of 0.5%, the 
effect was severe. Haemoglobin is known to absorb light over a very broad range of 
wavelengths including the emission and excitation wavelengths of PicoGreen®.  
 
To overcome this problem, additional steps were introduced to remove the probable 
interfering compound. This was achieved through lysis of the RBC using saponin, 
followed by a series of washes with 1×PBS. By this process the fluorescence of 
PicoGreen® was easily detectable and the assay became a highly sensitive and reproducible 
tool for assessing the efficacy of antimalarial drugs. The IC50 values of some antimalarial 
drugs obtained with the improved PicoGreen® method were compared with that obtained 
with the traditional [3H]-hypoxanthine incorporation method.  
 
Guided by the kinetic information in chapter four of this thesis some purine analogues 
were carefully selected from the library of Dan Brown, the MRC Laboratory of Molecular 
Biology, Cambridge, UK and Gerrit-Jan Koomen, University of Amsterdam, The 
Netherlands. In vitro antimalarial potential of the analogues were determined using the 
improved PicoGreen® method. 
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7.3 PicoGreen® fluorescence is directly proportional to 
DNA concentration  
In order to confirm the relationship between fluorescence of PicoGreen® and the DNA 
concentration reported in literature (http://www.probes.com/media/pis/mp07581.pdf; 
Corbett et al., 2004), a concentration range of 1 ng/mL to 1000 ng/mL salmon sperm DNA 
(Sigma-Aldrich, Poole, UK) was prepared by serial dilution with nucleic acid- and DNase-
free water (ICN). One hundred and fifty microlitres of each dilution were dispensed into 
wells of a 96-well microtitre plate (Greiner Bio-One) followed by the addition of 50 µl 
lysis/fluorescence-mix consisting of PicoGreen® (1:200 in TE buffer, pH 7.5) and Triton 
X-100 (final concentration, 2%) in nucleic acid- and DNase-free water. After incubation of 
the plate in the dark at room temperature for up to 30 minutes, fluorescence intensity was 
measured at 485 nM (Excitation) and 528 nM (Emission) using a Perkin Elmer LS 55 
Luminescence Spectrophotometer. Control wells were set up on each plate. The control 
wells consisted of the highest concentration of salmon sperm DNA solution without 
PicoGreen® or lysis/fluorescence-mix alone in nucleic acid- and DNase-free water 
respectively. The mean background reading from the two control wells was subtracted 
from the test fluorescence reading to give the final fluorescence measurement. 
Fluorescence readings, which consisted of arbitrary units ranging from 1 to 1000, were 
plotted against salmon sperm DNA concentrations. The experiment was repeated in the 
absence of Triton X-100 from the lysis/fluorescence mix. All experiments were performed 
in triplicate and repeated in three independent experiments. 
 
Observations made in this experiment showed a linear relationship between PicoGreen® 
fluorescence and salmon sperm DNA concentration (Figure 7.1). This observation is 
consistent with that reported by Corbett and colleagues in 2004 (Corbett et al, 2004). It 
was further observed that the presence of 2% Triton X-100 in the fluorescence-mix did not 
significantly change the slope of the line (P-value from student’s t-test = 0.481), implying 
that the fluorescence signal from the DNA- PicoGreen® interaction was not affected by the 
presence of Triton X-100.  
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Figure 7.1:Relationship between PicoGreen® fluorescence and salmon sperm DNA. 
The figure shows the relationship between PicoGreen® fluorescence and salmon sperm DNA 
in the presence (open squares) or absence (black triangles) of 2% Triton X-100. Background 
fluorescence, defined as fluorescence detected in the absence of added DNA, was subtracted 
from each data point. Fluorescence is measured as arbitrary units (A.U.). Data shown are the 
mean of 3 independent determinations. The box below the graph shows the r2  value for 
linear regression line obtained using Prism 4. 
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7.4 Blood quenches fluorescence of PicoGreen®   
Following direct lysis of parasitized erythrocytes as described by Corbett and colleagues 
(Corbett et al, 2004), at best a very low level of PicoGreen® fluorescence was detected 
from wells containing P. falciparum-infected erythrocytes with haematocrit in the range of 
0.5 – 5% and up to 10% parasitaemia. Since this observation was unexpected, further 
investigations were conducted to identify the factor responsible for the quenching of 
PicoGreen® fluorescence. Non-infected blood was therefore diluted to give a range of 
haematocrits from 0.5 to 5% and samples were spiked with salmon sperm DNA at a fixed 
concentration of 1000 ng/ml. One hundred and fifty microlitres each of the mixtures were 
dispensed into the wells of an opaque 96-well microtitre plate. A volume of 50 µL of the 
lysis/fluorescence mix was added and the fluorescence signal determined as usual 
(described in section 7.3). The fluorescence readings were plotted against percent 
haematocrit. Negative control wells consisted of 150 µl blood at 1.0% haematocrit but 
without salmon sperm DNA, whilst the positive control wells consisted of 150 µl of 
salmon sperm DNA (1000 ng/ml) without blood. The negative control wells gave a 
background reading of 11.4 arbitrary fluorescence units (Table 7.1). No fluorescence signal 
above background was obtained for any of the samples containing blood with haematocrit 
range 0.5-5%. The positive control gave a fluorescence reading of 400 AU.  
 
Haematocrit Fluorescence reading (AU) 
0.5% 8.43 
2% 8.59 
3% 7.14 
4% 7.02 
5% 7.91 
Negative control 11.4 
Positive control 400 
 
Table 7.1 Fluorescence intensity reading for blood of haematocrit 1 – 5% spiked with 1000 
ng/ml salmon sperm DNA. 
The control consisted of 1.0% haematocrit blood in lysis/fluorescence-mix without salmon 
sperm DNA.  
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The result obtained from this investigation clearly showed that blood, or at least one of its 
constituents, quenches the fluorescence of PicoGreen®. It appears that that haemoglobin 
with its red pigment absorb most, if not all, of the fluorescence emitted by PicoGreen® (see 
absorbtion spectra in Figure 7.2). Attempts to solubilise and precipitate the haemoglobin 
with a cocktail of 5 parts of quaternary ammonium hydroxide, 2 parts 30% hydrogen 
peroxide and 2 parts glacial acetic acid, as reported by Biagini and colleagues (Biagini et 
al, 2004), did not reverse the observed quenching of PicoGreen® fluorescence. 
Furthermore, varying the emission and excitation wavelength did not improve the detection 
of the fluorescence signal. 
A B
C
 
Figure 7.2: The absorbtion spectra of oxygenated haemoglobin and deoxy haemoglobin. 
The figures marked A or B shows the absorbtion spectra of oxygenated haemoglobin (HbO2) 
and deoxyhaemoglobin (Hb) in the wavelength range 450 - 1000 nm. 
(Source:http://www.medphys.ucl.ac.uk/research/borg/research/NIR_topics/nirs.htm). The 
figure marked C shows the emission and excitation spectra of PicoGreen® 
(http://probes.invitrogen.com/servlets/spectra?fileid=7581dna). 
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7.5 Reversing the quenching effect of blood on 
PicoGreen® fluorescence by saponin treatment  
In order to overcome the quenching of PicoGreen® fluorescence, the method described by 
Corbett and colleagues (Corbett et al, 2004) was modified. The modification involves 
additional steps to remove the haemoglobin suspected to be responsible for the quenching 
of the PicoGreen® fluorescence. A suspension of asexual parasites of P. falciparum clone 
3D7 in a 2% haematocrit culture was serially diluted with uninfected erythrocytes (at 2% 
haematocrit) to yield parasitaemias of 0.5% to 15%. One hundred and fifty microlitres of 
each parasite concentration were dispensed into wells of two sets of microtitre plates. One 
set of the plates was processed to remove the haemoglobin as follows: (i) the microtitre 
plate containing the culture was centrifuged at 500 × g to pellet the cells; (ii) the 
supernatant was removed and the pellets were resuspended in saponin (0.15%, w/v) to lyse 
the erythrocytes and release the haemoglobin; (iii) the plate was centrifuged at 500 × g to 
sediment the parasites, and the supernatant was removed and discarded; (iv) traces of 
haemoblobin were removed through three washes with 1 × PBS; (v) The cell pellet was 
finally re-suspended in 150 µl 1 x PBS. The second set of plates remained untreated with 
saponin. Fifty microlitres of the lysis/fluorescence-mix was added to each well on the two 
sets of plates. The plates were incubated as previously in the dark at room temperature for 
30 minutes. Measurement of fluorescence signals at 485 nm (Excitation) and 528 nm 
(Emission) was then performed as previously described. Fluorescence reading was plotted 
against parasitaemia for each of the two sets of plates. 
 
After saponin treatment of parasite-infected erythrocytes, PicoGreen® fluorescence was 
restored, and a linear relationship was established between fluorescence of the dye and 
parasitaemia (Figure 7.2). The mean fluorescent signal obtained following saponin 
treatment was significantly different from that obtained in the untreated cultures (Student's 
t-test, P = 0.0009). 
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Figure 7.3: Effect of saponin treatment on PicoGreen® fluorescence. 
PicoGreen® fluorescence is shown following saponin treatment of the parasite culture, 
followed by washing to remove haemoglobin (∎), or with no saponin treatment (○), 
Parasitaemia was 1 – 10%. Background fluorescence was subtracted from each point. Lines 
were calculated by linear regression. The slope of the line for fluorescence in the absence of 
saponin treatment was significantly different from zero (P = 0.005; F-test), but was only 
1.5% of the slope for fluorescence after removal of haemoglobin (87 ± 4 versus 1.3 ± 0.3 
A.U.(%  parasitaemia)-1).  
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7.6 Comparison of the improved PicoGreen® method 
with [3H]-hypoxanthine uptake method 
Two culture-adapted standard laboratory lines of P. falciparum, 3D7 and K1, were tested 
for their sensitivity to chloroquine and pyrimethamine using the modified PicoGreen® 
method in parallel with the traditional [3H]- hypoxanthine accumulation test. The two 
selected parasite lines were known to differ in their sensitivity to antimalarial drugs in 
vitro: clone 3D7 is sensitive to chloroquine and pyrimethamine (Walliker et al, 1987) 
whilst K1 is resistant to both drugs (Thaithong, 1983).  
 
Parasites were maintained in continuous culture using standard methods (Trager & Jensen, 
1976;Haynes et al, 1976). Cultures used for the drug sensitivity assay contained 
predominantly ring-stages of the parasites. In some cases cultures were naturally 
synchronous, otherwise they were synchronized by brief incubation with 5% aqueous D-
sorbitol using the standard method (Lambros & Vanderberg, 1979). All drug sensitivity 
assays were performed in 96-well microtitre plates using the method described by 
Rieckmann and others(Rieckmann et al, 1978). Briefly, stocks of drugs were prepared 
initially in DMSO and then diluted serially with incomplete RPMI 1640 culture medium to 
achieve the desired concentration range. The final drug concentrations were 3.8 nM - 500 
nM for chloroquine (prepared from chloroquine sulphate, May and Baker, England), and 
15.6 nM - 2000 nM for pyrimethamine. The pyrimethamine was a gift from Prof. David 
Walliker (University of Edinburgh) to Dr Lisa Ranford-Cartwright (University of 
Glasgow). Each well of a microtitre plate was pre-dosed with 50 µl of the appropriate drug 
solution. Parasite cultures were diluted with fresh uninfected erythrocytes and RPMI1640 
culture medium to achieve a starting parasitaemia of 0.5-1.0% and haematocrit of 2%. Two 
hundred microlitres of the diluted parasite culture were added to each well of the pre-dosed 
plates. Control wells consisted of 50 µl culture medium without drugs (but containing the 
same amount of DMSO as in drug wells) and 200 µl parasitized or uninfected erythrocytes. 
The plates were incubated at 37 oC for 42-48 hours in a modular incubator (FlowLabs), 
gassed with a mixture of 3% CO2, 1% O2, 96% N2. 
 
For each test performed using the microfluorescence method, a second plate was set up for 
determination of IC50 by the [
3H]-hypoxanthine incorporation method. With regard to the 
isotopic method, cultures were initially plated as described and incubated at 37 °C for an 
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initial period of 24 hours. This was followed by the addition of 10 µl of 1.87 µM [3H]-
hypoxanthine with a specific activity of 37 GBq/mmol (Amersham Biosciences) to each 
well, and a further incubation for 24 hours. The cells were then harvested from each well 
onto a fibreglass filter paper using a Filtermate Harvester (Packard Instruments). The filter 
paper was dried, sealed in a plastic bag and 3 ml scintillation fluid (OptiPhase HiSafe 
(Perkin Elmer)) added. Radioactivity incorporated into the parasites was counted with a 
Microbeta Wallac Trilux liquid scintillation and luminescence counter.  
 
The IC50 value, representing 50% inhibition of uptake of [3H]-hypoxanthine, was 
determined from a non-linear regression analysis of log drug concentration against 
radiolabel incorporated into the parasites (Figure 7.4 and Figure 7.5). The IC50 value for 
chloroquine and pyrimethamine obtained using the PicoGreen® method was compared with 
the equivalent value determined using the traditional [3H]-hypoxanthine incorporation 
method. The overall results, which are shown in Table 7.2, indicate no statistically 
significant difference (Student’s t-test; P>0.05) in the IC50 values using the two methods. 
 
Mean IC50 values in nM (s.e.m.)  Parasite 
 Drug PicoGreen 
[3H]-
hypoxanthine 
P-value 
3D7 
 Chloroquine 6.3 (0.39) 7.2 (1.05) 0.468 
 Pyrimethamine 38.6 (7.6) 47.4 (9.6) 0.508 
K1 
 Chloroquine 141 (29.4) 128 (7.4) 0.693 
 Pyrimethamine 295 (115.2) 437 (133.4) 0.466 
 
Table 7.2 Mean IC50 values for chloroquine and pyrimethamine determined by the PicoGreen® 
or [3H]-hypoxanthine accumulation assay. 
Mean IC50 values for chloroquine and pyrimethamine were determined by the PicoGreen® or 
the [3H]-hypoxanthine accumulation assay for two laboratory lines of P. falciparum, 3D7 and 
K1. Data are the means of 3 independent determinations, and standard error of the mean 
(s.e.m.) in brackets. P-values were obtained from Student's t-test comparisons of IC50 values 
obtained for the two methods. 
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Figure 7.4: Representative graph showing chloroquine responses of P. falciparum lines 
obtained with the improved PicoGreen® method. 
A typical sigmoidal graph showing the responses of P. falciparum lines 3D7 (■) and K1 (○) to 
different concentrations of chloroquine obtained with the improved PicoGreen® method. 
Each data point is the mean of two wells. 
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Figure 7.5: Representative graph showing chloroquine responses of P. falciparum lines 
obtained with the traditional [3H]-hypoxanthine incorporation method. 
A typical sigmoidal graph showing the responses of P. falciparum lines 3D7 (■) and K1 (○) to 
different concentrations of chloroquine obtained with the traditional [3H]-hypoxanthine 
incorporation method. Each data point is the mean of two wells. 
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7.7 Test of purine analogues for antiplasmodial 
activities using the improved PicoGreen® method 
The anti plasmodial activity of novel purine analogues synthesized at the Medical Research 
Council, Cambridge, and the University of Amsterdam, were investigated using the 
improved PicoGreen® method. The JA series of compounds (obtained from Dan Brown, 
the MRC Laboratory of Molecular Biology, Cambridge, UK and the NA-series of 
compounds (obtained from Gerrit-Jan Koomen, University of Amsterdam, The 
Netherlands) are analogues of purine nucleosides or nucleobases, with substitutions at 
various positions. Compound JA-23 is an N6-substituted analogue of 2,6-diaminopurine 
riboside and compound, JA-32, is N6-hydroxyadenine and is a substituted adenine 
analogue. Of all the purine compounds tested JA-32 is the closest to hypoxanthine by 
structure. Some of the compounds and their structures are shown in Figure 7.6. 
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Figure 7.6: Structures of the purine analogues designated JA-32 and JA-23. 
These purines were received from Dan Brown, the MRC Laboratory of Molecular Biology, 
University of Cambridge.  
 
 
A 40mM stock solution of each compound was prepared by dissolving the powder in 100% 
dimethylsulfoxide (DMSO, Sigma). Working solutions were prepared from the stock with 
incomplete RPMI 1640. From the working solutions, a concentration range of the 
compounds was prepared by serial dilution. Fifty microlitres of each concentration of the 
drug (JA- NA- compounds) were dispensed into each well, followed by the addition of 200 
ml of P. falciparum culture to give a final parasitaemia of 0.5%, haematocrit of 
approximately 2% and DMSO concentrations ≤ 0.01%. The final concentration range of 
the compounds in the wells was 0.78-200 µM. Control wells consisted of 50 ml culture 
medium without drugs (but contained the same amount of DMSO as in drug wells) and 
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200 µl of parasitised or uninfected erythrocytes. A dilution series of chloroquine sulphate, 
at a final chloroquine concentration range of 3.9 -– 500 nM, was included on each plate as 
a control. The plates were incubated at 37°C for 42 – -48 hours in a modular incubator, 
gassed with a mixture of 3% CO2, 1% O2, 96% N2. The plates were processed using the 
improved PicoGreen® method, and the IC50 values determined appropriately. A 
representative curve obtained with these drugs is shown in Figure 7.7. A summary of the 
IC50 values for JA- and NA-compounds is shown in Table 7.3. Generally, the JA-
compounds were observed to have higher antiplasmodial activity than the NA-compounds. 
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Figure 7.7: Representative graph showing the response of P. falciparum 3D7 clone to purine 
analogues. 
The figure shows the responses of P. falciparum 3D7 clone to purine analogues JA-23 (■), 
JA-32 (▲), NA-130 (▼) and NA-137 (♦) obtained with the improved PicoGreen® method. Each 
data point is the mean of triplicate determinations and the error bars show the standard 
error of the mean. 
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Compound Mean IC50 ± S.E.M  
JA-23 6.0 ± 2.4 µM 
JA-32 2.0 ± 0.2 µM 
NA-130 112.6 ± 33.9 µM 
NA-137 112.9 ± 20 µM 
 
Table 7.3: In vitro antiplasmodial activity of purine analogues against P. falciparum clone 
3D7 using the improved PicoGreen® method. 
IC50 values presented are mean ± SEM of 3-4 determinations.  
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7.8 Discussion 
It is important to have a suitable method for assessing the potential of purine analogues as 
antimalarial drugs. Since the popular isotopic method using [3H]-hypoxanthine is 
unsuitable for assessment of purine nucleobases, the microfluorimetric method using 
PicoGreen® became the method of choice in this study. The PicoGreen® method seems to 
offer advantages over some of the existing methods, especially as it is devoid of issues 
concerning detection, storage and waste disposal of radioactive compounds. 
  
The outcome of a preliminary test using the PicoGreen® method showed a linear 
relationship between fluorescence of PicoGreen® and salmon sperm DNA concentration, 
with a clear signal from as little as 1 ng/ml DNA resuspended in PBS. However, the 
presence of uninfected erythrocytes, even at low haematocrit levels, abolished the 
fluorescence seen with salmon sperm DNA. Similarly, the fluorescence signal was barely 
detectable from cultures of P. falciparum-infected erythrocytes, even at high levels of 
parasitaemia. This phenomenon was attributable to the quenching of PicoGreen® 
fluorescence by haemoglobin, as the emission spectra for PicoGreen® and the absorption 
spectra for haemoglobin overlap in the relevant wavelengths (Figure 7.2).  
 
Based on these observations, the method was modified to include removal of the 
haemoglobin using saponin lysis of the erythrocyte followed by washing with PBS to 
remove the released haemoglobin. Fluorescence of the dye was thus restored and a linear 
relationship between fluorescence and percent parasitaemia was established. This linearity 
was reliable between 0.5 – 15% parasitaemia and was not affected by the synchronicity of 
the culture. The method thus facilitates the evaluation of the antiplasmodial activities of 
potential new chemotherapeutic compounds. 
 
Using the improved PicoGreen® method, the IC50 values of chloroquine and 
pyrimethamine against P. falciparum laboratory lines 3D7 and K1 were determined and 
compared with those obtained using the isotopic method with [3H]-hypoxanthine. The IC50 
values obtained by the two methods were statistically identical and consistent with 
literature values. The PicoGreen® method is not technically demanding, though caution 
must be exercised during the removal of the supernatant after saponin lysis or during 
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washing with PBS, in order not to lose part of the parasite pellet. The procedure lends itself 
well to scaling up and gives clear, accurate and indisputable results. 
 
The characterisation of the transporters of purines in P. falciparum, reported in chapter 
four of this thesis, paves the way for an intensive search of purine analogues as 
antimalarial drug candidates. Four transporters were found to be present in the parasite, 
and PfNT1 appears to be the most important. The presence of a high affinity hypoxanthine/ 
nucleoside transporter in the parasite’s plasma membrane can therefore be exploited for the 
efficient and selective targeting of purine antimetabolites. Interestingly, the outcome of a 
preliminary evaluation of hypoxanthine-like analogues received from the small libraries of 
a collaborator, Dan Brown, the MRC Laboratory of Molecular Biology, Cambridge, gave a 
promising results and confirmed the fact that PfNT1 can indeed be a good conduit for 
purine-based antimalarial drugs. Additionally, specific blockers of PfNT1, particularly 
those whose action may be non-competitive in nature, might make successful 
antimalarials, as PfNT1 is essential for growth under conditions of physiologically normal 
purine concentrations (El Bissati et al, 2006). It must however be emphasised that the 
presence of multiple transporters for purine salvage in P. falciparum poses a potential 
problem for the latter strategy, since there is the possibility of upregulation of the other 
transporters in compensation for the inhibition of purine uptake through PfNT1. 
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7.9 Conclusion 
This study establishes the value of the microfluorimetric method using PicoGreen® dye for 
in vitro drug sensitivity testing of P. falciparum. IC50 values obtained using the improved 
PicoGreen® method developed in this study were comparable with those of the traditional 
isotopic method for two different drugs (chloroquine or pyrimethamine) and two distinct 
parasite lines (3D7 or K1). Being simple and reliable, the modified PicoGreen® method 
should facilitate the screening of purine analogues for antiplasmodial activities. With the 
purine salvage mechanisms in P. falciparum parasites unveiled, it is now time to pursue a 
systematic purine-based antimalarial chemotherapy of malaria. 
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CHAPTER EIGHT 
8 General Discussion 
 
Neils Ben Quashie, 2008 Chapter Eight  
 
184
 
 
Purine nucleosides and nucleobases are essential to the malaria parasite as they form the 
basic constituents of nucleic acid and other important biomolecules. Since the parasite 
lacks the ability to synthesise these purines de novo, it has to rely solely on the host’s 
purine for survival and proliferation (El Bissati et al, 2006). Although it is known that 
uptake of purine from the host milieu into the parasite is through specialized transporters, 
the exact mechanism involved in this salvage is not well understood. Information available 
on the kinetic properties of the parasite’s purine transporters is shrouded in confusion and 
controversies. The availability of accurate and reliable information on the functional 
properties of purine transporters in P. falciparum should facilitate the development of a 
rational purine-based chemotherapy of malaria. The main aim of this project, therefore, 
was to provide detailed information on the kinetic characteristics of the transporters 
involved in purine salvage in P. falciparum, using biochemical and molecular methods.  
 
Earlier studies on purine metabolism in malaria parasites were performed in the avian 
parasite, P. lophurae (Tracy & Sherman, 1972) and the rodent malaria, P. berghei (Hansen 
et al, 1980).  In the year 2000, a gene encoding a purine transporter in P. falciparum was 
cloned and characterised after expression in Xenopus laevis oocytes. The investigations, 
carried out simultaneously by two independent groups of researchers, led to the 
identification of a low affinity adenosine transporter, denoted PfNT1 or PfENT1 (Parker et 
al, 2000;Carter et al, 2000). The Xenopus oocyte system has been widely used and 
accepted as a valuable tool for the expression of transporters and yielded highly valuable 
data on human transporters (Griffith & Jarvis, 1991;Wright et al, 2002;Beene et al, 2003). 
However, as is true with any heterologous expression system, the functional properties of 
the expressed proteins may be affected by the activities of indigenous proteins, codon 
preferences, post-translational modifications or membrane composition. It was thus 
reasoned that, since it has now become possible to study transport phenomena in the intact 
P. falciparum parasite, a study using freed (isolated) parasites would be complementary to 
the previous studies and secure accurate data of the kinetic characteristics of all the purine 
transporters expressed in the trophozoite stage.  
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8.1  Purine transport activity in P. falciparum parasites 
with intact erythrocyte membranes  
In P. falciparum infected red blood cells, the growing parasite requires purines for the 
synthesis of important biomolecules. Although it has previously been suggested that 
movement of nutrients into parasitized red blood cell was through the New Permeation 
pathway (NPP) [(Gero et al, 1999)], data obtained from the current study clearly showed 
that uptake of purines into the infected erythrocyte cytosol was through the host nucleoside 
and nucleobase transporters, hFNT1 and hENT1. Hypoxanthine and adenine appear to 
cross the erythrocyte membrane mainly through the hFNT1 and nucleosides such as 
adenosine entered predominantly through the hENT1. The evidence for these assertions is 
based on observations (section 3.3) showing that adenosine uptake into the parasitised 
erythrocytes was not inhibited by furosemide, which is a known inhibitor of the NPP (Kirk, 
2001). The observed free flow of purine into infected cells, even in the presence of high 
concentrations of furosemide, suggests that the NPP is not involved in nucleoside and 
nucleobase salvage in parasitised RBC. The NPP has also been reported to be non-
saturable (Kirk, 2001), yet purine transport into the parasitised RBC as observed in the 
current study, was clearly saturable with 1mM permeant. 
 
As reported in chapter three, the rate of adenosine uptake into P. falciparum-infected 
human RBC was approximately two fold higher than that of hypoxanthine. If hypoxanthine 
is, as reported, the preferred purine source for malaria parasites, it might be expected to 
have the highest rate of uptake. However, adenosine can easily be converted enzymatically 
to hypoxanthine, and the enzymes required, adenosine deaminase and purine nucleoside 
phosphorylase, are known to be present in the cytosol of the parasite (Gherardi & Sarciron, 
2007). This perhaps explains the major focus on adenosine in previous studies of purine 
transporters in P. falciparum, when it is well known that presence of hypoxanthine 
enhances the growth of the parasite in culture. 
 
The fate of the purine once it enters the cytosol of the erythrocyte was not investigated in 
the current study. However, given the reported presence of enzymes such as adenosine 
deaminase (Sherman, 1979;Gherardi & Sarciron, 2007) in the erythrocyte cytosol, it is 
likely that some of the nucleosides and nucleobases would be further metabolised 
accordingly. Since the erythrocyte is anucleate, purines may be necessary only for the 
synthesis of ATP and other biomolecules rather than for DNA or RNA. Therefore it is 
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expected that much of the purines salvaged from the external source would be available for 
use by the intracellular P. falciparum parasite to meet its physiological needs (see Table 
1.1 for physiological average of salvageable purine in mammalian cells).  
 
 
8.2  Purine transport activity in P. falciparum parasites 
with permeabilised erythrocyte membranes  
From the several published methods for the preparation of living P. falciparum parasites 
free of the host erythrocyte membrane, the method described by Ansorge and colleagues 
(1996) was chosen (Ansorge et al, 1996). The basis for the choice was its simplicity as 
well as the fact that it has been successfully used in other studies requiring permeabilised 
P. falciparum infected erythrocytes (Upston & Gero, 1995;Saliba et al, 1998). Even though 
the ghost of the erythrocytes in which the parasite originally resided is still present around 
the parasite in these preparations, it does not hinder the free movement of compounds into 
the parasite (Ansorge et al, 1996). The parasitophorus vacuole membrane remains intact 
around the parasite, but this is not a barrier to the translocation of compounds (Ansorge et 
al, 1996). P. falciparum- infected erythrocytes were permeabilised by this means in the 
current study. A series of investigations were carried out using the permeabilised cell 
(Chapter Four), which led to the characterisation of the proteins involved in purine salvage 
into P. falciparum. This allowed for the development of a model showing the proteins 
responsible for purine uptake from the external environment into the cytosol of the parasite 
(see Figure 8.1. for the model). 
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Figure 8.1: Model of purine uptake into intraerythrocytic P. falciparum trophozoites. 
Double-headed arrows indicate presumed equilibrative transport, whereas the single headed 
arrow of PfNT1 indicates possible active transport. However, the assignment of active or 
equilibrative transport is speculative and was not investigated in the current study. hFNT1 
and hENT1 are endogenous to the human erythrocyte whereas the origin of the NPP is 
unknown. The thickness of arrows for the P. falciparum transporters is meant to convey the 
relative flux of purines. NPP, New Permeation Pathways; PV, Parasitophorous vacuole; IEC, 
infected erythrocyte cytoplasm; Pf, Plasmodium falciparum. 
 
 
Observations reported in chapter three of this thesis indicates that hypoxanthine is rapidly 
transported into P. falciparum trophozoites through a saturable, high affinity transporter, 
designated PfNT1. This protein was also found to transport adenosine, and is sensitive to 
inhibition by guanine, inosine and to a lesser extent guanosine, but not to adenine. A 
separate transporter with a lower affinity for adenosine (denoted PfLAAT) was also found 
to be present in the plasma membrane of the isolated parasite. Two other separate adenine 
transporters denoted PfADET1 and PfADET2, both being saturable, were found to be 
present. PfADET1 was observed to have a high affinity for adenine, while PfADET2 has 
low affinity for this permeant. Due to technical problems already discussed in chapter four 
of this thesis, the kinetic parameters of PfADET2 could not be accurately determined. The 
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adenine transporters were observed in this study to have the highest diffusion component 
compared with adenosine and the other permeants. This observation is consistent with 
published data for toxoplasma (de Koning et al, 2005). This is believed to be due to the 
comparatively lower number of electronegative atoms in adenine capable of hydrogen 
bond formation, relative to the other natural purines. The number of these electronegative 
atoms in a compound has an inverse relation with the rate of diffusion of that compound 
across the plasma membrane (Alberts et al, 1994). Since the number of such atoms is much 
higher in adenosine compared to adenine (due to the presence of the sugar moiety), the rate 
of diffusion is much higher with adenine than the adenosine diffusion rate.  
 
There is considerable controversy about whether Plasmodium can utilise adenine at all, as 
several groups report the inability to identify genes encoding adenine 
phosphoribosyltransferase (APRT) and methylthioadenosine phosphorylase in any of the 
Plasmodium spp (Chaudhary et al, 2004;Ting et al, 2005) nor is there any evidence for the 
activity of adenine deaminase (Ting et al, 2005). Yet, the characterisation of APRT from 
P. chabaudi and P. falciparum has been reported (Walter & Konigk, 1974;Queen et al, 
1989). In addition, P. falciparum is reportedly able to grow in vitro on adenine as the sole 
purine source (Geary et al, 1985) and P. knowlesi incorporated adenine into nucleic acids 
(Gutteridge & Trigg, 1970). Although these latter observations could be explained by 
conversion of the adenine to hypoxanthine in the host cell, Van Dyke reported that the free 
parasite can also incorporate adenine into nucleic acids, albeit at 1% of the efficiency by 
which hypoxanthine is incorporated (Van Dyke, 1975). However the reported uptake of 
adenine by P. falciparum trophozoites in the current study and its seemly upregulation 
after deletion of the high affinity hypoxanthine transporter PfNT1, would be compatible 
with the view that adenine can be utilised in some way but is unlikely to play any major 
role in the overall synthesis of nucleotides. It is conceivable that the parasite has a different 
use for low levels of adenine, which it cannot generate itself from other purines (Ting et al, 
2005), or that adenine at high concentrations could be deaminated by adenosine deaminase. 
In fact, the presence of PfADET 1 and PfADET2 in the parasite is difficult to explain 
currently, as the contribution of adenine to purine metabolism in the parasite is unclear. 
Probably these transporters play major role during conditions of low levels of 
hypoxanthine and adenosine, or that P. falciparum requires adenine for a function 
unrelated to nucleotide synthesis. Alternatively, PfADET 1 and PfADET2 could be 
‘primitive transporters’ which have been retained after PfNT1 had emerged through years 
of evolution. 
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8.3  Purine transport in P. falciparum parasites lacking 
PfNT1. 
Transgenic parasites lacking a full length PfNT1 gene were generated (chapter five). The 
high affinity transport of adenosine and hypoxanthine observed in wild-type parasites was 
completely abolished in the transgenic parasite (3D7∆PfNT1), whereas there was no 
difference in the rate of uptake of adenosine through PfLAAT between the wild type and 
3D7∆PfNT1 parasites (chapter six). The initial rate of adenine uptake through PfADET1 
was similar in both the gene-disrupted parasites and wild-type parasites. However there 
was a higher uptake of adenine during the period of maximum uptake into the transgenic 
parasites compared to wild-type (Figure 6.4, chapter six). We speculate that this observed 
difference in level of adenine uptake could compensate for the loss of the high affinity 
hypoxanthine/nucleoside transport in 3D7∆PfNT1 parasites. 
 
From a critical analysis of the data obtained in this study, it can be deduced that PfNT1 is 
likely to be the most important purine transporter for P. falciparum. This conclusion is 
based on: (1) its high affinity, allowing salvage at relatively low purine concentrations, (2) 
the preference for hypoxanthine, which was experimentally shown to be the most 
important source for the parasite, (3) its high capacity for both hypoxanthine and adenosine 
and (4) the observation that ∆PfNT1 parasites are unable to survive without high 
concentrations of purines supplemented to the media. This saturable high affinity 
hypoxanthine/nucleoside transporter has some characteristics comparable to those reported 
by Carter’s group and Parker’s group(Parker et al, 2000;Carter et al, 2000), such as the 
ability to transport a broad range of purine nucleosides but not pyrimidines. The major 
difference between PfNT1 and the previously published transporters is the Km value 
observed for adenosine. As reported in chapter six, PfNT1 has a much lower Km value than 
that reported for any of the three previously published reports (see Table 8.1). However the 
Km value of the previously reported adenosine transporter is similar to that reported for 
PfLAAT in this thesis. 
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Reported Km (µM) 
Carter et al., 
2000 
Parker et al., 
2000 
Downie et al., 
2006 
Quashie’s PhD 
thesis 
Purine 
PfNT1 PfENT1  PfNT1 PfLAAT
Hypoxanthine  410*  0.34  
Adenosine 13.2* 320* 1450/1860* 2.0 197 
Inosine    2.0  
Adenine  320*  >500  
 
Table 8.1:Comparison of Km Values obtained from various studies. 
* NB=Km from uptake using the Xenopus laevis oocyte. 
 
 
As can been seen on table 8.1 the hypoxanthine/adenosine transporters (PfNT1) reported in 
chapter four were of high affinity, contrasting with the relatively low affinity of the 
adenosine/hypoxanthine transporters denoted PfNT1/PfENT1 in previous work. One 
possible explanation for the apparent discrepancy is that the previous kinetic studies were 
performed in Xenopus oocyte expression systems, under conditions using relatively higher 
permeant concentration (>1µM). When exogenous purine concentrations are high, it would 
not be possible to identify high affinity transporters, as they would be rapidly saturated 
with the permeant. The studies presented in Chapter four used purine concentrations 
approximately four-fold lower, thus allowing the identification and characterisation of the 
high affinity transport activity. 
 
During the current study, two further reports on purine transport using isolated P. 
falciparum parasites were published by the groups of Kirk (Downie et al, 2006) and 
Mamoun (El Bissati et al, 2006). Findings from these studies have not eased existing 
confusions on purine transporters in P. falciparum. In the first publication, El Bissati and 
co-workers disrupted the gene encoding the nucleoside transporter PfNT1 in P. falciparum 
and studied the characteristics of the resultant phenotype (El Bissati et al, 2006). They 
demonstrated that their ∆PfNT1 clones were auxotrophic for hypoxanthine, inosine, and 
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adenosine under physiological conditions and could only survive when the growth medium 
was supplemented with excess purine. Additionally the uptake of hypoxanthine into their 
∆PfNT1clones was significantly reduced, whereas adenosine and inosine transport were 
only partially affected. They reported that their finding supports the ‘conjecture that 
nucleosides such as adenosine do not gain direct access to the parasite and that they require 
prior conversion into hypoxanthine using host enzymes, reactions that occur within the 
RBC cytoplasm followed by PfNT1-mediated transport into the parasite’. This assertion 
does contradict earlier reports (Parker et al, 2000;Carter et al, 2000) that adenosine is a 
major purine transported into the parasite. Such a situation makes the presence of 
significant levels of adenosine deaminase in the parasite’s cytosol difficult to explain. 
However their report that their ∆PfNT1clones needed excess purine to survive in culture is 
consistent with observations made in the current study (see chapter five). Findings by El 
Bissati and co are consistent with observations reported in this thesis that PfNT1 is 
responsible for the high affinity transport of hypoxanthine in P. falciparum and that this 
nucleobase is required to sustain growth of the parasites in vitro.  
 
In the second publication, the group of Kirk (Downie et al, 2006) reported that salvage of 
nucleosides such as adenosine into freed parasites was through a low affinity transporter: 
the kinetic characteristics of which is similar to those of PfNT1 expressed in Xenopus 
oocytes [Km (adenosine) = 1.86 ± 0.28 mM; Km (thymidine) = 1.33±0.17 mM]. The group 
concluded that their data were consistent with PfNT1 serving as a major route for the 
uptake of nucleosides across the parasite plasma membrane.  
 
It is however worth noting that in the most recent studies (Downie et al, 2006;El Bissati et 
al, 2006) high concentrations (micromolar range) of radiolabelled permeants were used in 
the uptake assays. As previously discussed, under such circumstances measurement of the 
transport activity of the high affinity transporter would not be possible, as the transporter 
would be saturated by the permeant. Any kinetic value measured would be that of the low 
affinity transporter. The use of 25 µM of [3H]-adenosine in the current study was intended 
to saturate the high affinity transporter and thus allow measurement of the low affinity 
adenosine transporter (PfLAAT). The Km value of 197 ± 20 µM obtained for this 
transporter (PfLAAT) was lower than that reported (1.45mM) by the group of Kirk 
(Downie et al, 2006) for their transporter which we assert to be the same. Our assertion is 
supported by the observed rapidity at which adenosine uptake reached equilibrium, and the 
insensitivity of the transporter to the nucleoside transport inhibitor, dipyridamole. As to the 
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difference between the Km value obtained by Downie and co and that in this study, 
physical conditions such as the difference in temperature (4°C or 6°C) at which the two 
uptake assays were performed, could perhaps, partly be an explanation. 
 
In the current study, the ENT gene of the other three identified members of the purine 
transporters in P.falciparum were successfully disrupted and designated, 3D7∆PfNT2 (for 
Pf14_0662), 3D7∆PfNT3 (for MAL8pl.32 ) and 3D7∆PfNT4 (for Pfa0160c). It is hoped 
that once clones are prepared from these and the kinetic property of the phenotype 
determined, a proper understanding of the entire purine transport in P. falciparum will be 
achieved.  
 
Based on data obtained in the current study, it can be concluded that P. falciparum 
trophozoites expresses both high affinity purine nucleobase/nucleoside transport activities 
and a low affinity/ high capacity adenosine transport activities in addition to a saturable 
transport system for adenine. These findings are similar to the system of purine transport 
observed in the related apicomplexan parasite T. gondii. Available literature indicates the 
existence in T. gondii of a low affinity adenosine transporter denoted TgAT1 (Schwab et 
al, 1995;de Koning et al, 2003), as well as a high affinity adenosine transporter denoted 
TgAT2 that could also transport inosine (de Koning et al, 2003). However a major 
difference between purine salvage in the two apicomplexan species is that, unlike P. 
falciparum, T. gondii expresses a separate high affinity transporters for purine nucleosides 
(TgAT2) and the oxopurine nucleobases (TgNBT1). It is also worth noting that, just as 
observed for PfNT1 in the current study, TgNBT1 does not transport adenine (de Koning 
et al, 2003). 
 
 
8.4 Purine-based antimalarial drugs 
With detailed information on the kinetic properties of purine transporters made available 
through investigations carried out in this project, the stage has been set for an intense 
search for novel purine-based antimalarial drugs. In vitro assessment of purine analogues 
to ascertain their antiplasmodial potential would require the availability of a simple and 
reliable drug sensitivity testing method.  
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The traditional hypoxanthine uptake method (Desjardins et al, 1979) for assessing drug 
efficacy in vitro was found to be inappropriate for assessment of the suitability of purine 
analogues as potential antimalarial candidate. This is because the test compound could 
compete directly with the radiolabel for the transporter binding site or the enzymes for 
purine metabolism. The microscopic method(Rieckmann et al, 1978;WHO, 1990), which 
is the gold standard, is labour-intensive and time consuming and thus not suitable for even 
a semi-high throughput screening approach. A previously published microfluorimetric 
method (Corbett et al, 2004) involving the use of PicoGreen® dye to stain parasite’s DNA 
was found to be the most appropriate for assessments of the purine analogues tested in 
preliminary experiments. However, the PicoGreen® method was initially found to be 
extremely insensitive due to quenching of the fluorescence signal, as discussed in chapter 
seven. The method was therefore modified appropriately to mend the defect and then used 
to assess the antimalarial potential of some purine analogues received from the libraries of 
collaborators. The modification involved removal by saponin lysis of the haemoglobin 
from red blood cells in the culture, which was thought to quench fluorescence of 
PicoGreen®. The improved method was found to provide reliable and reproducible results.  
 
Using the newly improved PicoGreen® method, the antimalarial activity of a limited 
number of purine analogues, designated JA-compounds and NA-compounds, were 
investigated. JA-32 was found to be the compound with the most promising antiplasmodial 
activity. Interestingly, among the series of compounds from the library tested, JA-32 is the 
one with a chemical structure closest to hypoxanthine. This observation perhaps underlines 
the importance of hypoxanthine as the preferred purine source and the major permeant for 
PfNT1. With the presence of multiple purine transporters as observed in this study, a single 
purine-based antiplasmodial compound may not be enough to completely block the uptake 
of purine and thus prevent or slow the growth of the parasite. It is possible that when a 
major purine transporter is inhibited through competitive inhibition with a purine analogue, 
the parasite could obtain purines through the other transporters to compensate for the loss. 
This phenomenon was evident in the current study when adenine uptake was elevated in 
parasites lacking PfNT1 (see Figure 6.4). Furthermore, the affinity of PfNT1 for 
hypoxanthine being already very high, a competitive inhibitor would need to either display 
an extremely and uniquely high affinity for the transporter, or be present locally in very 
high concentrations. Even then, the blockage of hypoxanthine uptake and utilization n the 
infected erythrocyte may well lead to a build up of free hypoxanthine generated by 
Neils Ben Quashie, 2008 Chapter Eight  
 
194
adenosine deaminase and purine nucleoside phosphorylase, and again out-compete the 
inhibitor. 
The work presented in this thesis has investigated purine uptake into trophozoite stages of 
P. falciparum. The results obtained do not exclude the possibility that some of the 
identified purine transporters of P. falciparum play important role in nucleoside transport 
at the other stages of the parasite life cycle.  
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9.1 Composition of solutions 
9.1.1 Cryopreservation solution 
Glycerol 28% 
Sorbitol 3% 
NaCl 0.65%   
Made with distilled water, filter sterilised and stored at 40C. 
9.1.2 Cytomix 
KCl 120 mM 
CaCl2 0.15 mM 
EGTA 2 mM 
MgCl2 5 mM 
K2HPO4/KH2PO4 at pH 7.6 10 mM 
Hepes at pH 7.6 25 mM 
9.1.3  Denaturation solution for Southern blot 
NaCl 1.5 M 
NaOH  0.5 M 
Made with distilled water. 
9.1.4 6 X DNA loading dye 
Bromophenol blue 25 mg 
Xylene cyanol FF 25 mg 
Sucrose  4g 
Made with double distilled water to 10 ml 
.  
9.1.5 LB agar 
Lennox L agar 35 g 
Made with distilled water in 1 litre litre and autoclaved. Liquified by melting the agar 
before making agar plates. 
9.1.6 LB medium 
Tryptone 10 g 
Yeast extract 5 g 
NaCl 10 g 
Made with distilled water in 1 litre and pH adjusted at 7.0 with 5 M NaOH followed by 
autoclaving.  
9.1.7 Neutralisation solution for Southern blot 
NaCl 1.5 M  
Tris-HCl at pH 7.2  0.5 M 
EDTA 1 mM 
Made with distilled water. 
9.1.8 SOC 
Tryptone  20 g 
Yeast extract 5 g 
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NaCl 0.5 g 
Dissolved in water 
250 mM KCl 10 ml 
2 M MgCl2 5 ml 
Made with distilled water in 1 litre and pH adjusted at 7.0 with 5 M NaOH followed by 
autoclaving. When cooled down 
1 M sterile glucose 20 ml added. 
 
9.1.9 20 X SSC 
NaCl  3 M 
Sodium citrate (.2 H2O) 0.3 M  
Made with distilled water and the pH was adjusted to 7.0 with NaOH. Diluted to 10 X / 
6X/5 X before use. 
9.1.10 50 X TAE 
Tris base  2 M 
Glacial acetc acid 57.1 ml 
EDTA at pH 8.0 50 mM 
Made with distilled water in 1 litre. Diluted to 1 X before use. 
9.1.11 5 X TBE 
Tris base 450 mM 
Boric acid 27.5 g 
EDTA at pH 8.0 10 mM 
Made with distilled water in 1 litre. Diluted to 1 X before use. 
 
9.1.12 1 X TE 
1 M Tris.HCl 10 ml 
0.5 M EDTA at pH 8.0 2 ml 
Made with distilled water in 1 litre. 
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